Master guide for poisoning with mnemonics in detail

Reading File
Now let me search the medical library in parallel for comprehensive poisoning content.
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
I found a forensic medicine textbook (36th edition, 2026) which is ideal. Let me read the comprehensive poisoning content from it and Goldman-Cecil simultaneously.
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive information from multiple authoritative sources. Let me compile the master guide with mnemonics.

🧪 MASTER GUIDE TO POISONING - With Mnemonics

Sources: Goldman-Cecil Medicine, Tintinalli's Emergency Medicine, Essentials of Forensic Medicine & Toxicology (36th ed., 2026), Goodman & Gilman's Pharmacology

PART 1: APPROACH TO THE POISONED PATIENT

Initial Assessment - Mnemonic: "ABCDE TOXIN"

  • A - Airway (protect, intubate if needed)
  • B - Breathing (O2, ventilate)
  • C - Circulation (IV access, fluids, monitor)
  • D - Disability/CNS (GCS, pupils, seizures)
  • E - Exposure/Eliminate (decontaminate, antidotes)
  • T - Toxidrome recognition
  • O - Obtain history
  • X - eXtra labs (glucose, electrolytes, LFTs, RFTs, TFTs)
  • I - Investigations (ECG, imaging, drug levels)
  • N - Neutralize / Notify poison control

PART 2: TOXIDROMES (Toxic Syndromes)

Toxidromes are clusters of signs and symptoms caused by specific classes of poisons. They guide empirical treatment before a specific toxicant is confirmed.

2.1 CHOLINERGIC Toxidrome (Organophosphates, Carbamates)

Mechanism: Inhibition of acetylcholinesterase → acetylcholine accumulation → overstimulation of muscarinic + nicotinic + CNS receptors
MUSCARINIC effects - Mnemonic: "SLUDGE BAM"
LetterFeature
SSalivation
LLacrimation
UUrination
DDefecation
GGI distress (cramps, diarrhea)
E -Emesis
BBradycardia
AAbdominal pain
MMiosis
Alternative mnemonic: "DUMBELS"
LetterFeature
DDefecation, Diarrhea
UUrination
MMiosis
BBradycardia, Bronchospasm, Bronchorrhea
EEmesis
LLacrimation
SSalivation, Sweating
NICOTINIC effects - Mnemonic: "MTWTF" (Days of week)
  • M - Muscle weakness/fasciculations
  • T - Tachycardia (nicotinic can override bradycardia)
  • W - Weakness (paralysis)
  • T - Tremors
  • F - Flushing
Or simpler: "MATCH"
  • M - Mydriasis (nicotinic), Muscle fasciculations
  • A - Agitation
  • T - Tachycardia, Tremors
  • C - Cramps
  • H - Hypertension
CNS: Seizures, coma, anxiety, restlessness
Antidotes for Organophosphate Poisoning:
  1. Atropine - Competitive antagonist at muscarinic receptors (end point: drying of secretions, not pupil dilation). Initial: 1.2-3 mg IV, doubled every 5 min. Hundreds of mg may be needed.
  2. Pralidoxime (2-PAM) - Reactivates cholinesterase BEFORE aging occurs. Must be given early.
  3. Benzodiazepines - For seizures
Mnemonic for aging of organophosphates: "SEPIA"
  • S - Soman (fastest aging - minutes)
  • E - Ethyl Sarin
  • P - Parathion (hours to days)
  • I - Intermediate
  • A - Aging irreversible = 2-PAM won't work

2.2 ANTICHOLINERGIC Toxidrome

Causes: Atropine, antihistamines, TCAs, antipsychotics, jimsonweed (Datura), mushrooms
Mnemonic: "Hot as a Hare, Blind as a Bat, Dry as a Bone, Red as a Beet, Mad as a Hatter"
FeatureMnemonic
Hyperthermia"Hot as a Hare"
Mydriasis"Blind as a Bat"
Dry skin/mucosa, urinary retention"Dry as a Bone"
Flushing"Red as a Beet"
Delirium, hallucinations"Mad as a Hatter"
Tachycardia
Decreased bowel sounds
Antidote: Physostigmine (for severe CNS effects)

2.3 SYMPATHOMIMETIC (Adrenergic) Toxidrome

Causes: Cocaine, amphetamines, ephedrine, phencyclidine (PCP)
Mnemonic: "FAST HHH"
  • F - Fever (hyperthermia)
  • A - Agitation, Anxiety
  • S - Sweating (diaphoresis - key difference from anticholinergic)
  • T - Tachycardia, Tremors
  • H - Hypertension
  • H - Hyperreflexia
  • H - Hyperthermia
Key distinguishing feature from anticholinergic: DIAPHORESIS (sweating is present)
Treatment: Benzodiazepines (first line), phentolamine (for severe hypertension), cooling

2.4 OPIOID Toxidrome

Classic Triad - Mnemonic: "PIN"
  • P - Pinpoint pupils (miosis)
  • I - Impaired breathing (respiratory depression)
  • N - No consciousness (CNS depression/coma)
Other features: Bradycardia, hypotension, hypothermia, decreased bowel sounds
Antidote: Naloxone (Narcan) 0.4-2 mg IV/IM/IN - repeat every 2-3 min as needed (short half-life - may need infusion for long-acting opioids)

2.5 SEDATIVE-HYPNOTIC Toxidrome

Causes: Benzodiazepines, barbiturates, alcohol, GHB, baclofen
Features:
  • CNS depression, slurred speech
  • Respiratory depression
  • Ataxia, confusion, amnesia
  • Normal pupils (unlike opioids - important distinction)
Antidote: Flumazenil (for benzodiazepines only) - use cautiously (can precipitate seizures)

2.6 SEROTONIN Syndrome

Causes: SSRIs, SNRIs, MAOIs, tramadol, triptans, linezolid, dextromethorphan combinations
Mnemonic: "CLAMP" (Hunter Criteria)
  • C - Clonus (inducible/spontaneous/ocular) - KEY feature
  • L - Long hyperthermia (fever)
  • A - Agitation
  • M - Myoclonus, hyperreflexia
  • P - Pressured speech (autonomic instability)
Hunter Criteria for diagnosis (any ONE):
  1. Spontaneous clonus
  2. Inducible clonus + agitation OR diaphoresis
  3. Ocular clonus + agitation OR diaphoresis
  4. Tremor + hyperreflexia
  5. Hypertonia + temperature >38°C + ocular or inducible clonus
Antidote: Cyproheptadine (5-HT2A antagonist); benzodiazepines for agitation/seizures

2.7 Toxidrome Comparison Table

FeatureCholinergicAnticholinergicSympathomimeticOpioidSedative
HR
BP
Pupils↓ (miosis)↑ (mydriasis)↑ (mydriasis)↓ (miosis)Normal
Temp
SkinWet/sweatyDry/flushedDiaphoreticNormalNormal
Bowel soundsNormal
Secretions↑↑ (SLUDGE)Normal

PART 3: SPECIFIC POISONS & ANTIDOTES

Mnemonic for Key Antidotes: "N-ACETYL FACTS"

PoisonAntidoteMnemonic aid
Paracetamol (Acetaminophen)N-Acetylcysteine (NAC)"N-acetyl for N-Acetaminophen"
OrganophosphatesAtropine + Pralidoxime"2-PAM reactivates before aging"
OpioidsNaloxone"Nal-oxone blocks opioid rece-one"
BenzodiazepinesFlumazenil"Flu-maze-nil for benzo's fog"
Warfarin/AnticoagulantsVitamin K + FFP"K for Koagulation"
IronDeferoxamine"De-FER-oxamine for FERrous iron"
Heavy metals (As, Pb, Hg)BAL (Dimercaprol) / DMSA"BAL chelates bivalent metals"
CyanideHydroxocobalamin / Amyl nitrite + Sodium thiosulfate"Cobalt binds cyanide"
Carbon monoxide100% O2 / Hyperbaric O2"Oxygen displaces CO from Hb"
Methanol/Ethylene glycolFomepizole (4-MP) / Ethanol"Fomepizole blocks alcohol DH"
DigoxinDigibind (Fab fragments)"Anti-Dig Fab"
Beta-blockersGlucagon + Calcium"Glu-Ca for Beta block"
Tricyclics (TCAs)Sodium bicarbonate"Bicarb for TCA arrhythmia"
HeparinProtamine sulfate"Pro-tamine reverses Pro-tein heparin"
IsoniazidPyridoxine (Vit B6)"B6 for INH seizures"
MethemoglobinemiaMethylene blue"Blue for MetHb (also blue in color)"

PART 4: INDIVIDUAL POISON PROFILES

4.1 PARACETAMOL (Acetaminophen) Poisoning

Doses:
  • Therapeutic adult: 500-1000 mg/dose (max 4 g/day)
  • Toxic: ≥150 mg/kg (single ingestion)
  • Lethal: >350 mg/kg
Mechanism: ~10% metabolized by CYP2E1 to toxic NAPQI → depletes glutathione → centrilobular hepatic necrosis
Clinical Stages - Mnemonic: "4 PHASES"
PhaseTimeFeatures
I0-24hN/V, malaise, pallor
II24-72hRUQ pain, LFT elevation begins, apparent improvement
III72-96hPeak hepatotoxicity (jaundice, coagulopathy, encephalopathy)
IV4 days-2 weeksRecovery OR fulminant hepatic failure
Antidote: N-Acetylcysteine (NAC) - replenishes glutathione; best within 8-10h, still useful up to 24h+ Monitoring: Rumack-Matthew nomogram (serum level vs. time since ingestion)
King's College Criteria for Liver Transplant (paracetamol OD):
  • pH < 7.3 (after resuscitation), OR
  • ALL three: PT >100s + Creatinine >300 µmol/L + Grade III-IV encephalopathy

4.2 SALICYLATE (Aspirin) Poisoning

Fatal doses:
  • Sodium salicylate / Aspirin: 15-20 g
  • Methyl salicylate (oil of wintergreen): 5-15 mL
Mechanism: Uncouples oxidative phosphorylation, stimulates respiratory center, inhibits Krebs cycle
Classic acid-base disturbance - Mnemonic: "RAMMPAGE"
  • Early: Respiratory Alkalosis (hyperventilation from direct brainstem stimulation)
  • Late: Metabolic Acidosis (AGMA from lactic acid, ketones)
  • Classic picture in adults: Mixed respiratory alkalosis + metabolic acidosis
  • Children: metabolic acidosis predominates
Severity by level:
LevelFeatures
<300 mg/LMild: tinnitus, N/V, vertigo
300-700 mg/LModerate: dehydration, tachypnea, respiratory alkalosis → metabolic acidosis
>700 mg/LSevere: arrhythmias, pulmonary edema, cerebral edema, seizures, coma, renal failure
Treatment:
  • Urinary alkalinization with IV sodium bicarbonate (ion trapping - prevents CNS entry)
  • Hemodialysis for severe cases
  • No specific antidote

4.3 ORGANOPHOSPHATE / CARBAMATE Poisoning

Examples: Parathion, malathion, diazinon, chlorpyrifos; nerve agents (sarin, VX, tabun)
Key distinction:
  • Organophosphates: IRREVERSIBLE cholinesterase inhibition (aging occurs)
  • Carbamates: REVERSIBLE inhibition (no aging, 2-PAM generally not needed)
"Aging" concept: Permanent, irreversible binding of OP to cholinesterase. Soman ages fastest (minutes). After aging, 2-PAM is ineffective.
Management:
  1. Decontamination (remove clothes, copious water wash - protect healthcare workers)
  2. Atropine: 1.2-3 mg IV, double every 5 min - end point = dry chest/secretions
  3. Pralidoxime: Must be given BEFORE aging - reactivates enzyme
  4. Benzodiazepines for seizures
  5. Succinylcholine AVOIDED (metabolized by plasma cholinesterase → prolonged paralysis)

4.4 CYANIDE Poisoning

Sources: Combustion of synthetic materials (fires), industrial exposure, plants (amygdalin/bitter almonds), sodium nitroprusside toxicity
Mechanism: Inhibits cytochrome c oxidase (Complex IV) → histotoxic hypoxia → cells cannot use O2 despite normal PaO2
Classic feature: Venous blood appears bright red (high venous O2 saturation - cells can't use O2) Smell: Bitter almonds (only 40% of people can detect)
Mnemonic: "CYANIDE = COMPLEX IV KILLER"
Antidote regimen:
  1. Hydroxocobalamin (preferred) - cobalt binds cyanide; turns urine red
  2. Amyl nitrite (inhale) → Sodium nitrite (IV) → create methemoglobin which binds cyanide
  3. Sodium thiosulfate - converts cyanide to thiocyanate (renally excreted)
  4. HBO for combined CO+cyanide poisoning

4.5 CARBON MONOXIDE (CO) Poisoning

Mechanism: CO binds Hb with 250x affinity of O2 → carboxyhemoglobin (COHb) → tissue hypoxia
Classic presentations by COHb level:
COHb%Features
10-20%Headache, nausea
20-40%Confusion, weakness
40-60%Syncope, seizures
>60%Death
Mnemonic: "CHERRY RED" = Classic (but rare in living patients)
Key point: Pulse oximetry reads FALSELY NORMAL (can't distinguish COHb from OxyHb). Need CO-oximetry.
Treatment:
  • 100% O2 via non-rebreather mask (reduces CO half-life from 5h → 1h)
  • Hyperbaric O2: 2.5-3 ATA (reduces half-life to 20-30 min) - indicated for LOC, neurologic symptoms, COHb >25%, pregnancy

4.6 METHANOL & ETHYLENE GLYCOL Poisoning

Mechanism: Metabolized by alcohol dehydrogenase (ADH) to toxic metabolites:
  • Methanol → Formaldehyde → Formic acid (retinal/optic nerve damage → blindness)
  • Ethylene glycol → Glycolic acid → Oxalic acid → calcium oxalate crystals (kidney)
Mnemonic: "BLIND METHANOL, STONE GLYCOL"
  • Methanol = BLINDNESS (optic nerve)
  • Ethylene glycol = kidney STONES (oxalate crystals)
Both cause: High anion gap metabolic acidosis (HAGMA), increased osmolar gap
Treatment:
  • Fomepizole (4-MP): Competitive inhibitor of ADH - preferred antidote
  • Ethanol: Alternative (competes for ADH - but harder to titrate)
  • Hemodialysis: Removes toxic metabolites
  • Bicarb for acidosis

4.7 TRICYCLIC ANTIDEPRESSANT (TCA) Poisoning

Mechanism: Na+ channel blockade, anticholinergic effects, alpha-1 blockade, antihistamine
Classic triad - Mnemonic: "3 C's"
  • CNS depression (sedation, seizures)
  • Cardiac toxicity (wide QRS, VT, VF)
  • Cholinergic blockade (anticholinergic features)
ECG: Key findings:
  • QRS >100ms = seizure risk
  • QRS >160ms = VT risk
  • Terminal R wave in aVR >3mm (most specific for TCA toxicity)
  • Brugada pattern (V1-V3)
Treatment:
  • Sodium bicarbonate IV: Narrows QRS, treats arrhythmias (by raising pH and increasing Na+)
  • Avoid physostigmine
  • Benzodiazepines for seizures
  • Lipid emulsion therapy for refractory cases

4.8 IRON Poisoning

Stages - Mnemonic: "ABCDE"
StageTimingFeatures
A - GI0-6hN/V, diarrhea, hematemesis
B - Latent6-12hApparent improvement (deceptive)
C - Cardiovascular12-24hShock, metabolic acidosis, coagulopathy
D - Delayed hepatic2-5 daysHepatic failure
E - Enteric scarring2-8 weeksGI obstruction from scarring
Antidote: Deferoxamine - chelates free iron → ferrioxamine complex (excreted renally; urine turns "vin rose" color)

4.9 HEAVY METAL POISONING

Mnemonic: "BAD Metals need BAL / DMSA"
MetalKey FeatureAntidote
Lead (Pb)Burton's lines (blue-black gum line), basophilic stippling, neurologicalDMSA (succimer), BAL for encephalopathy
Mercury (Hg)"Mad Hatter" - tremor, erethism (neuropsych), Minamata diseaseDMSA, BAL
Arsenic (As)Mees' lines, Aldrich-Mees lines on nails, rain-drop pigmentation, garlic breathBAL (dimercaprol), DMSA
ThalliumAlopecia (hair loss), Mees' lines, painful neuropathyPrussian blue
BAL (British Anti-Lewisite/Dimercaprol): Chelates arsenic, mercury, lead (with BAL first for severe lead encephalopathy)

4.10 DIGOXIN Poisoning

Mechanism: Inhibits Na+/K+-ATPase → increased intracellular Ca2+ → arrhythmias
Mnemonic: "DIGOXIN TOXIC"
  • D - Digitalis effect on ECG (scooped ST "Salvador Dali" sagging)
  • I - Increased vagal tone (bradycardia, AV block)
  • G - GI symptoms (N/V, anorexia)
  • O - Objects appear yellow/green (xanthopsia)
  • X - Xtra potassium worsens toxicity (hypokalemia potentiates)
ECG patterns: Bidirectional VT, regularized AF, paroxysmal atrial tachycardia with block
Antidote: Digibind (Digoxin-specific Fab antibody fragments)
  • Avoid cardioversion (may cause refractory VF)
  • Treat hyperkalemia carefully (NOT calcium - may worsen)

4.11 BETA-BLOCKER & CALCIUM CHANNEL BLOCKER Poisoning

Mnemonic: "BRAVAD" for treatment of both:
  • Benzodiazepines (if seizures)
  • Resuscitation fluids
  • Atropine (for bradycardia)
  • Vasopressors (norepinephrine)
  • Ampicillin... no - ACLS/glucagon
  • D - Dextrose (for insulin-euglycemia)
Specific treatments:
AgentSpecific AntidoteMechanism
Beta-blockersGlucagonBypasses β-receptor, raises cAMP
CCBsCalcium + High-dose insulinRestores Ca2+ signaling
Both refractoryHigh-dose Insulin Euglycemia (HDIE)Inotropic effect on carbohydrate metabolism
Both refractoryLipid emulsion (Intralipid)"Lipid sink" sequesters drug

PART 5: DECONTAMINATION PRINCIPLES

Mnemonic: "GET SAFE"

  • G - Gastric lavage (within 1h of large ingestion, airway protected)
  • E - External decontamination (skin/eye exposure)
  • T - Triggered emesis - AVOID (ipecac no longer recommended)
  • S - Single-dose Activated Charcoal (most useful, within 1-2h)
  • A - Alkalinize urine (salicylates, phenobarbital - ionizes drug in urine)
  • F - Fluid management
  • E - Enhanced elimination (hemodialysis, hemoperfusion, charcoal repeat doses)

Activated Charcoal

  • Works by adsorption - most drugs EXCEPT:
  • Mnemonic: "CHASM" = NOT adsorbed by charcoal
    • C - Caustics (acids/alkalis)
    • H - Heavy metals (iron, lithium, lead)
    • A - Alcohols (methanol, ethanol, ethylene glycol)
    • S - Solvents
    • M - Minerals (electrolytes, K+)

Multi-Dose Activated Charcoal (MDAC)

Used for drugs with enterohepatic recirculation:
  • Mnemonic: "CAPS D"
    • C - Carbamazepine
    • A - Amitriptyline/dapsone
    • P - Phenobarbital/phenytoin
    • S - Salicylates/theophylline
    • D - Digoxin

PART 6: ENHANCED ELIMINATION

MethodBest ForDrugs
HemodialysisSmall volume of distribution, water-solubleMethanol, ethylene glycol, lithium, salicylates
HemoperfusionHigh protein bindingTheophylline, carbamazepine
Urinary alkalinizationWeak acidsSalicylates, phenobarbital
Urinary acidificationWeak basesAmphetamines (rarely used now)
MDACEnterohepatic circulationSee CAPS D above

PART 7: COMMON ANTIDOTES - MASTER TABLE

PoisonAntidoteDose/Notes
AcetaminophenN-Acetylcysteine150 mg/kg IV loading
OpioidsNaloxone0.4-2 mg IV/IM/IN
BenzodiazepinesFlumazenil0.2 mg IV, cautiously
OrganophosphatesAtropine + PralidoximeAtropine until secretions dry
CyanideHydroxocobalamin5 g IV
CO100% O2 / HBO
Methanol/EGFomepizole15 mg/kg IV loading
TCAsSodium bicarb1-2 mEq/kg IV
DigoxinDigoxin FabBased on serum level
IronDeferoxamine15 mg/kg/h IV
Beta-blockersGlucagon3-10 mg IV bolus
CCBsCalcium + InsulinCa gluconate 3 g IV
WarfarinVitamin K + FFP
HeparinProtamine1 mg per 100 units heparin
INH (isoniazid)Pyridoxine (B6)Gram-for-gram if dose known
MethemoglobinemiaMethylene blue1-2 mg/kg IV
Heavy metalsBAL / DMSA / EDTADepends on metal
Arsenic/Lead/MercuryBAL (dimercaprol)
ThalliumPrussian blue
SulfonylureasOctreotidePrevents recurrent hypoglycemia
DabigatranIdarucizumab5 g IV
Rivaroxaban/ApixabanAndexanet alfa

PART 8: SPECIAL POISONING TOPICS

8.1 Snake Bite Management - Mnemonic: "LMNO"

  • L - Local care (immobilize, keep at heart level)
  • M - Monitor vitals, coagulation, urine
  • N - No tourniquet, No incision, No mouth suction
  • O - Offer antivenom if systemic features present

8.2 Food Poisoning - Onset Time Clues

Mnemonic: "S-6, C-8-16, ETEC-16+"
ToxinIncubationKey Feature
Staph aureus, B. cereus (short)1-6hPreformed toxin, vomiting prominent
C. perfringens, B. cereus (long)8-16hIn-vivo toxin
ETEC, STEC, Salmonella, Vibrio>16hInvasive/in-vivo
Botulism12-36hDescending flaccid paralysis

8.3 Botulinum Toxin

Mechanism: Blocks ACh release at NMJ (SNARE protein cleavage) → descending flaccid paralysis Mnemonic for clinical features: "4 D's"
  • Diplopia
  • Dysarthria
  • Dysphagia
  • Descending paralysis
Treatment: Antitoxin (heptavalent HBAT), supportive ventilation

8.4 Caustic Poisoning

Mnemonic: "ACIDS vs ALKALIS"
AgentDamage typeKey feature
AcidsCoagulative necrosisSelf-limiting eschar; stomach > esophagus
AlkalisLiquefaction necrosisDeeper penetration; esophagus > stomach
Management: NO emesis, NO neutralization, early endoscopy

PART 9: FORENSIC TOXICOLOGY ESSENTIALS

Types of Poisons (Medicolegal)

Mnemonic: "COPS MIP"
  • C - Corrosives (acids, alkalis)
  • O - Organic (plant alkaloids: aconite, digitalis, oleander)
  • P - Putrefactive/Gaseous (CO, HCN, H2S)
  • S - Systemic (metals: As, Pb, Hg)
  • M - Medicinal overdose
  • I - Insecticides/Agricultural
  • P - Psychoactive/Neurological

Postmortem Clues to Poison Identity

FindingSuspect Poison
Cherry red lividityCarbon monoxide
Garlic odorArsenic, organophosphates, phosphorus
Almond odorCyanide
Yellow adipocereYellow phosphorus
Constricted pupilsOpioids, organophosphates
Hematemesis + corrosionAcids/alkalis
Centrilobular necrosisParacetamol, carbon tetrachloride

PART 10: QUICK REFERENCE - MASTER MNEMONIC MAP

SituationMnemonicMeaning
Cholinergic featuresSLUDGE / DUMBELSSalivation, Lacrimation, Urination, Defecation, GI, Emesis
AnticholinergicHot Hare, Blind Bat, Dry Bone, Red Beet, Mad HatterHyperthermia, Mydriasis, Dry skin, Flushing, Delirium
DecontaminationGET SAFEGastric lavage, External decon, Triggered emesis (avoid), Activated charcoal, Sodium bicarb, Fluids, Enhanced elimination
Charcoal ineffectiveCHASMCaustics, Heavy metals, Alcohols, Solvents, Minerals
Multi-dose charcoalCAPS DCarbamazepine, Amitriptyline/Dapsone, Phenobarbital, Salicylates/Theophylline, Digoxin
Hemodialysis"AEIOU"Alcohols (toxic), Ethylene glycol, Isopropanol, OU (outliers: lithium, salicylates)
Opioid triadPINPinpoint pupils, Impaired breathing, No consciousness
Salicylate acid-baseRAMMPAGERespiratory Alkalosis → Metabolic Acidosis
Botulism4 D'sDiplopia, Dysarthria, Dysphagia, Descending paralysis
Digoxin ECGScooped ST/Salvador Dali signReversed tick ST depression
CO poisoningCHERRY REDClassic (rare in living patients)

Sources: Goldman-Cecil Medicine International Edition | Tintinalli's Emergency Medicine: A Comprehensive Study Guide | The Essentials of Forensic Medicine and Toxicology, 36th ed. (2026) | Goodman & Gilman's Pharmacological Basis of Therapeutics | Barash Clinical Anesthesia

Generate a quick-reference guide on antidote dosing and administration protocols and give example clinical case with each different poisoning management.

Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
I now have comprehensive dosing data from authoritative textbooks. Let me compile the complete quick-reference guide with clinical cases.

⚡ QUICK-REFERENCE GUIDE: ANTIDOTE DOSING, ADMINISTRATION PROTOCOLS & CLINICAL CASES

Sources: Washington Manual of Medical Therapeutics | Tintinalli's Emergency Medicine | Goldman-Cecil Medicine | Rosen's Emergency Medicine | The Essentials of Forensic Medicine & Toxicology (36th ed., 2026)

SECTION 1: MASTER ANTIDOTE DOSING TABLE


1. N-ACETYLCYSTEINE (NAC) - Paracetamol Poisoning

ParameterDetail
IndicationParacetamol (acetaminophen) overdose
RouteIV (preferred) or oral
IV Protocol (3-bag Prescott regimen)
Bag 1 (loading)150 mg/kg in 200 mL D5W over 60 min
Bag 250 mg/kg in 500 mL D5W over 4 hours
Bag 3100 mg/kg in 1000 mL D5W over 16 hours
Total IV dose300 mg/kg over 21 hours
Oral protocol140 mg/kg loading, then 70 mg/kg q4h x 17 doses
Time windowMost effective <8-10h; still give up to 24h+ in severe cases
MechanismReplenishes glutathione; neutralizes NAPQI
Side effectsAnaphylactoid reaction (esp. with loading dose) - slow infusion; treat with antihistamines

2. NALOXONE - Opioid Poisoning

ParameterDetail
IndicationOpioid overdose (respiratory depression, coma)
IV/IM/SC dose0.4-2 mg IV; repeat every 2-3 min (up to 10 mg total before re-evaluating diagnosis)
Intranasal4 mg/0.1 mL per nostril (FDA-approved)
OnsetIV: 1-2 min; IM/SC: 2-5 min; IN: 2-5 min
Duration30-90 min (SHORTER than most opioids)
Continuous infusion"Wake-up dose" x 2/3 = hourly infusion rate (titrate to respiratory rate ≥12)
Neonates10 µg/kg IV/IM/SC
Long-acting opioids (methadone, fentanyl patches)Infusion mandatory; admit to monitored unit
Discharge after heroin ODSafe after 1h if normal vitals and mental status
CautionPrecipitates acute withdrawal in opioid-dependent patients - start low (0.04 mg)

3. ATROPINE - Organophosphate / Carbamate Poisoning

ParameterDetail
IndicationCholinergic crisis (OP/carbamate, nerve agents, muscarine-containing mushrooms)
Initial doseAdults: 1.2-3 mg IV (depending on severity); Children: 0.02 mg/kg IV
TitrationDouble the dose every 5-10 min until secretions dry
End pointDrying of bronchial secretions + clear chest on auscultation + HR >80 bpm
NOT end pointPupil dilation, tachycardia
Massive ingestionsHundreds of mg may be required - pre-alert pharmacy
If no IV2-6 mg IM as first dose
Maintenance10-20% of total loading dose per hour by infusion
CautionTachycardia is NOT a contraindication (may reflect hypoxia from bronchospasm)

4. PRALIDOXIME (2-PAM) - Organophosphate Poisoning

ParameterDetail
IndicationOrganophosphate poisoning ONLY (not carbamates - not needed/potentially harmful)
MechanismReactivates cholinesterase BEFORE irreversible aging
Loading dose1-2 g IV over 15-30 min
Maintenance500 mg/h continuous infusion OR 1 g q4-6h
Time windowMust be given BEFORE aging; most OP compounds age within hours (soman: minutes)
RouteIV preferred; IM if no IV access
Stop whenAtropine no longer needed, fasciculations resolved

5. HYDROXOCOBALAMIN - Cyanide Poisoning

ParameterDetail
IndicationCyanide poisoning (fire victims, industrial exposure, laetrile, nitroprusside toxicity)
Dose5 g IV over 15 minutes (preferred first-line)
Repeat dose5 g IV if no clinical response (max cumulative 10 g)
MechanismCobalt binds cyanide → forms cyanocobalamin (Vit B12) excreted renally
Side effectsTransient hypertension, tachycardia, red/pink discoloration of skin + urine (harmless); may interfere with pulse oximetry briefly
Alternative (if hydroxocobalamin unavailable)Step 1: Sodium nitrite 300 mg (10 mL of 3% solution) IV over 5-20 min; Step 2: Sodium thiosulfate 12.5 g IV (50 mL of 25% solution)
Combined CO + CNHydroxocobalamin preferred (sodium nitrite worsens CO poisoning)
Key lab clueLactate ≥8-10 mmol/L in correct context = cyanide until proven otherwise

6. FOMEPIZOLE (4-Methylpyrazole) - Methanol / Ethylene Glycol

ParameterDetail
IndicationMethanol or ethylene glycol poisoning
Loading dose15 mg/kg IV (infuse over 30 min)
Maintenance10 mg/kg IV q12h x 4 doses, then 15 mg/kg q12h (enzyme auto-induction occurs after 48h)
Stop whenToxic alcohol level <20 mg/dL AND metabolic acidosis resolved
During hemodialysisGive dose at start of HD; then q4h during HD; resume q12h after HD
MechanismCompetitive inhibitor of alcohol dehydrogenase (ADH) → blocks toxic metabolite formation
Vitamins (adjunct)Methanol: Folate/leucovorin 1 mg/kg (max 50 mg) IV q4-6h; EG: Thiamine 100 mg + Pyridoxine 50 mg IV
Hemodialysis indicated ifpH ≤7.15, coma, seizures, end-organ damage, very high levels

7. DIGOXIN-SPECIFIC FAB (Digibind / DigiFab) - Digoxin Toxicity

ParameterDetail
IndicationLife-threatening digoxin toxicity (VT, VF, complete heart block, severe hyperkalemia K+ >5.5 in acute OD)
Dose calculationMethod 1: Dose (vials) = [Serum digoxin level (ng/mL) × weight (kg)] ÷ 100
Method 2: Ingested dose (mg) × 0.8 ÷ 0.5 = number of vials
Unknown amount10 vials empirically (acute); 6 vials (chronic)
Onset20-30 min; complete response by 4-6h
RouteIV over 30 min (bolus if cardiac arrest)
After Fab givenTotal serum digoxin rises (bound Fab not active) - do not re-dose based on levels
CautionAvoid calcium for hyperkalemia (may precipitate refractory VF)

8. SODIUM BICARBONATE - Tricyclic Antidepressant (TCA) Poisoning

ParameterDetail
IndicationTCA poisoning with QRS >100 ms, ventricular arrhythmia, or refractory hypotension
Dose1-2 mEq/kg IV bolus (repeat until QRS narrows)
TargetSerum pH 7.45-7.55 (not >7.55)
Maintenance3 ampoules NaHCO3 in 1L D5W at 2x maintenance rate
MechanismRaises pH (reverses Na+ channel block) + increases Na+ gradient
ECG triggerQRS >100 ms = seizure risk; QRS >160 ms = VT risk; R-wave in aVR >3 mm
Lipid emulsion1.5 mL/kg 20% Intralipid bolus for refractory cases
AvoidPhysostigmine, flumazenil (can worsen seizures)

9. DEFEROXAMINE - Iron Poisoning

ParameterDetail
IndicationSerum iron >500 µg/dL; or toxic symptoms (shock, acidosis, altered consciousness)
Dose15 mg/kg/h IV continuous infusion
Max rate35 mg/kg/h (hypotension risk at faster rates)
DurationContinue until "vin rosé" (wine-rose) color urine returns to normal
End pointsResolution of symptoms + serum iron <350 µg/dL + normal urine
MechanismChelates free iron → ferrioxamine complex (renally excreted)
Urine colorOrange-rose ("vin rosé") = ferrioxamine being excreted

10. METHYLENE BLUE - Methemoglobinemia

ParameterDetail
IndicationSymptomatic methemoglobinemia >20-25%; or MetHb >30% even if asymptomatic
Dose1-2 mg/kg IV over 5 min (1-2% solution)
RepeatRepeat in 1h if no response (max cumulative 7 mg/kg)
MechanismActs as cofactor for NADPH to reduce MetHb back to functional Hb
CautionDo NOT use if G6PD deficiency (will cause hemolysis; use ascorbic acid instead)
ParadoxHigh doses of methylene blue itself can cause methemoglobinemia

11. PYRIDOXINE (Vitamin B6) - Isoniazid (INH) Poisoning

ParameterDetail
IndicationINH overdose (seizures unresponsive to benzodiazepines)
DoseGram-for-gram: mg of INH ingested = mg of pyridoxine to give IV
Unknown amount5 g IV (adults); 70 mg/kg (children)
RouteIV over 5-10 min; IM if IV unavailable
MechanismINH depletes pyridoxal phosphate (GABA synthesis cofactor) → refractory seizures
Key teachingBenzodiazepines alone fail in INH seizures - ALWAYS add pyridoxine

12. FLUMAZENIL - Benzodiazepine Poisoning

ParameterDetail
IndicationBenzodiazepine OD (diagnostic + reversal)
Dose0.2 mg IV over 30 sec; repeat 0.3 mg at 1 min; then 0.5 mg q1min up to 3 mg total
Duration30-60 min only (MUCH shorter than BZDs) - re-sedation common
ContraindicationsChronic BZD users (precipitates seizures); TCA co-ingestion; epilepsy; increased ICP
Do NOT use forMixed overdoses; unknown ingestions; seizure patients

13. GLUCAGON - Beta-Blocker Poisoning

ParameterDetail
IndicationBeta-blocker toxicity with bradycardia/hypotension unresponsive to atropine
Loading dose3-10 mg IV over 1-2 min
Infusion3-5 mg/h (adjust per response)
MechanismBypasses β-receptor → activates adenylyl cyclase via glucagon receptor → ↑ cAMP → positive inotrope/chronotrope
Side effectsNausea/vomiting (pretreat with antiemetics)
Also usefulCalcium channel blocker toxicity (adjunct)

14. HIGH-DOSE INSULIN (HDI) + Euglycemia Therapy

ParameterDetail
IndicationRefractory beta-blocker or calcium channel blocker toxicity
BolusRegular insulin 1 unit/kg IV + Dextrose 50% 50 mL (if glucose <400 mg/dL)
InfusionRegular insulin 0.5-2 units/kg/h + Dextrose 10% infusion (titrate to glucose 100-200 mg/dL)
MonitorBlood glucose q15-30min; potassium q1h
MechanismCarbohydrate metabolism in cardiac myocytes; positive inotropy independent of receptor

SECTION 2: CLINICAL CASES WITH FULL MANAGEMENT


CASE 1: PARACETAMOL (Acetaminophen) Overdose

Scenario:
A 24-year-old woman presents 5 hours after taking "a whole bottle of Tylenol" (approximately 15 g) after an argument. She appears well with mild nausea. Vitals: BP 118/76, HR 88, RR 16, Temp 37.1°C. Labs: Serum acetaminophen level = 280 µg/mL at 5 hours post-ingestion. LFTs normal. INR 1.0.
Step-by-step Management:
  1. Plot on Rumack-Matthew nomogram - 280 µg/mL at 5h = above treatment line → NAC indicated
  2. IV NAC immediately:
    • Bag 1: 150 mg/kg (9 g for 60 kg patient) in 200 mL D5W over 60 min
    • Bag 2: 50 mg/kg in 500 mL D5W over 4 hours
    • Bag 3: 100 mg/kg in 1000 mL D5W over 16 hours
  3. If anaphylactoid reaction (flushing, urticaria) during Bag 1: Stop infusion → diphenhydramine 50 mg IV → restart at slower rate
  4. Repeat LFTs, INR, creatinine at 24h
  5. Psychiatric evaluation before discharge
  6. Discharge criteria: LFTs normal, INR <2, NAC course complete, psychiatry clearance
Key Teaching Point: Do NOT wait for LFTs to rise. Treat based on the nomogram. NAC works best before hepatotoxicity begins.

CASE 2: ORGANOPHOSPHATE Poisoning

Scenario:
A 45-year-old farmer is brought in by family - found unconscious in his field. On exam: miosis, excessive salivation dripping from his mouth, wheezing, incontinence of urine and stool, HR 48, BP 80/50. Clothes smell of pesticide. Fasciculations noted in arms.
Step-by-step Management:
  1. Decontaminate FIRST - Remove all clothing (bag in biohazard), copious soap + water wash (staff use nitrile gloves - NOT latex)
  2. Airway - 100% O2, suction secretions; intubate early (succinylcholine AVOIDED - use rocuronium instead)
  3. Atropine (IMMEDIATELY):
    • Start: 3 mg IV
    • Double every 5 min → 6 mg → 12 mg → 24 mg...
    • Target: Chest clear on auscultation (may need 50-100+ mg)
    • This patient may need 200+ mg if massive ingestion
  4. Pralidoxime 2-PAM: 2 g IV over 15-30 min → 500 mg/h infusion (give ASAP - before aging)
  5. Benzodiazepines (if seizures): Diazepam 5-10 mg IV
  6. Fluids for hypotension
  7. Monitor: Cholinesterase levels, ECG, LFTs
Key Teaching Points:
  • Tachycardia is NOT a contraindication to atropine (reflects bronchospasm/hypoxia)
  • Pupil dilation is NOT the end point - dried secretions are
  • Do NOT use succinylcholine for intubation

CASE 3: OPIOID Overdose

Scenario:
A 32-year-old man found unresponsive in a public bathroom. Empty syringe nearby. RR 4/min, GCS 3, pupils pinpoint bilaterally, cyanotic. BP 90/60, HR 52.
Step-by-step Management:
  1. Jaw thrust, BVM ventilation with 100% O2 immediately
  2. Naloxone 0.4 mg IV - (Start low if opioid dependence suspected - precipitates withdrawal)
    • Response in 2 min → if no response → 0.4 mg q2-3 min up to 10 mg
    • This patient responds at 0.8 mg total (RR improves to 14, GCS improves)
  3. Caution: Effect wears off in 30-90 min - opioid will still be present
  4. Naloxone infusion: "Wake-up dose" was 0.8 mg → infusion = (2/3 × 0.8 mg) = 0.53 mg/h IV
  5. Observe minimum 4-6 hours after last naloxone dose (8h for long-acting opioids)
  6. Admit to monitored unit with infusion running
  7. Pulse oximetry and serial neuro checks
If fentanyl suspected: Higher naloxone doses (2-4 mg) may be needed initially
Key Teaching Point: Naloxone duration (30-90 min) is shorter than most opioids - never discharge after a single reversal without adequate observation. Calculate and run infusion for significant overdose.

CASE 4: CYANIDE Poisoning (Fire Victim)

Scenario:
A 38-year-old firefighter rescued from a burning warehouse (synthetic materials). GCS 8, BP 80/50, HR 130, RR 28, O2 sat 88% on room air. Lactate = 14 mmol/L. COHb = 15%.
Step-by-step Management:
  1. 100% O2 via non-rebreather mask (treats both CO and CN poisoning)
  2. Hydroxocobalamin 5 g IV over 15 minutes (preferred - safe with elevated COHb, unlike sodium nitrite)
  3. Repeat 5 g if no hemodynamic improvement after first dose (max 10 g)
  4. Sodium thiosulfate 12.5 g IV if available (adjunct - accelerates detox)
  5. Aggressive fluid resuscitation for shock
  6. Vasopressors (norepinephrine) if refractory hypotension
  7. Consider hyperbaric O2 if dual CO+CN and inadequate response to antidotes
  8. Do NOT give sodium nitrite when CO poisoning coexists (worsens hypoxia)
Key Teaching Point: High lactate in a fire victim despite apparent adequate O2 should trigger immediate empirical hydroxocobalamin - don't wait for cyanide levels.

CASE 5: METHANOL Poisoning

Scenario:
A 55-year-old homeless man presents with sudden severe visual blurring "like looking through a fog," and abdominal pain 12 hours after drinking from an unlabeled bottle. Visual acuity severely reduced. ABG: pH 7.12, HCO3 8 mEq/L. Anion gap = 28. Osmolar gap = 35.
Step-by-step Management:
  1. Secure IV access; ABG + electrolytes + osmolar gap + methanol level
  2. Fomepizole: 15 mg/kg IV over 30 min (IMMEDIATELY - do not wait for methanol level)
  3. Sodium bicarbonate 1-2 mEq/kg IV (temporize severe acidosis - pH 7.12 is life-threatening)
  4. Folate/Leucovorin 50 mg IV q4-6h (promotes formic acid metabolism → CO2 + H2O)
  5. Hemodialysis - URGENT in this patient (visual deficits = end-organ damage; pH ≤7.15; high levels):
    • Continue fomepizole every 4 hours DURING hemodialysis
    • HD removes methanol AND formic acid
  6. Monitor methanol level - stop fomepizole when <20 mg/dL + no acidosis
Visual outcome: With early treatment, vision may partially recover - ophthalmology consult immediately
Key Teaching Point: Both high anion gap + high osmolar gap together = toxic alcohol poisoning until proven otherwise. Treat empirically while awaiting levels.

CASE 6: TRICYCLIC ANTIDEPRESSANT (TCA) Overdose

Scenario:
A 19-year-old with depression took "all her amitriptyline pills" 2 hours ago. Initially drowsy, now GCS 7, HR 145, BP 80/50. ECG: QRS = 148 ms, right axis deviation, prominent R in aVR. Seizing on arrival.
Step-by-step Management:
  1. Airway first - intubate (GCS 7 + seizures); hyperventilate to pH 7.50-7.55 (this itself narrows QRS via alkalosis)
  2. Benzodiazepines for seizures: Lorazepam 2-4 mg IV
  3. Sodium bicarbonate - IMMEDIATELY for QRS >100 ms:
    • 1-2 mEq/kg IV bolus (50-100 mL of 8.4%)
    • Repeat until QRS narrows to <100 ms
    • Maintain pH 7.45-7.55 with infusion
  4. IV fluids (1-2 L NS) for hypotension; norepinephrine if refractory
  5. Monitor ECG continuously - watch for QRS widening, VT
  6. If refractory VT/arrest: 20% Intralipid (Lipid Emulsion) 1.5 mL/kg IV bolus
  7. Avoid: Flumazenil (can precipitate seizures), phenytoin (may worsen cardiac toxicity), physostigmine
Key Teaching Point: Terminal R-wave in aVR >3 mm or S wave in lead I is highly specific for TCA toxicity. Sodium bicarbonate is both the treatment for arrhythmia AND hypotension - give it early and generously.

CASE 7: SALICYLATE (Aspirin) Poisoning

Scenario:
A 65-year-old man presents confused and tachypneic after reportedly ingesting "a large amount of aspirin." Vitals: Temp 38.8°C, HR 118, RR 32. ABG: pH 7.48, pCO2 20 (low), HCO3 14 (low). Serum salicylate = 520 mg/L. Tinnitus reported by family.
Step-by-step Management:
  1. IV access, continuous monitoring
  2. Activated charcoal 50-100 g PO/NG (aspirin forms concretions in stomach - charcoal helps)
  3. Urinary alkalinization (key treatment):
    • 3 ampoules (150 mEq) NaHCO3 in 1L D5W + 40 mEq KCl
    • Run at 200-250 mL/h
    • Target: Urine pH ≥7.5-8.0 (ionizes salicylate in urine → ion trapping → enhanced excretion)
    • MUST replace potassium - hypokalemia prevents alkalinization
  4. Forced fluids with bicarb infusion (correct dehydration)
  5. Hemodialysis indications: Salicylate >700 mg/L, AMS, pulmonary edema, refractory acidosis, renal failure
  6. Do NOT intubate unnecessarily - loss of compensatory hyperventilation (respiratory alkalosis) can rapidly worsen acidosis
Key Teaching Point: Never intubate a salicylate patient without recognizing their respiratory drive is compensating. If intubated, match their pre-intubation minute ventilation (high RR + high TV) to prevent fatal acidosis.

CASE 8: DIGOXIN Toxicity

Scenario:
A 78-year-old woman on digoxin 0.25 mg/day for AF presents with vomiting, yellow-tinged vision, and palpitations. ECG: bidirectional ventricular tachycardia, HR 42, complete heart block. Digoxin level = 4.8 ng/mL, K+ = 6.1 mEq/L, Creatinine = 2.4 mg/dL.
Step-by-step Management:
  1. IV access; NPO; continuous telemetry
  2. Digibind dose calculation:
    • Vials = (4.8 ng/mL × 78 kg) ÷ 100 = 3.7 vials → round up to 4-6 vials (chronic toxicity: use 6 vials empirically)
  3. Administer Digibind IV over 30 min (bolus if cardiac arrest)
  4. Hyperkalemia management:
    • Sodium bicarbonate (K+ redistribution)
    • Calcium resonium/kayexalate orally
    • Do NOT give calcium chloride/gluconate (classically taught as risk of "stone heart" - ventricular fibrillation in hypercalcemia setting)
  5. Pacing (external/transvenous) for complete heart block unresponsive to Fab
  6. After Fab: Total serum digoxin level rises (now measures bound Fab-digoxin) - ignore levels
  7. Monitor potassium carefully (can fall after Fab given)
Key Teaching Point: Bidirectional VT = classic ECG of severe digoxin toxicity. Never cardiovert without Fab on board - risk of refractory VF. Fab normalizes K+ automatically.

CASE 9: BETA-BLOCKER Overdose

Scenario:
A 50-year-old man with hypertension takes all his metoprolol (approximately 2000 mg). He arrives drowsy, BP 70/40, HR 32, blood glucose 48 mg/dL (hypoglycemia from beta blockade).
Step-by-step Management:
  1. Dextrose 50% 50 mL IV for hypoglycemia (glucagon alone may cause vomiting without glycogen stores)
  2. Atropine 1 mg IV (often ineffective in beta-blocker OD but trial warranted)
  3. Glucagon 5 mg IV bolus over 1-2 min; then 3-5 mg/h infusion
    • Premedicate with ondansetron (glucagon causes emesis)
  4. Calcium chloride 1 g (10 mL of 10%) IV over 5-10 min (adjunct)
  5. If refractory (no improvement):
    • High-dose Insulin (HDI): 1 unit/kg regular insulin IV + 50 mL D50 bolus → insulin infusion 0.5-1 unit/kg/h + 10% dextrose
    • Monitor glucose q15 min + K+ q1h
  6. Lipid Emulsion (Intralipid): 1.5 mL/kg 20% IV bolus for refractory arrest (lipid-soluble beta-blockers: propranolol, labetalol)
  7. ECMO/mechanical support as last resort for refractory cardiogenic shock
Key Teaching Point: Beta-blocker OD causes hypoglycemia (unique to this class vs. CCBs which cause hyperglycemia). The order of treatment: atropine → glucagon → calcium → HDI → lipid → ECMO.

CASE 10: ISONIAZID (INH) Seizures

Scenario:
A 35-year-old TB patient presents with refractory generalized seizures after accidentally ingesting his entire month's supply of isoniazid. Three rounds of diazepam and lorazepam have failed. Persistent status epilepticus.
Step-by-step Management:
  1. Airway, breathing, circulation - intubate if needed
  2. Pyridoxine (Vitamin B6) IMMEDIATELY:
    • Unknown dose ingested → give 5 g IV (70 mg/kg in children) over 5-10 min
    • If amount known (e.g., 50 × 300 mg tablets = 15 g INH) → give 15 g pyridoxine gram-for-gram
  3. Concurrent benzodiazepines (continue alongside pyridoxine)
  4. Seizures typically stop within minutes of pyridoxine administration
  5. Monitor glucose (INH inhibits gluconeogenesis → hypoglycemia)
  6. Supportive care - LFTs (INH is hepatotoxic), monitor for lactic acidosis
Key Teaching Point: The single most important teaching point in INH poisoning: BZDs alone WILL FAIL. Pyridoxine is the definitive treatment. GABA synthesis requires pyridoxal phosphate as cofactor; INH depletes it.

CASE 11: CARBON MONOXIDE Poisoning

Scenario:
A family of four is brought in from their home after their gas heater malfunctioned in winter. Father (40): headache, confusion, COHb 35%. Mother (38): syncope, COHb 28%. Two children (8 and 10 years): nausea/headache, COHb 18%. Mother is 16 weeks pregnant.
Step-by-step Management:
For Father (COHb 35% + neurological symptoms):
  1. 100% O2 via tight-fitting non-rebreather mask immediately
  2. Hyperbaric O2 (HBO) indicated:
    • COHb >25% + neurological symptoms
    • Reduces CO half-life: Room air 5h → 100% O2 = 60-90 min → HBO 2.5 ATA = 20-30 min
  3. ECG (CO causes myocardial injury - troponin)
  4. Neurological assessment - "delayed neurological sequelae" can occur weeks later
For Mother (pregnant, COHb 28%):
  1. HBO therapy regardless of COHb level - fetus is more susceptible; fetal COHb clears more slowly
  2. HBO for ALL pregnant patients with CO poisoning regardless of severity
For Children (COHb 18% with symptoms):
  1. 100% O2 via pediatric NRB mask
  2. HBO threshold lower in children (more sensitive CNS)
Key Teaching Point: Pulse oximetry reads FALSELY NORMAL with CO poisoning - it cannot distinguish COHb from OxyHb. Only CO-oximetry (ABG co-oximeter) gives true values. Pregnancy = automatic HBO referral.

CASE 12: IRON Poisoning (Pediatric)

Scenario:
An 18-month-old (12 kg) is found with an empty children's chewable iron tablet bottle (50 tablets × 18 mg elemental iron = 900 mg). Currently vomiting blood and has bloody diarrhea 3 hours post-ingestion. BP 70/40 (shock). Serum iron = 620 µg/dL.
Step-by-step Management:
  1. Resuscitate: 20 mL/kg NS IV bolus; repeat as needed
  2. Deferoxamine immediately (serum iron >500 µg/dL + symptomatic shock):
    • 15 mg/kg/h IV (max 35 mg/kg/h)
    • = 15 × 12 kg = 180 mg/h for this child
  3. Monitor urine - "vin rosé" (orange-pink) color confirms ferrioxamine excretion; continue until urine clears
  4. Abdominal X-ray (iron tablets are radiopaque - confirm tablets present)
  5. Activated charcoal NOT effective for iron
  6. Gastric lavage within 1h if large ingestion still in stomach
  7. Watch for Phase 2 "honeymoon" period (apparent improvement 6-12h) - do NOT discharge, Phase 3 cardiovascular collapse follows
  8. LFTs, coagulation, glucose q4-6h
Key Teaching Point: Iron causes a classic 5-phase illness; the apparent improvement in Phase 2 is deceptive and dangerous. Serum iron >500 µg/dL = treat regardless of symptoms. Deferoxamine is mandatory.

SECTION 3: SPECIAL ANTIDOTE PROTOCOLS - QUICK REFERENCE CARD

┌─────────────────────────────────────────────────────────────────┐
│           CRITICAL ANTIDOTES - MEMORY CARD                      │
├────────────────┬────────────────────┬───────────────────────────┤
│ POISON         │ ANTIDOTE           │ KEY DOSE                  │
├────────────────┼────────────────────┼───────────────────────────┤
│ Paracetamol    │ NAC                │ 150 mg/kg IV load         │
│ Opioids        │ Naloxone           │ 0.4-2 mg IV; 2/3 rule    │
│ OP/Carbamate   │ Atropine + 2-PAM   │ Atropine: double q5min   │
│ Cyanide        │ Hydroxocobalamin   │ 5 g IV over 15 min        │
│ CO             │ 100% O2 / HBO      │ 2.5 ATA if neurological  │
│ Methanol/EG    │ Fomepizole         │ 15 mg/kg load; q12h      │
│ Digoxin        │ Digibind           │ Level × wt ÷ 100 = vials │
│ TCA            │ NaHCO3             │ 1-2 mEq/kg IV; pH 7.50   │
│ Iron           │ Deferoxamine       │ 15 mg/kg/h IV             │
│ Beta-blocker   │ Glucagon + HDI     │ 5 mg bolus; 1 u/kg ins   │
│ BZD            │ Flumazenil         │ 0.2 mg q1min up to 3 mg  │
│ INH            │ Pyridoxine B6      │ Gram for gram; 5 g if ?  │
│ MetHb          │ Methylene Blue     │ 1-2 mg/kg IV              │
│ Heavy metals   │ BAL / DMSA         │ BAL: 3-5 mg/kg IM q4h    │
│ Warfarin       │ Vit K + 4-factor   │ Vit K 10 mg IV slow      │
│ Heparin        │ Protamine          │ 1 mg per 100 units hep   │
│ Dabigatran     │ Idarucizumab       │ 5 g IV (2 × 2.5 g)       │
│ Rivaroxaban    │ Andexanet alfa     │ Weight/dose-based         │
│ Sulfonylurea   │ Octreotide         │ 50 µg SC/IV q6-12h        │
└────────────────┴────────────────────┴───────────────────────────┘

SECTION 4: MONITORING PARAMETERS AFTER ANTIDOTE ADMINISTRATION

AntidoteMonitorFrequency
NACLFTs, INR, creatinine, paracetamol levelAt 24h and 48h
NaloxoneRR, GCS, SpO2Continuous; q15 min
AtropineChest auscultation, HR, secretionsEvery 5 min during titration
HydroxocobalaminLactate, BP, skin/urine colorContinuous
FomepizoleMethanol/EG level, pH, osmolar gapq4-6h; during HD
DigibindECG, K+, digoxin level (after 6h)Continuous ECG; K+ q2h
NaHCO3 (TCA)QRS width, pH, K+Continuous ECG; q2h bloods
DeferoxamineUrine color, Fe level, LFTsUrine hourly; Fe q6h
HDI (BB/CCB)Glucose, K+, BPGlucose q15 min; K+ q1h
Methylene blueSpO2 (misleading), MetHb level, HbMetHb level at 1h

Sources: The Washington Manual of Medical Therapeutics | Tintinalli's Emergency Medicine: A Comprehensive Study Guide | Goldman-Cecil Medicine | Rosen's Emergency Medicine: Concepts and Clinical Practice | The Essentials of Forensic Medicine and Toxicology, 36th ed. (2026) | Goodman & Gilman's The Pharmacological Basis of Therapeutics

ICU DRUGS DILUTIONS MASTER GUIDE WITH CLINICAL CASE EXAMPLES COVERING ALL MEDICATION USED IN ICU

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
I have gathered sufficient data from authoritative ICU, anesthesia, and critical care textbooks. Now compiling the comprehensive master guide.---

💊 ICU DRUGS: MASTER DILUTIONS & ADMINISTRATION GUIDE WITH CLINICAL CASES

Sources: Goldman-Cecil Medicine | Barash Clinical Anesthesia, 9e | Miller's Anesthesia, 10e | Washington Manual of Medical Therapeutics | Tintinalli's Emergency Medicine | Goodman & Gilman's Pharmacology
Standard ICU Dilution Convention: Most ICU infusions follow the "Rule of 6" or are expressed as mcg/kg/min or mcg/min. All rates given assume a 70 kg adult unless stated. Always use an infusion pump. Central line preferred for vasopressors and concentrated solutions.

MODULE 1: VASOPRESSORS & INOTROPES

Standard Dilution Principle

Most vasopressors: dilute in Normal Saline (NS) or D5W. Concentration depends on fluid restriction needs. The standard "ready-to-use" concentration for most ICUs is given below.

1.1 NOREPINEPHRINE (Levophed) - First-Line Vasopressor

ParameterDetail
IndicationSeptic shock, distributive shock, hypotension (1st line per Surviving Sepsis Guidelines)
Available vial4 mg/4 mL (1 mg/mL)
Standard dilution4 mg (4 mL) in 250 mL NS = 16 mcg/mL
Concentrated dilution8 mg in 250 mL NS = 32 mcg/mL (fluid-restricted patients)
Dose range0.01-3 mcg/kg/min (usual effective: 0.1-0.5 mcg/kg/min)
Rate calculationRate (mL/h) = [Dose (mcg/kg/min) × Weight (kg) × 60] ÷ Concentration (mcg/mL)
Example (70 kg, 0.1 mcg/kg/min)[0.1 × 70 × 60] ÷ 16 = 26 mL/h
RouteCentral line required (peripheral only in emergency, max 12h)
TitrationIncrease by 0.05-0.1 mcg/kg/min every 5-10 min to target MAP ≥65 mmHg
Side effectsPeripheral vasoconstriction, ischemia, bradycardia reflex, arrhythmias
Receptor activityα1 > α2 > β1

1.2 EPINEPHRINE (Adrenaline)

ParameterDetail
IndicationRefractory shock, septic shock (add-on), anaphylaxis, cardiac arrest
Available vial1 mg/mL (1:1000) or 0.1 mg/mL (1:10,000)
Standard dilution4 mg in 250 mL NS = 16 mcg/mL
Dose range0.01-1 mcg/kg/min (ICU infusion); cardiac arrest: 1 mg IV q3-5 min
Example (70 kg, 0.1 mcg/kg/min)[0.1 × 70 × 60] ÷ 16 = 26 mL/h
Anaphylaxis bolus0.3-0.5 mg IM (thigh); IV 0.1 mg of 1:10,000 slowly if in arrest
Receptor activityβ1 = β2 > α1 (low dose) → α1 dominates (high dose)
Side effectsTachyarrhythmias, hyperglycemia, lactic acidosis (at high doses), myocardial ischemia

1.3 DOPAMINE

ParameterDetail
IndicationBradycardic hypotension; 2nd/3rd line in cardiogenic shock (now less preferred)
Available vial200 mg/5 mL (40 mg/mL)
Standard dilution400 mg in 250 mL NS = 1600 mcg/mL
Dose ranges (by receptor)
Low dose (dopaminergic)1-3 mcg/kg/min: renal/splanchnic vasodilation (not clinically proven to be renoprotective)
Medium dose (β1 dominant)3-10 mcg/kg/min: positive inotrope + chronotrope
High dose (α1 dominant)>10 mcg/kg/min: vasoconstriction
Example (70 kg, 5 mcg/kg/min)[5 × 70 × 60] ÷ 1600 = 13 mL/h
NoteMore arrhythmias than norepinephrine in septic shock - use with caution

1.4 VASOPRESSIN (ADH)

ParameterDetail
IndicationSeptic shock refractory to norepinephrine (2nd-line vasopressor); vasodilatory shock
Available vial20 units/mL
Standard dilution40 units in 250 mL NS = 0.16 units/mL
Fixed dose0.03-0.04 units/min (NOT titrated to effect - fixed dose)
Rate at 0.03 units/min[0.03 × 60] ÷ 0.16 = 11 mL/h
Maximum0.06 units/min (higher doses cause splanchnic/coronary ischemia)
MechanismV1 receptor → smooth muscle vasoconstriction (catecholamine-independent)
AdvantageConserves endogenous vasopressin depleted in prolonged septic shock
Side effectsHyponatremia, water retention, coronary ischemia at high doses, skin necrosis

1.5 PHENYLEPHRINE

ParameterDetail
IndicationHypotension with tachyarrhythmia (pure α1 = no increase in HR); intraoperative hypotension
Available vial10 mg/mL
Standard dilution100 mg in 250 mL NS = 400 mcg/mL
Dose range0.5-5 mcg/kg/min; bolus: 50-200 mcg IV
Example (70 kg, 1 mcg/kg/min)[1 × 70 × 60] ÷ 400 = 10.5 mL/h
Advantage over NENo tachycardia, safe in most arrhythmias
CautionReduces cardiac output (pure vasoconstriction increases afterload)

1.6 DOBUTAMINE (Inotrope)

ParameterDetail
IndicationCardiogenic shock, low-output states, acute decompensated heart failure
Available vial250 mg/20 mL (12.5 mg/mL)
Standard dilution500 mg in 250 mL NS = 2000 mcg/mL
Dose range2-20 mcg/kg/min
Example (70 kg, 5 mcg/kg/min)[5 × 70 × 60] ÷ 2000 = 10.5 mL/h
Receptorβ1 > β2 (inotrope + mild vasodilator)
Side effectsTachycardia, arrhythmias, hypotension (vasodilation), tolerance with prolonged use
NoteNOT a vasopressor - may drop BP if patient is already vasodilated

1.7 MILRINONE (Phosphodiesterase-3 Inhibitor)

ParameterDetail
IndicationLow cardiac output, cardiogenic shock, heart failure (when β-receptors downregulated)
Available vial10 mg/10 mL (1 mg/mL)
Standard dilution40 mg in 200 mL NS = 200 mcg/mL
Loading dose50 mcg/kg over 10 min (often omitted in hypotensive patients)
Maintenance0.375-0.75 mcg/kg/min
Example (70 kg, 0.5 mcg/kg/min)[0.5 × 70 × 60] ÷ 200 = 10.5 mL/h
MechanismInhibits PDE-3 → ↑cAMP → inotropy + vasodilation (bypasses β-receptor)
Renal adjustmentReduce dose in renal failure (renally cleared)
Side effectsHypotension, ventricular arrhythmias, thrombocytopenia

Vasopressor Comparison Table (Goldman-Cecil Medicine)

AgentDose Rangeα1β1β2DAPrimary Use
Norepinephrine0.01-3 mcg/kg/min4+2+00Septic shock (1st line)
Epinephrine0.01-1 mcg/kg/min4+4+4+0Anaphylaxis, refractory shock
Dopamine1-20 mcg/kg/min2+3+1+4+Bradycardic hypotension
Phenylephrine0.5-5 mcg/kg/min4+000Tachycardic hypotension
Vasopressin0.03-0.04 units/minV1000Adjunct septic shock
Dobutamine2-20 mcg/kg/min04+2+0Cardiogenic shock

MODULE 2: SEDATION & ANALGESIA (SAT/SBT Protocol)

SCCM PADIS Guidelines 2018: Target lightest effective sedation (RASS -1 to 0 for most patients). Analgesia-first approach. Daily SAT (Spontaneous Awakening Trial) + SBT (Spontaneous Breathing Trial).

2.1 PROPOFOL

ParameterDetail
IndicationICU sedation (1st line for mechanically ventilated patients), procedural sedation
Available10 mg/mL (1% lipid emulsion) or 20 mg/mL (2%)
Supplied ready to useNO dilution needed; use as supplied
Sedation dose5-50 mcg/kg/min (0.3-3 mg/kg/h)
Example (70 kg, 20 mcg/kg/min)20 × 70 × 60 ÷ 10,000 = 8.4 mL/h of 1% propofol
Induction (ICU rapid intubation)1-2 mg/kg IV
Caloric load1.1 kcal/mL (10% lipid) - account in nutrition!
TriglyceridesCheck q48-72h if on >48h
Max dose to avoid PRIS<4 mg/kg/h (67 mcg/kg/min) for <48h
PRIS (Propofol Infusion Syndrome)Metabolic acidosis + rhabdomyolysis + cardiac failure - STOP propofol
AdvantagesShort-acting, easy titration, reduces duration of MV vs. BZDs, anticonvulsant
DisadvantagesHypotension, myocardial depression, hypertriglyceridemia, PRIS, no analgesia, no amnesia at low doses

2.2 MIDAZOLAM (Benzodiazepine)

ParameterDetail
IndicationICU sedation (2nd line), alcohol withdrawal, seizure prophylaxis in ICU
Available vial5 mg/mL
Standard dilution50 mg in 50 mL NS = 1 mg/mL (or 100 mg in 100 mL = 1 mg/mL)
Sedation infusion0.02-0.1 mg/kg/h
Example (70 kg, 0.05 mg/kg/h)0.05 × 70 = 3.5 mL/h (at 1 mg/mL)
Bolus for acute agitation1-5 mg IV slow push
AccumulationActive metabolite (1-OH midazolam) accumulates in renal failure and obesity - prolonged awakening
AdvantagesAmnesia, anxiolysis, anticonvulsant, antiemetic, inexpensive, good for alcohol withdrawal
DisadvantagesLonger ICU stay vs. propofol, delirium risk, accumulation in renal/hepatic impairment

2.3 DEXMEDETOMIDINE (Precedex)

ParameterDetail
IndicationLight-to-moderate ICU sedation, post-extubation sedation, agitated delirium, alcohol/opioid withdrawal
Available vial200 mcg/2 mL (100 mcg/mL)
Standard dilution200 mcg in 48 mL NS = 4 mcg/mL (or 400 mcg in 100 mL = 4 mcg/mL)
Loading dose1 mcg/kg over 10 min (often omitted in hemodynamically unstable patients)
Maintenance0.2-0.7 mcg/kg/h (up to 1.5 mcg/kg/h)
Example (70 kg, 0.5 mcg/kg/h)0.5 × 70 ÷ 4 = 8.75 mL/h
Mechanismα2-agonist → sedation without respiratory depression; anxiolysis; some analgesia
Key advantagePatients arousable and cooperative; preserves respiratory drive; reduces delirium vs. BZDs
DisadvantagesBradycardia and hypotension (especially with loading dose); expensive; NOT for deep sedation/paralysis
DurationOnset 5-10 min; half-life ~2h; longer in hepatic impairment

2.4 KETAMINE (Dissociative Anesthetic / Analgesic)

ParameterDetail
IndicationAnalgesic adjunct in ICU, procedural sedation, bronchospasm, opioid-sparing
Available vial500 mg/10 mL (50 mg/mL)
Standard dilution for infusion500 mg in 500 mL NS = 1 mg/mL
Sub-anesthetic analgesic infusion1-2 mcg/kg/min (0.06-0.12 mg/kg/h) per Barash
Procedural sedation1-2 mg/kg IV (onset 60 sec, duration 10-15 min)
Induction/RSI1-2 mg/kg IV
MechanismNMDA receptor antagonist → dissociative analgesia + anesthesia
AdvantagesBronchodilator, maintains airway reflexes and hemodynamics, opioid-sparing, analgesia
DisadvantagesEmergence delirium, hallucinations (pretreat with midazolam 1-2 mg), raises ICP (controversial), increases secretions
Adjunct (midazolam)1-2 mg IV to prevent emergence phenomena

2.5 FENTANYL (ICU Analgesia - First Line)

ParameterDetail
IndicationICU analgesia (1st line), mechanically ventilated patients
Available vial50 mcg/mL (2 mL = 100 mcg, 5 mL = 250 mcg)
Standard dilution1000 mcg in 100 mL NS = 10 mcg/mL
Infusion dose25-200 mcg/h (0.5-2 mcg/kg/h)
Example (70 kg, 1 mcg/kg/h)1 × 70 ÷ 10 = 7 mL/h
Bolus (procedural)25-100 mcg IV slow push
AdvantagesFast onset (1-2 min IV), short duration, no histamine release, safe in renal failure
Preferred over morphineIn renal failure, hemodynamic instability, and bronchospasm
Side effectsRespiratory depression, constipation, tolerance, chest rigidity (at high rapid doses)

2.6 MORPHINE

ParameterDetail
IndicationICU analgesia, acute pulmonary edema (relieves dyspnea/preload), severe pain
Available vial10 mg/mL or 15 mg/mL
Standard dilution50 mg in 50 mL NS = 1 mg/mL
Infusion dose2-10 mg/h
Bolus2-4 mg IV q2-4h (titrate)
Side effectsHistamine release (avoid in asthma), hypotension, nausea
AVOID in renal failureActive metabolite morphine-6-glucuronide accumulates → respiratory depression

2.7 HYDROMORPHONE (Dilaudid)

ParameterDetail
IndicationICU analgesia; morphine-intolerant patients
Available vial2 mg/mL or 4 mg/mL
Standard dilution20 mg in 100 mL NS = 0.2 mg/mL
Infusion dose0.5-3 mg/h
Bolus0.2-0.6 mg IV q2-4h
Potency5-7x more potent than morphine
AdvantageLess histamine release, safer in mild renal impairment vs. morphine

2.8 LORAZEPAM (Ativan) - Benzodiazepine

ParameterDetail
IndicationSeizures, alcohol withdrawal (preferred), acute agitation, procedural
Available vial2 mg/mL or 4 mg/mL
Standard dilution40 mg in 100 mL NS = 0.4 mg/mL
Infusion dose1-10 mg/h
Bolus0.5-4 mg IV q2-4h
Status epilepticus0.1 mg/kg IV (max 4 mg per dose, repeat in 10 min)
Advantage over midazolamNo active metabolites, safer in renal failure
CautionProlonged infusion → propylene glycol accumulation (osmolar gap acidosis)

MODULE 3: NEUROMUSCULAR BLOCKING AGENTS (NMBAs)

Indications in ICU: Ventilator dyssynchrony, ARDS (protective ventilation), raised ICP, tetanus, status epilepticus, during therapeutic hypothermia. Use alongside adequate sedation + analgesia ALWAYS. Monitor with TOF (Train of Four - target 1-2 twitches).

3.1 CISATRACURIUM (Nimbex) - Preferred ICU NMBA

ParameterDetail
IndicationARDS requiring paralysis, refractory ventilator dyssynchrony
Available vial2 mg/mL (10 mL) or 5 mg/mL
Standard dilution200 mg in 200 mL NS = 1 mg/mL (or 100 mg in 100 mL = 1 mg/mL)
Loading dose0.15-0.2 mg/kg IV (over 5-10 sec)
Maintenance infusion0.5-10 mcg/kg/min (usually 1-3 mcg/kg/min)
Example (70 kg, 3 mcg/kg/min)[3 × 70 × 60] ÷ 1000 = 12.6 mL/h
MechanismHofmann elimination (non-enzymatic) + ester hydrolysis → no organ dependency
AdvantageSafe in hepatic AND renal failure (unique); no histamine release; no autonomic effects
MonitoringTOF 1-2 twitches of 4; stop daily for assessment (like SAT)

3.2 VECURONIUM

ParameterDetail
IndicationIntubation, short-term paralysis in ICU
Available vial10 mg powder (reconstitute with 10 mL = 1 mg/mL)
Standard dilution100 mg in 100 mL NS = 1 mg/mL
Loading dose0.1 mg/kg IV (intubation); 0.01 mg/kg (maintenance bolus)
Infusion0.8-1.2 mcg/kg/min
Example (70 kg, 1 mcg/kg/min)[1 × 70 × 60] ÷ 1000 = 4.2 mL/h
CautionAccumulates in hepatic/renal failure; active metabolite (3-desacetylvecuronium) accumulates → prolonged paralysis

3.3 ROCURONIUM (Zemuron)

ParameterDetail
IndicationRSI (when succinylcholine contraindicated), ICU paralysis
Available vial10 mg/mL (5 mL = 50 mg)
Standard dilution500 mg in 250 mL NS = 2 mg/mL
RSI dose1.2 mg/kg IV (onset ~60 sec at this dose)
Maintenance infusion10-12 mcg/kg/min
ReversalSugammadex 16 mg/kg IV for immediate reversal
Advantage over succinylcholineSafe in hyperkalemia, burns, denervation, crush injury

3.4 SUCCINYLCHOLINE

ParameterDetail
IndicationRSI (fastest onset - 45-60 sec)
Available vial20 mg/mL (200 mg/10 mL)
Dose1-1.5 mg/kg IV (intubation); 2 mg/kg (infants)
Duration5-10 min (ultra-short - depolarizing agent)
ABSOLUTE CONTRAINDICATIONSHyperkalemia, burns (>48h), spinal cord injury, crush injury, denervation, OP poisoning, myopathies
CautionRaises K+ by ~0.5 mEq/L; malignant hyperthermia trigger

MODULE 4: CARDIAC DRUGS IN ICU

4.1 AMIODARONE

ParameterDetail
IndicationVentricular arrhythmias (VT, VF), AF with hemodynamic compromise, refractory tachyarrhythmias
Available vial150 mg/3 mL (50 mg/mL)
Standard dilution900 mg in 500 mL D5W = 1.8 mg/mL
Loading dose (VT/VF arrest)300 mg IV push (from prefilled syringe); repeat 150 mg if needed
Loading dose (stable VT/AF)150 mg in 100 mL D5W over 10 min
Maintenance infusion1 mg/min x 6 hours, then 0.5 mg/min x 18 hours
Rate at 1 mg/min[1 × 60] ÷ 1.8 = 33 mL/h
Rate at 0.5 mg/min[0.5 × 60] ÷ 1.8 = 16.7 mL/h
24h max2.2 g/day
Oral loading200-400 mg TDS x 1 week, then 200 mg OD maintenance
Side effectsHypotension (infusion-related), bradycardia, phlebitis (peripheral IV), pulmonary toxicity (chronic), thyroid dysfunction, hepatotoxicity, corneal deposits
Use D5W onlyPrecipitates with NS at concentrations >2 mg/mL

4.2 ADENOSINE

ParameterDetail
IndicationParoxysmal SVT (diagnosis + termination); Wolff-Parkinson-White (if narrow complex)
Available6 mg/2 mL (3 mg/mL)
No dilution - IV push only
Dose6 mg rapid IV push → flush immediately with 20 mL NS; if no response in 1-2 min → 12 mg; repeat 12 mg once more
Half-life<10 seconds (enzymatically degraded by adenosine deaminase)
TechniqueMUST be given as rapid bolus into antecubital or larger vein + immediate flush
Side effectsTransient asystole (tell patient!), flushing, dyspnea, chest tightness (transient)
AVOID inAsthma (bronchospasm), 2nd/3rd degree heart block, WPW with AF (wide complex)
Theophylline interactionTheophylline blocks adenosine receptors → higher doses needed

4.3 METOPROLOL (IV)

ParameterDetail
IndicationRate control in AF/flutter, SVT, hypertensive urgency, NSTEMI
Available vial5 mg/5 mL (1 mg/mL)
IV dose5 mg IV over 5 min; repeat q5min x 3 (total 15 mg)
Oral transition25-100 mg PO BID (Metoprolol succinate XL)
Side effectsBradycardia, hypotension, bronchospasm (avoid in asthma)

4.4 DILTIAZEM (IV)

ParameterDetail
IndicationRate control in AF with preserved LV function
Available vial25 mg/5 mL (5 mg/mL)
Standard dilution125 mg in 125 mL NS = 1 mg/mL
Bolus dose0.25 mg/kg IV over 2 min (typical 20 mg); if no response: 0.35 mg/kg (25 mg)
Maintenance infusion5-15 mg/h
Example at 10 mg/h10 mL/h (at 1 mg/mL)
AVOID inSystolic HF (EF <40%), hypotension, pre-excitation syndromes, wide complex tachycardia

4.5 NICARDIPINE (IV) - Hypertensive Emergency

ParameterDetail
IndicationHypertensive emergency/urgency (preferred in neurological emergencies)
Available vial25 mg/250 mL premixed = 0.1 mg/mL
Standard dilution25 mg in 250 mL NS = 0.1 mg/mL
Initial dose5 mg/h
TitrationIncrease by 2.5 mg/h every 5-15 min
Maximum15 mg/h
Rate at 5 mg/h50 mL/h (at 0.1 mg/mL)
Side effectsHeadache, flushing, tachycardia, phlebitis

4.6 LABETALOL (IV) - Hypertensive Emergency

ParameterDetail
IndicationHypertensive emergency (especially post-stroke, aortic dissection, pre-eclampsia)
Available vial100 mg/20 mL (5 mg/mL)
Standard dilution200 mg in 200 mL NS = 1 mg/mL
Bolus20 mg IV over 2 min; repeat 40-80 mg q10min (max 300 mg total)
Infusion0.5-2 mg/min = 30-120 mL/h (at 1 mg/mL)
MechanismCombined α1 + β1 + β2 blockade (1:7 ratio)
AdvantageDoes not increase HR; safe in aortic dissection; first-line in stroke hypertension

4.7 SODIUM NITROPRUSSIDE

ParameterDetail
IndicationHypertensive emergency, acute aortic dissection, acute HF (afterload reduction)
Available vial50 mg/2 mL
Standard dilution50 mg in 250 mL D5W = 200 mcg/mL (protect from light with foil)
Dose range0.3-10 mcg/kg/min
Example (70 kg, 1 mcg/kg/min)[1 × 70 × 60] ÷ 200 = 21 mL/h
Maximum durationShort-term only (<72h at <3 mcg/kg/min) due to cyanide toxicity risk
Cyanide toxicityMonitor for lactic acidosis, altered mental status - treat with hydroxocobalamin
Light sensitiveWrap syringe and tubing in foil

4.8 NITROGLYCERIN (GTN IV)

ParameterDetail
IndicationAcute coronary syndromes, hypertensive emergency, acute pulmonary edema
Available50 mg/10 mL (5 mg/mL)
Standard dilution50 mg in 250 mL D5W = 200 mcg/mL (non-PVC tubing - adsorbs to PVC)
Dose range5-200 mcg/min
Example at 20 mcg/min[20 × 60] ÷ 200 = 6 mL/h
Side effectsHeadache, hypotension, reflex tachycardia, methemoglobinemia (high doses)
ToleranceDevelops within 24h of continuous infusion
Non-PVC tubing essentialStandard PVC tubing absorbs up to 80% of the drug

MODULE 5: ANTICOAGULATION IN ICU

5.1 UNFRACTIONATED HEPARIN (UFH) - Weight-Based Protocol

ParameterDetail
IndicationDVT/PE treatment, ACS, mechanical heart valves, VTE prophylaxis, CRRT
Available5000 units/mL or 25,000 units/500 mL = 50 units/mL
Standard dilution (infusion)25,000 units in 250 mL NS = 100 units/mL
VTE treatment loading dose80 units/kg IV bolus (max 5000 units for most)
VTE maintenance infusion18 units/kg/h → adjust per aPTT nomogram
Example (70 kg)Load: 5600 units; Maintenance start: 1260 units/h = 12.6 mL/h (at 100 units/mL)
Target aPTT60-100 seconds (1.5-2.5x normal) for therapeutic anticoagulation
aPTT Adjustment NomogramaPTT <40: Bolus 80 units/kg + ↑ rate 4 units/kg/h; aPTT 40-59: Bolus 40 units/kg + ↑ 2 units/kg/h; aPTT 60-100: No change; aPTT 101-120: ↓ 2 units/kg/h; aPTT >120: Hold 1h then ↓ 3 units/kg/h
VTE prophylaxis5000 units SC q8-12h (no infusion)
ReversalProtamine sulfate: 1 mg per 100 units heparin given in last 2h
HIT monitoringCheck platelets q2-3 days; if HIT suspected, STOP heparin → use argatroban or fondaparinux

5.2 ENOXAPARIN (Low Molecular Weight Heparin)

ParameterDetail
IndicationDVT/PE treatment and prophylaxis, ACS
VTE treatment1 mg/kg SC q12h OR 1.5 mg/kg SC q24h
Prophylaxis40 mg SC q24h (high-risk medical/surgical)
Renal impairmentCrCl <30 mL/min: 1 mg/kg SC q24h for treatment; 30 mg q24h for prophylaxis
MonitoringAnti-Xa level (peak 4h post-dose): therapeutic 0.6-1.0 IU/mL (q12h dosing)
ReversalProtamine sulfate 1 mg per 1 mg enoxaparin (partial reversal only - protamine doesn't fully reverse LMWH)
AVOID ifCrCl <15 mL/min (use UFH); morbid obesity (renal clearance altered - monitor anti-Xa)

5.3 ARGATROBAN (Direct Thrombin Inhibitor) - HIT Management

ParameterDetail
IndicationHeparin-induced thrombocytopenia (HIT), when heparin anticoagulation needed but HIT present
Available250 mg/2.5 mL (100 mg/mL)
Standard dilution250 mg in 250 mL NS = 1 mg/mL
Starting infusion2 mcg/kg/min (reduce to 0.5 mcg/kg/min in hepatic impairment)
Example (70 kg)2 × 70 = 140 mcg/min × 60 = 8400 mcg/h = 8.4 mL/h
Target aPTT1.5-3x baseline (45-100 sec)
Check aPTT2h after start, then adjust; check q2-4h until stable
Renal adjustmentNone required (hepatically metabolized)

MODULE 6: INSULIN INFUSION (Tight Glycemic Control)

ParameterDetail
IndicationICU hyperglycemia >180 mg/dL (10 mmol/L) - per SCCM/ADA guidelines
Target glucose140-180 mg/dL (7.8-10 mmol/L) for most ICU patients
AvailableRegular (soluble) insulin 100 units/mL
Standard dilution100 units Regular insulin in 100 mL NS = 1 unit/mL
Starting infusion0.5-1 unit/h; adjust per ICU insulin protocol (glucose-based algorithm)
Common algorithmGlucose 180-240: 1 unit/h; 241-300: 2 units/h; 301-360: 3 units/h; >360: 4 units/h
Bolus (acute correction)0.1 unit/kg IV for glucose >300 mg/dL unresponsive to infusion
Monitoring frequencyq1h until stable on protocol; q2h when stable for 4h; q4h when very stable
Hypoglycemia protocolGlucose <70: Stop infusion + D50% 25 mL IV; recheck in 15 min
Insulin requirement increases withSteroids, sepsis, TPN/EN, catecholamine infusions
NoteAvoid <110 mg/dL (Normoglycemia NOT beneficial - increases mortality per NICE-SUGAR trial)

MODULE 7: ELECTROLYTE REPLACEMENT INFUSIONS

7.1 POTASSIUM CHLORIDE (KCl)

ParameterDetail
IndicationHypokalemia (K+ <3.5 mEq/L)
Oral (preferred when tolerated)40-80 mEq PO for K+ 3.0-3.5; 80-120 mEq for K+ <3.0
IV concentration (peripheral)MAX 10 mEq/100 mL → max 10-20 mEq/h
IV concentration (central)MAX 20-40 mEq/100 mL → up to 40 mEq/h (with cardiac monitoring)
NEVER IV pushFatal arrhythmias/cardiac arrest
Continuous cardiac monitoringRequired for IV KCl infusion
RecheckSerum K+ 1-2h after each replacement; recheck Mg2+ (correct hypomagnesemia - refractory hypokalemia until Mg corrected)

7.2 MAGNESIUM SULFATE (MgSO4)

ParameterDetail
IndicationHypomagnesemia, Torsades de Pointes, eclampsia/pre-eclampsia, severe asthma
Available2 g/10 mL (20%) or 4 g/20 mL (20%)
Torsades de Pointes2 g IV over 1-2 min (bolus)
Eclampsia loading4 g IV over 20-30 min → maintenance 1-2 g/h
Hypomagnesemia2-4 g in 100 mL NS over 1h (peripheral) or 20 min (central)
Severe asthma2 g IV over 20 min
MonitoringUrine output, deep tendon reflexes (loss of DTR at 7-10 mEq/L), respiratory rate
Toxicity levelsLoss of DTR: 5-9 mg/dL; Respiratory arrest: 10-13 mg/dL; Cardiac arrest: >15 mg/dL
Antidote for toxicityCalcium gluconate 1 g IV over 3 min

7.3 CALCIUM GLUCONATE / CALCIUM CHLORIDE

ParameterDetail
IndicationHypocalcemia, hyperkalemia (cardiac protection), hypermagnesemia
Calcium gluconate1-3 g IV over 10-30 min (peripheral line safe) - provides 90 mg elemental Ca2+ per g
Calcium chloride1 g IV over 5-10 min (central line preferred - very vesicant) - provides 270 mg elemental Ca2+ per g (3x more potent)
Hyperkalemia (cardiac protection)Calcium gluconate 1-3 g IV over 2-5 min; onset 1-3 min, duration 30-60 min
Cardiac arrest (hypocalcemia)Calcium chloride 1 g IV push
CCB toxicityCalcium chloride 1-3 g IV over 5-10 min

7.4 SODIUM BICARBONATE

ParameterDetail
IndicationMetabolic acidosis, hyperkalemia (redistribution), TCA OD, urinary alkalinization
Available8.4% (1 mEq/mL), 50 mL ampoule = 50 mEq
Metabolic acidosisDose (mEq) = 0.3 × Weight (kg) × Base Deficit; give half over first 4-6h
Cardiac arrest1 mEq/kg IV; repeat 0.5 mEq/kg q10 min
TCA toxicity1-2 mEq/kg IV bolus; target pH 7.45-7.55
Hyperkalemia (temporary)50-100 mEq IV over 5-10 min (redistributes K+ into cells)

7.5 PHOSPHATE REPLACEMENT

ParameterDetail
IndicationHypophosphatemia (PO4 <1.5 mg/dL or symptomatic)
AvailableSodium phosphate 3 mmol/mL (15 mmol per 5 mL vial)
Mild (2.3-3.0 mg/dL)Oral phosphate supplements preferred
Moderate (1.5-2.3 mg/dL)0.16-0.32 mmol/kg IV over 4-6h (≈15 mmol in 250 mL NS)
Severe (<1.5 mg/dL)0.32-0.64 mmol/kg IV over 8-12h
Refeeding syndromeAggressive phosphate + K+ + Mg2+ replacement

MODULE 8: ANTIEPILEPTIC DRUGS (AEDs) IN ICU

8.1 PHENYTOIN / FOSPHENYTOIN

ParameterDetail
IndicationStatus epilepticus (2nd line after BZDs), seizure prophylaxis
Phenytoin dilutionOnly in NS (precipitates in dextrose); max 50 mg/min rate
Phenytoin loading dose15-20 mg/kg IV at max 50 mg/min (cardiac monitoring required)
Example (70 kg)1050-1400 mg at ≤50 mg/min = minimum 21-28 minutes
Maintenance5-7 mg/kg/day in divided doses q8h
Fosphenytoin loading15-20 mg PE/kg IV at max 150 mg PE/min (faster, safer, water-soluble)
Target serum levelTotal: 10-20 mcg/mL; Free: 1-2 mcg/mL
Side effectsCardiac (hypotension, arrhythmia - from rapid infusion), "purple glove" syndrome (phenytoin extravasation), nystagmus, ataxia

8.2 LEVETIRACETAM (Keppra)

ParameterDetail
IndicationSeizures, status epilepticus, prophylaxis (TBI, post-neurosurgery)
Available500 mg/5 mL (100 mg/mL)
Standard dilution1500 mg in 100 mL NS = 15 mg/mL
Loading dose20-60 mg/kg IV (max 4500 mg) over 15 min
Standard load1500-3000 mg IV over 15 min
Maintenance500-1500 mg IV/PO q12h
Renal adjustmentReduce dose if CrCl <50 mL/min
AdvantagesFewer drug interactions, no hepatic metabolism, safe in liver disease, no QT prolongation
Side effectsBehavioral disturbance (agitation, psychosis), somnolence

8.3 VALPROATE (Sodium Valproate)

ParameterDetail
IndicationStatus epilepticus (3rd line), generalized seizures, migraine
Available500 mg/5 mL (100 mg/mL)
Loading dose20-40 mg/kg IV over 10 min
Maintenance10-20 mg/kg/day divided q6-8h
AVOID inLiver disease, urea cycle disorders, pregnancy (teratogenic), mitochondrial disease
MonitorLFTs, ammonia, coagulation, platelets

MODULE 9: STRESS ULCER PROPHYLAXIS & GI DRUGS

9.1 PANTOPRAZOLE / OMEPRAZOLE (IV)

ParameterDetail
IndicationStress ulcer prophylaxis (MV >48h, coagulopathy), acute upper GI bleed
AvailablePantoprazole 40 mg/vial (reconstitute in 10 mL NS = 4 mg/mL)
ProphylaxisPantoprazole 40 mg IV q24h
GI bleed treatmentPantoprazole 80 mg IV bolus → 8 mg/h infusion for 72h
Standard dilution for infusion80 mg in 100 mL NS = 0.8 mg/mL; 8 mg/h = 10 mL/h

9.2 METOCLOPRAMIDE

ParameterDetail
IndicationGastric dysmotility, gastroparesis in ICU (promoting EN), nausea/vomiting
Dose10 mg IV q6-8h (slow IV over 3-5 min)
Side effectsExtrapyramidal reactions (acute dystonia, tardive dyskinesia with prolonged use), QT prolongation
Limit use<5 days to avoid tardive dyskinesia

MODULE 10: ANTIBIOTICS COMMON IN ICU (IV Dosing)

Note: Doses given for normal renal function (70 kg adult). Always adjust for renal/hepatic impairment and use PK/PD principles in ICU.
AntibioticStandard ICU DoseDilutionNotes
Piperacillin-Tazobactam4.5 g IV q6h (extended 4h infusion)4.5 g in 100 mL NSExtended infusion improves PK for time-dependent killing
Meropenem1-2 g IV q8h1g in 100 mL NS over 30 min (3h for resistant organisms)Carbapenem; reduce dose in renal failure
Vancomycin15-25 mg/kg IV q8-12h OR AUC-guided500-1000 mg in 250 mL NS over 60-90 minTarget AUC/MIC 400-600; TDM essential; red man syndrome if too fast
Linezolid600 mg IV q12hPremixed 2 mg/mL over 30-120 minMRSA alternative; MAO inhibitor - serotonin syndrome risk
Ceftriaxone1-2 g IV q12-24h1-2g in 100 mL NS over 30 minBiliary excretion
Metronidazole500 mg IV q8hPremixed 500 mg/100 mL over 30-60 minAnaerobes, C. diff
Ciprofloxacin400 mg IV q8-12h400 mg/200 mL premixed over 60 minQT prolongation risk
ColistinLoading 9 million IU → 4.5 MIU q12hDilute in 50-100 mL NSMDR gram-negative last resort; nephrotoxic
Fluconazole400-800 mg IV q24h (load 800 mg)Premixed 2 mg/mL over 60-120 minAzole; QT, drug interactions
Micafungin100-150 mg IV q24h150 mg in 100 mL NS over 60 minEchinocandin; 1st line invasive candidiasis
Amphotericin B (liposomal)3-5 mg/kg IV q24hIn D5W 1-2 mg/mL over 2hOnly in D5W; premedicate with antipyretics
Acyclovir (HSV encephalitis)10 mg/kg IV q8hDilute in NS to ≤7 mg/mL over 1hRenal toxicity - ensure hydration
Gentamicin (once-daily)5-7 mg/kg IV q24hIn 100 mL NS over 30-60 minHartford nomogram for dosing; TDM for trough <1
Daptomycin6-10 mg/kg IV q24hIn NS over 30 minMRSA bacteremia/endocarditis; check CPK weekly

MODULE 11: SPECIAL ICU INFUSIONS

11.1 OCTREOTIDE - Variceal Bleeding

ParameterDetail
IndicationAcute variceal bleeding, carcinoid crisis, sulfonylurea-induced hypoglycemia
Standard dilution500 mcg in 50 mL NS = 10 mcg/mL
Variceal bleed bolus50-100 mcg IV push
Maintenance infusion25-50 mcg/h × 72-120 hours
Rate at 25 mcg/h2.5 mL/h (at 10 mcg/mL)
Sulfonylurea OD50-100 mcg SC/IV q6-12h (prevents recurrent hypoglycemia)

11.2 N-ACETYLCYSTEINE (NAC) - Paracetamol OD

ParameterDetail
Bag 1 (Loading)150 mg/kg in 200 mL D5W over 60 min
Bag 250 mg/kg in 500 mL D5W over 4 hours
Bag 3100 mg/kg in 1000 mL D5W over 16 hours
Total300 mg/kg over 21 hours
CautionAnaphylactoid: slow infusion + antihistamine if reaction occurs

11.3 TERLIPRESSIN - Hepatorenal Syndrome / Variceal Bleeding

ParameterDetail
IndicationHepatorenal syndrome type 1, refractory variceal bleed
Dose (HRS)0.5-2 mg IV q4-6h (bolus)
Dose (variceal bleed)2 mg IV q4h, then 1 mg q4h if bleeding controlled
DurationUp to 14 days for HRS
Side effectsHyponatremia, ischemia (cardiac, splanchnic, peripheral)

11.4 DEXAMETHASONE (IV) - ICU Uses

ParameterDetail
IndicationBacterial meningitis (before 1st antibiotic dose), ARDS (COVID protocol), CINV prophylaxis, cord compression, severe community pneumonia
Bacterial meningitis0.15 mg/kg IV q6h × 4 days (start 15-20 min before 1st antibiotics)
ARDS / COVID6 mg IV/PO q24h × 10 days (RECOVERY trial)
Cerebral edema4-8 mg IV q6h
Anti-emetic4-8 mg IV once

MODULE 12: CLINICAL CASES - ICU DRUG MANAGEMENT


CASE 1: SEPTIC SHOCK - Vasopressor Escalation

Scenario:
A 62-year-old diabetic man admitted with community-acquired pneumonia (CURB-65 = 4). Despite 3L crystalloid, BP = 72/45 mmHg, MAP 54 mmHg, HR 126, SpO2 88%, RR 34, GCS 13. Lactate = 4.2 mmol/L. Temp 39.4°C. Intubated. Cultures drawn.
ICU Drug Management:
  1. Intubation drugs:
    • Ketamine 100 mg (1.5 mg/kg) IV for induction (preserves hemodynamics)
    • Rocuronium 100 mg (1.5 mg/kg) IV for RSI
    • Start propofol infusion 5-10 mcg/kg/min + fentanyl 50 mcg/h
  2. Vasopressor 1 - Norepinephrine (immediate start):
    • Dilution: 8 mg in 250 mL NS = 32 mcg/mL (concentrated - fluid restricted)
    • Start: 0.1 mcg/kg/min = [0.1 × 70 × 60] ÷ 32 = 13 mL/h
    • Titrate up by 0.05 mcg/kg/min every 5-10 min to MAP ≥65 mmHg
  3. Escalation - Vasopressin added (NE at 0.25 mcg/kg/min):
    • Dilution: 40 units in 250 mL NS = 0.16 units/mL
    • Fixed dose: 0.03 units/min = 11 mL/h (do not titrate)
  4. Antibiotics (within 1 hour):
    • Piperacillin-tazobactam 4.5 g IV q6h (extended 4h infusion) + Azithromycin 500 mg IV q24h
  5. Stress ulcer prophylaxis: Pantoprazole 40 mg IV q24h
  6. DVT prophylaxis: Enoxaparin 40 mg SC q24h (once bleeding risk assessed)
  7. Glycemic control: Insulin infusion targeting glucose 140-180 mg/dL
  8. Hydrocortisone (if NE >0.25 mcg/kg/min): 200 mg/day IV (50 mg q6h or 200 mg continuous)
Monitoring: MAP q15min, lactate q2h, CVP, urine output hourly (target >0.5 mL/kg/h)

CASE 2: ARDS - Sedation, Paralysis, Ventilator Management

Scenario:
A 45-year-old woman (70 kg) with influenza pneumonia, PaO2/FiO2 ratio = 80, bilateral infiltrates, no cardiac cause. Intubated. Severe ventilator dyssynchrony despite deep sedation. RASS -5 not achievable on propofol + fentanyl alone.
ICU Drug Management:
  1. Sedation optimized:
    • Propofol: 30 mcg/kg/min = [30 × 70 × 60] ÷ 10,000 = 12.6 mL/h of 1% propofol
    • Fentanyl: 100 mcg/h = 10 mL/h (at 10 mcg/mL)
  2. Neuromuscular blockade (NMBA - cisatracurium preferred):
    • Dilution: 200 mg in 200 mL NS = 1 mg/mL
    • Loading dose: 0.15 mg/kg = 10.5 mg IV push
    • Maintenance: 3 mcg/kg/min = [3 × 70 × 60] ÷ 1000 = 12.6 mL/h
    • Monitor TOF (Train of Four) - target 1-2 twitches
  3. ARDS ventilation settings: TV 6 mL/kg IBW, PEEP 12-16 cmH2O, plateau <30 cmH2O, FiO2 0.8
  4. Corticosteroids (severe ARDS):
    • Dexamethasone 6 mg IV q24h (RECOVERY protocol)
  5. Prone positioning: 16h prone daily while NMBA running
  6. Daily NMBA interruption assessment (like SAT): Check TOF - allow 4/4 before cognitive testing
  7. DVT prophylaxis: Enoxaparin 40 mg SC q24h (unless using CRRT - switch to UFH)
Duration of NMBA: Typically 24-48h for severe ARDS; reassess daily

CASE 3: CARDIOGENIC SHOCK - Inotrope + Vasopressor

Scenario:
A 68-year-old man post-anterior STEMI (door-to-balloon 90 min). BP 85/60, HR 105, cold clammy extremities, JVP elevated, bibasal crackles, SpO2 90%, cardiac output low on Swan-Ganz (CI 1.6 L/min/m2), PCWP 26 mmHg. Intubated for respiratory failure.
ICU Drug Management:
  1. Inotrope (dobutamine):
    • Dilution: 500 mg in 250 mL NS = 2000 mcg/mL
    • Start: 5 mcg/kg/min = [5 × 70 × 60] ÷ 2000 = 10.5 mL/h
    • Titrate to CI >2.2 L/min/m2 and UO improvement
  2. If BP still inadequate (MAP <65) - Add norepinephrine:
    • Dilution: 8 mg in 250 mL NS = 32 mcg/mL
    • Start: 0.05 mcg/kg/min → titrate
  3. Furosemide (diuresis for pulmonary edema):
    • 40-80 mg IV bolus; or furosemide infusion 5-20 mg/h if refractory
    • Dilution: 250 mg in 250 mL NS = 1 mg/mL; 10 mg/h = 10 mL/h
  4. Amiodarone (if ventricular arrhythmias develop):
    • 150 mg in 100 mL D5W over 10 min → then 900 mg in 500 mL D5W at 1 mg/min (33 mL/h) x 6h → 0.5 mg/min (16.7 mL/h) x 18h
  5. Anticoagulation: Heparin 60 units/kg bolus → 12 units/kg/h infusion (ACS protocol)
  6. Sedation (light - RASS -1 to 0):
    • Fentanyl 50-75 mcg/h + propofol 5-15 mcg/kg/min
Monitoring: Cardiac output q4h, MAP, urine output hourly, SVR, troponins

CASE 4: HYPERTENSIVE EMERGENCY (Malignant Hypertension)

Scenario:
A 55-year-old man with known hypertension presents with BP 220/130 mmHg, severe headache, blurred vision, papilledema, creatinine acutely risen to 3.2 mg/dL. ECG: LVH. No stroke on CT head.
ICU Drug Management:
  1. Nicardipine (first-line):
    • Dilution: 25 mg in 250 mL NS = 0.1 mg/mL
    • Start: 5 mg/h = 50 mL/h
    • Titrate by 2.5 mg/h every 5-15 min to target BP reduction
    • Target: Reduce MAP by ≤25% in first hour; then to 160/100 over 2-6h
  2. Alternative: Labetalol
    • 20 mg IV over 2 min; repeat 40-80 mg q10 min (max 300 mg)
    • OR infusion: 200 mg in 200 mL NS = 1 mg/mL at 1-2 mg/min
  3. If cerebral edema / hypertensive encephalopathy:
    • Mannitol 20%: 1 g/kg IV over 30 min
    • Elevate head of bed 30°
  4. Avoid nifedipine sublingual (unpredictable rapid drop → stroke/MI)
  5. Close BP monitoring: Arterial line; BP q5-15 min during titration

CASE 5: STATUS EPILEPTICUS - Stepwise ICU Protocol

Scenario:
A 30-year-old woman with known epilepsy, convulsing for 35 minutes without stopping (refractory status epilepticus). Now intubated. GCS 5 post-ictal.
ICU Drug Management (STEPWISE):
Phase 1 - Initial (0-5 min):
  • Lorazepam 4 mg IV over 2 min (or diazepam 10 mg IV)
  • Repeat once after 5 min if still seizing
Phase 2 - 2nd line (5-20 min - given if Phase 1 fails):
  • Levetiracetam 60 mg/kg IV (max 4500 mg) over 10-15 min
  • Dilution: 3000 mg in 100 mL NS, infuse over 10 min
  • OR Fosphenytoin 20 mg PE/kg at max 150 mg PE/min
  • OR Valproate 40 mg/kg IV over 10 min
Phase 3 - 3rd line / Refractory SE (>30-45 min):
  • Propofol infusion: Start 1-2 mg/kg IV bolus → 5-10 mg/kg/h infusion (titrate to burst suppression on EEG)
  • OR Midazolam: 0.2 mg/kg IV bolus → 0.05-0.4 mg/kg/h infusion
  • OR Thiopental/pentobarbital (for super-refractory SE)
Alongside all phases:
  • Thiamine 100 mg IV (before any dextrose)
  • Glucose 50% 50 mL IV (if hypoglycemia)
  • Continuous EEG monitoring
  • Correct precipitants (electrolytes, drug levels, infection)
  • Levetiracetam 1500 mg IV q12h as maintenance

CASE 6: ICU AF with Rapid Ventricular Response

Scenario:
Post-operative day 1 after aortic valve replacement. Patient develops rapid AF at HR 148, BP 100/65, SpO2 94%. Echo shows preserved EF 55%. No pre-excitation.
ICU Drug Management:
  1. Amiodarone (preferred in post-cardiac surgery):
    • Loading: 150 mg in 100 mL D5W over 10 min (15 mL/h rapid)
    • Maintenance: 900 mg in 500 mL D5W = 1.8 mg/mL
    • 1 mg/min × 6h = 33 mL/h → then 0.5 mg/min × 18h = 16.7 mL/h
  2. If hemodynamically unstable (BP <90): Synchronized DC cardioversion 120-200J immediately
  3. Electrolyte correction:
    • KCl: Target K+ >4.0 mEq/L (post-cardiac surgery); give IV KCl 20 mEq over 2h via central line
    • MgSO4: 2 g IV over 30 min (Mg+ >2.0 mEq/L)
  4. Rate control (if cardioversion not planned, EF preserved):
    • Diltiazem: 0.25 mg/kg (15-20 mg) IV over 2 min → if rate >110: 0.35 mg/kg → then 5-15 mg/h infusion
  5. Anticoagulation: Heparin infusion (therapeutic) if AF >48h; timing per surgical bleeding risk

CASE 7: DIABETIC KETOACIDOSIS (DKA) in ICU

Scenario:
A 22-year-old with Type 1 DM, vomiting for 2 days. Glucose 520 mg/dL, pH 7.05, HCO3 8 mEq/L, K+ 3.2 mEq/L, anion gap 32, urine ketones 4+, BP 90/60 (dehydrated), HR 128. Intubated for GCS 8.
ICU Drug Management:
  1. IV Fluid resuscitation:
    • Normal saline 1L over first hour → 0.9% NS at 500 mL/h for 4h → switch to 0.45% NS with KCl when glucose <250
  2. Potassium replacement BEFORE insulin:
    • K+ = 3.2 mEq/L → replace first: 40 mEq KCl in 1000 mL NS over 4h (central line)
    • Start insulin only when K+ ≥3.5 mEq/L
  3. Insulin infusion:
    • Dilution: 100 units Regular insulin in 100 mL NS = 1 unit/mL
    • Start: 0.1 unit/kg/h = 7 units/h = 7 mL/h
    • When glucose <250: Switch to D5W + reduce insulin to 0.05 unit/kg/h; add dextrose to maintain glucose 150-200 mg/dL until anion gap closed
  4. Potassium replacement ongoing:
    • Check K+ q1-2h; replace 10-40 mEq/h to keep K+ ≥3.5-5.0
  5. Bicarbonate: Only if pH <6.9: 50 mEq NaHCO3 in 200 mL NS over 1h (avoid routinely - worsens hypokalemia)
  6. Phosphate: Replace if PO4 <1.0 mg/dL (common in DKA)
Resolution criteria: Glucose <200 AND bicarbonate ≥15 mEq/L AND pH >7.3 AND anion gap closed

QUICK DRUG REFERENCE: DILUTION SUMMARY CARD

╔══════════════════╦═══════════════════════════╦════════════════════╗
║ DRUG             ║ STANDARD DILUTION         ║ CONCENTRATION      ║
╠══════════════════╬═══════════════════════════╬════════════════════╣
║ Norepinephrine   ║ 4 mg in 250 mL NS         ║ 16 mcg/mL          ║
║ Epinephrine      ║ 4 mg in 250 mL NS         ║ 16 mcg/mL          ║
║ Dopamine         ║ 400 mg in 250 mL NS       ║ 1600 mcg/mL        ║
║ Vasopressin      ║ 40 units in 250 mL NS     ║ 0.16 units/mL      ║
║ Phenylephrine    ║ 100 mg in 250 mL NS       ║ 400 mcg/mL         ║
║ Dobutamine       ║ 500 mg in 250 mL NS       ║ 2000 mcg/mL        ║
║ Milrinone        ║ 40 mg in 200 mL NS        ║ 200 mcg/mL         ║
╠══════════════════╬═══════════════════════════╬════════════════════╣
║ Propofol 1%      ║ Ready to use              ║ 10 mg/mL           ║
║ Midazolam        ║ 50 mg in 50 mL NS         ║ 1 mg/mL            ║
║ Dexmedetomidine  ║ 200 mcg in 48 mL NS       ║ 4 mcg/mL           ║
║ Ketamine         ║ 500 mg in 500 mL NS       ║ 1 mg/mL            ║
║ Fentanyl         ║ 1000 mcg in 100 mL NS     ║ 10 mcg/mL          ║
║ Morphine         ║ 50 mg in 50 mL NS         ║ 1 mg/mL            ║
║ Lorazepam        ║ 40 mg in 100 mL NS        ║ 0.4 mg/mL          ║
╠══════════════════╬═══════════════════════════╬════════════════════╣
║ Cisatracurium    ║ 200 mg in 200 mL NS       ║ 1 mg/mL            ║
║ Vecuronium       ║ 100 mg in 100 mL NS       ║ 1 mg/mL            ║
╠══════════════════╬═══════════════════════════╬════════════════════╣
║ Amiodarone       ║ 900 mg in 500 mL D5W      ║ 1.8 mg/mL          ║
║ Diltiazem        ║ 125 mg in 125 mL NS       ║ 1 mg/mL            ║
║ Nicardipine      ║ 25 mg in 250 mL NS        ║ 0.1 mg/mL          ║
║ Labetalol        ║ 200 mg in 200 mL NS       ║ 1 mg/mL            ║
║ Nitroprusside    ║ 50 mg in 250 mL D5W       ║ 200 mcg/mL         ║
║ GTN              ║ 50 mg in 250 mL D5W       ║ 200 mcg/mL         ║
╠══════════════════╬═══════════════════════════╬════════════════════╣
║ Heparin UFH      ║ 25,000 units in 250 mL NS ║ 100 units/mL       ║
║ Argatroban       ║ 250 mg in 250 mL NS       ║ 1 mg/mL            ║
║ Insulin (Regular)║ 100 units in 100 mL NS    ║ 1 unit/mL          ║
╠══════════════════╬═══════════════════════════╬════════════════════╣
║ MgSO4 (eclampsia)║ 4 g in 100 mL NS          ║ 40 mg/mL           ║
║ KCl              ║ 40 mEq in 1000 mL NS      ║ 40 mEq/L           ║
║ NaHCO3 8.4%      ║ Ready to use              ║ 1 mEq/mL           ║
╠══════════════════╬═══════════════════════════╬════════════════════╣
║ Octreotide       ║ 500 mcg in 50 mL NS       ║ 10 mcg/mL          ║
║ Pantoprazole     ║ 80 mg in 100 mL NS        ║ 0.8 mg/mL          ║
╚══════════════════╩═══════════════════════════╩════════════════════╝

UNIVERSAL RATE CALCULATION FORMULA

┌─────────────────────────────────────────────────────────────┐
│         INFUSION RATE (mL/h) =                              │
│                                                             │
│   Dose (mcg/kg/min) × Weight (kg) × 60 min/h               │
│   ─────────────────────────────────────────────             │
│          Concentration (mcg/mL)                             │
│                                                             │
│   OR for non-weight-based drugs:                            │
│                                                             │
│   Dose (mg/h or mcg/min × 60) ÷ Concentration (mg/mL)      │
└─────────────────────────────────────────────────────────────┘
Example: Norepinephrine 0.1 mcg/kg/min, 70 kg patient, 16 mcg/mL concentration = (0.1 × 70 × 60) ÷ 16 = 26.25 mL/h

CRITICAL SAFETY RULES IN ICU DRUG PREPARATION

RuleDetails
AmiodaroneD5W only (not NS at >2 mg/mL); protect from light
GTN / NitroprussideNon-PVC tubing mandatory; protect nitroprusside from light
KClNEVER IV push; max 40 mEq/h via central line with cardiac monitoring
PotassiumAlways correct Mg2+ simultaneously - refractory hypokalemia until Mg replaced
PropofolCheck triglycerides q48-72h; account for lipid calories; change tubing q12h
VancomycinInfuse over minimum 60 min (red man syndrome); AUC-guided dosing
CisatracuriumNEVER without adequate sedation + analgesia + TOF monitoring
SuccinylcholineCheck for hyperkalemia risk before use
Insulin infusionGlucose and K+ monitoring q1h minimum initially
VasopressorsCentral line preferred; if peripheral, check site q1-2h for extravasation
FentanylDo not mix with other drugs; separate line preferred

Sources: Goldman-Cecil Medicine International Edition | Barash, Cullen and Stoelting's Clinical Anesthesia, 9e | Miller's Anesthesia, 10e | Washington Manual of Medical Therapeutics | Tintinalli's Emergency Medicine | Goodman & Gilman's Pharmacological Basis of Therapeutics

Post-mortem report in proper full format for death due to Electric shock,drowning,hanging,RTA,CARDIAC ARREST,POISONING and other common modes of deaths for FMT MEDICAL OFFICER For medico legal cases with different common forms used in medico

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
I have sufficient foundational data from the Essentials of Forensic Medicine & Toxicology (36th ed., 2026) and Parikh's Textbook. Now I'll compile the comprehensive post-mortem report templates.Here is the complete master guide:

⚕️ POST-MORTEM EXAMINATION REPORT

Master Guide for Forensic Medical Officers — Medico-Legal Cases

Sources: The Essentials of Forensic Medicine & Toxicology, 36th ed. (2026) | Parikh's Textbook of Medical Jurisprudence, Forensic Medicine & Toxicology | PC Dikshit's Textbook of Forensic Medicine & Toxicology

PART A: STANDARD FORMS & LEGAL FRAMEWORK


FORM 1: REQUISITION / INQUEST ORDER (Police Form)

┌─────────────────────────────────────────────────────────────────────────┐
│           INQUEST PANCHNAMA / REQUISITION FOR POST-MORTEM               │
│                    (Under Sec. 174 / 176 Cr.P.C.)                       │
│                 [Now under BNSS 2023 - Sec. 194 / 195]                  │
├─────────────────────────────────────────────────────────────────────────┤
│ To,                                                                     │
│ The Medical Officer / Forensic Medicine Department,                     │
│ _________________________ Hospital / Medical College                    │
│                                                                         │
│ Sir,                                                                    │
│ You are hereby requested to conduct the Post-Mortem Examination of      │
│ the dead body described below and furnish a report regarding the        │
│ cause of death.                                                         │
│                                                                         │
│ CR No. / Station Diary No.: _______________________                     │
│ Under Section: _____________________ IPC / BNS                         │
│                                                                         │
│ DETAILS OF THE DECEASED:                                                │
│ Name: _______________________________ Age: _____ Sex: __________        │
│ Address: ___________________________________________________            │
│ Religion: __________________ Occupation: ___________________            │
│                                                                         │
│ CIRCUMSTANCES:                                                          │
│ Date & Time of Alleged Death: ______________________________            │
│ Date & Time Body Found: ____________________________________            │
│ Place of Death/Found: ______________________________________            │
│ Circumstances as Reported: _________________________________            │
│ ____________________________________________________________            │
│                                                                         │
│ Body identified by: ________________________ (Name & relation)          │
│                                                                         │
│ Seal of body: Intact / Broken                                           │
│ Labels: Present / Absent                                                │
│                                                                         │
│ Inquest conducted by:                                                   │
│ Name: _________________________ Designation: ___________________        │
│ Station: ________________ District: ___________________________         │
│                                                                         │
│ Date: __________________ Signature: ___________________________         │
└─────────────────────────────────────────────────────────────────────────┘

FORM 2: STANDARD POST-MORTEM EXAMINATION REPORT

┌─────────────────────────────────────────────────────────────────────────┐
│              POST-MORTEM EXAMINATION REPORT                             │
│          (Medico-Legal Case - Government of India)                      │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: _____________ Date: _____________ Time: _____________    │
│ Hospital/Institution: __________________________________________        │
│ Department of Forensic Medicine & Toxicology                            │
├─────────────────────────────────────────────────────────────────────────┤
│ SECTION I: IDENTIFICATION DATA                                          │
│                                                                         │
│ Name of Deceased: ___________________________ Age: ____ Sex: ______     │
│ Religion: _______________ Occupation: ____________________________      │
│ Address: _______________________________________________________        │
│ Name of Relative/Identifier: _______________________________            │
│ Relation: __________________                                            │
│                                                                         │
│ Requisition from: ______________ No.: _________ Date: _________         │
│ Police Station: ________________ District: ____________________         │
│ CR/FIR No.: _________________ Under Section: __________________         │
├─────────────────────────────────────────────────────────────────────────┤
│ SECTION II: BODY DETAILS ON ARRIVAL                                     │
│                                                                         │
│ Body received on: ____________ Time: ____________                       │
│ Examination started: _________ Time: ____________                       │
│ Examination completed: _______ Time: ____________                       │
│                                                                         │
│ Body wrapped in: ___________ Seals: Intact / Broken                     │
│ Labels: Present / Absent                                                │
│ Accompanied by: ___________________________________________              │
├─────────────────────────────────────────────────────────────────────────┤
│ SECTION III: EXTERNAL EXAMINATION                                       │
│                                                                         │
│ A. Build: Well-nourished / Average / Thin / Obese / Emaciated           │
│ B. Nutrition: Good / Moderate / Poor                                    │
│ C. Height: _______ cm  Weight: _______ kg                               │
│                                                                         │
│ POSTMORTEM CHANGES:                                                     │
│ 1. Postmortem Lividity (Livor Mortis):                                  │
│    Distribution: ________________________                               │
│    Color: _______________________________                               │
│    Fixed / Shifting: ____________________                               │
│    Estimated PMI: _______________________                               │
│                                                                         │
│ 2. Rigor Mortis:                                                        │
│    Present / Absent / Partially resolved                                │
│    Distribution: ________________________                               │
│    Estimated PMI: _______________________                               │
│                                                                         │
│ 3. Decomposition:                                                       │
│    Absent / Early / Advanced                                            │
│    Features: ____________________________                               │
│                                                                         │
│ EXTERNAL INJURIES (describe each with location, size, nature):          │
│ 1. ____________________________________________________________          │
│ 2. ____________________________________________________________          │
│ 3. ____________________________________________________________          │
│ (Attach injury diagram if needed)                                       │
│                                                                         │
│ EYES:                                                                   │
│    Cornea: Clear / Opaque  Conjunctiva: Pale / Congested / Petechiae    │
│    Pupils: Dilated / Constricted / Equal / Unequal                      │
│    Size R: _____ mm  L: _____ mm                                        │
│                                                                         │
│ FACE: Cyanosed / Pale / Congested / Normal                              │
│                                                                         │
│ MOUTH/LIPS:                                                             │
│    Color: ____________  Froth: Present / Absent                         │
│    Teeth: Complete / Missing _______ Bite marks: ___________            │
│    Tongue: Bitten / Not bitten  Protruding / Not protruding             │
│                                                                         │
│ NECK:                                                                   │
│    Ligature mark: Present / Absent                                      │
│    If present: Position / Direction / Width / Depth / Character         │
│    ___________________________________________________________           │
│                                                                         │
│ CHEST: Symmetrical / Asymmetrical                                       │
│                                                                         │
│ ABDOMEN: Distended / Normal / Scaphoid                                  │
│                                                                         │
│ GENITALIA: Normal / Abnormal ___________                                │
│ Evidence of sexual assault: Yes / No                                    │
│                                                                         │
│ LOWER LIMBS / UPPER LIMBS:                                              │
│    Venepuncture marks: ________                                         │
│    Other marks: _______________                                         │
│                                                                         │
│ CLOTHING:                                                               │
│    Description: ___________________________________________              │
│    Condition: Intact / Torn / Stained / Absent                          │
│    Staining: Blood / Mud / Soot / Others: ________________              │
├─────────────────────────────────────────────────────────────────────────┤
│ SECTION IV: INTERNAL EXAMINATION                                        │
│                                                                         │
│ SCALP: ____________________________________________________              │
│ SKULL: Fracture: Yes / No  Site: ___________________________            │
│ BRAIN:                                                                  │
│    Weight: _______ g  (Normal: 1200-1450 g)                             │
│    Cerebral edema: Present / Absent                                     │
│    Contusions: ____________  Lacerations: _________________             │
│    Epidural/Subdural/Subarachnoid hemorrhage: _______________           │
│    Petechiae: _______________                                           │
│    Gyri: Flattened / Normal  Herniations: ____________________          │
│                                                                         │
│ NECK DISSECTION:                                                        │
│    Hyoid bone: Intact / Fractured  Site: ___________________            │
│    Thyroid cartilage: Intact / Fractured                                │
│    Cricoid: Intact / Fractured                                          │
│    Larynx: Congested / Edematous / Normal                               │
│    Trachea: _______________________________________________              │
│    Carotid arteries: ______________________________________              │
│    Neck muscles: __________________________________________              │
│    Cervical vertebrae: ____________________________________              │
│    Spinal cord: ____________________________________________             │
│                                                                         │
│ CHEST CAVITY:                                                           │
│    Pleural cavity: Fluid: _____ mL (R) / _____ mL (L)                  │
│    Pneumothorax: Present / Absent                                       │
│    Ribs: Fractures at: _____________________________________             │
│    Sternum: _______________________________________________              │
│                                                                         │
│ HEART:                                                                  │
│    Weight: _______ g  (Normal: 250-350 g)                               │
│    Pericardium: Intact / Hemopericardium _____ mL                       │
│    Chambers: Dilated / Normal  Right / Left                             │
│    Coronary arteries: ______________________________________             │
│    Myocardium: Pale / Normal / Hemorrhagic                              │
│    Valves: Normal / Diseased: __________________________                │
│    Aorta: ___________________________________________________            │
│                                                                         │
│ LUNGS:                                                                  │
│    Weight: R: _______ g  L: _______ g  (Normal: ~400 g each)           │
│    Color: ____________  Consistency: _______________                    │
│    Crepitations: Present / Absent                                       │
│    Cut surface: ___________________________________________              │
│    Froth: Present / Absent  Blood-stained: Yes / No                     │
│    Petechiae (Tardieu spots): Present / Absent                          │
│    Pulmonary edema: Present / Absent                                    │
│    Consolidation: ________  Emphysema: ____________________             │
│                                                                         │
│ ABDOMEN:                                                                │
│    Peritoneum: _____________________________________________             │
│    Free fluid: _______ mL  Nature: _______________________              │
│    Bowel: ___________________________________________________            │
│                                                                         │
│ LIVER:                                                                  │
│    Weight: _______ g  (Normal: 1400-1600 g)                             │
│    Color/Texture: ___________________________________________            │
│    Congestion: ____________  Necrosis: ____________________              │
│                                                                         │
│ SPLEEN:                                                                 │
│    Weight: _______ g  (Normal: 150-200 g)                               │
│    Congestion: ____________                                             │
│                                                                         │
│ KIDNEYS: (each)                                                         │
│    Weight: R: _____ g  L: _____ g  (Normal: 120-160 g each)            │
│    Cortex: ___________________________________________________           │
│                                                                         │
│ STOMACH:                                                                │
│    Contents: ________________________________________________            │
│    Volume: ________ mL  Nature: ____________________________            │
│    Mucosa: Congested / Hemorrhagic / Normal                             │
│                                                                         │
│ SMALL INTESTINE / LARGE INTESTINE: ___________________________          │
│                                                                         │
│ URINARY BLADDER: ___________________________________________             │
│    Contents: _________ mL                                              │
│    Urine: Normal / Abnormal _______________                             │
│                                                                         │
│ UTERUS / OVARIES / TESTES (if applicable): ___________________          │
│                                                                         │
│ ADRENALS: ___________________________________________________            │
│                                                                         │
│ VERTEBRAL COLUMN / SPINAL CORD: ____________________________            │
├─────────────────────────────────────────────────────────────────────────┤
│ SECTION V: SAMPLES PRESERVED                                            │
│                                                                         │
│ For Chemical Analysis / Histopathology:                                 │
│ 1. Stomach + contents: Yes / No                                         │
│ 2. Small intestine (30 cm): Yes / No                                    │
│ 3. Liver (500 g): Yes / No                                              │
│ 4. Kidney (one whole): Yes / No                                         │
│ 5. Blood (50-100 mL in sealed container): Yes / No                      │
│ 6. Urine: Yes / No                                                      │
│ 7. Bile: Yes / No                                                       │
│ 8. Vitreous humor: Yes / No                                             │
│ 9. Brain tissue: Yes / No                                               │
│ 10. Lung tissue: Yes / No                                               │
│ 11. Fingernail clippings: Yes / No                                      │
│ 12. Hair (root included): Yes / No                                      │
│ 13. Bone (if chronic poisoning suspected): Yes / No                     │
│ 14. Swabs (if sexual assault): Yes / No                                 │
│ 15. Histopathology sections: Yes / No                                   │
│                                                                         │
│ Preserved in: Saturated NaCl solution / Rectified spirit / No           │
│ preservative (for alcohol analysis)                                     │
│                                                                         │
│ Sent to: FSL / Chemical Examiner on: ___________                        │
│ Reference No.: ______________________________________________            │
├─────────────────────────────────────────────────────────────────────────┤
│ SECTION VI: OPINION                                                     │
│                                                                         │
│ CAUSE OF DEATH:                                                         │
│                                                                         │
│ I (a): ______________________________________________________            │
│        (Immediate cause)                                                │
│                                                                         │
│ I (b): ______________________________________________________            │
│        (Antecedent cause)                                               │
│                                                                         │
│ II:    ______________________________________________________            │
│        (Contributing conditions)                                        │
│                                                                         │
│ Manner of Death: Natural / Accident / Suicide / Homicide /              │
│                  Undetermined                                           │
│                                                                         │
│ Estimated Time Since Death (PMI): ___________________                   │
│                                                                         │
│ Age as assessed: ___________________________________________             │
│                                                                         │
│ Any other opinion: _________________________________________             │
├─────────────────────────────────────────────────────────────────────────┤
│ SECTION VII: CERTIFICATION                                              │
│                                                                         │
│ Examined by:                                                            │
│                                                                         │
│ Name: _______________________________ Qualification: ___________        │
│ Designation: _______________________________________________             │
│ Department: ________________________________________________             │
│ Institution: _______________________________________________             │
│                                                                         │
│ Signature: _________________________                                    │
│                                                                         │
│ Witnessed by:                                                           │
│ 1. Name: _____________________ Designation: ________________            │
│ 2. Name: _____________________ Designation: ________________            │
│                                                                         │
│ Seal of Institution: ________________                                   │
│ Date: _______________________                                           │
└─────────────────────────────────────────────────────────────────────────┘

PART B: CAUSE-OF-DEATH SPECIFIC PM FINDINGS & COMPLETED REPORTS


REPORT 1: DEATH DUE TO HANGING (Suicidal)

┌─────────────────────────────────────────────────────────────────────────┐
│                   POST-MORTEM EXAMINATION REPORT                        │
│                       DEATH BY HANGING                                  │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 01/2026      Date: 09/07/2026    Time: 10:00 AM          │
│ Hospital: General Hospital, ________________                            │
│ Dept. of Forensic Medicine & Toxicology                                 │
├─────────────────────────────────────────────────────────────────────────┤
│ DECEASED: Ramesh Kumar, 35 years, Male                                  │
│ Occupation: Farmer  Address: Village _________, Dist. _________         │
│ Requisition: PI ____________, PS _____________, CR No. _______          │
│ Under Section: 194 BNSS (formerly 174 CrPC)                             │
│ Body received: 09/07/2026 at 08:00 AM                                   │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION:                                                   │
│                                                                         │
│ Build: Average.  Nutrition: Moderate.                                   │
│ Height: 165 cm.  Weight: 58 kg.                                         │
│                                                                         │
│ POSTMORTEM CHANGES:                                                     │
│ Livor Mortis: Present over lower extremities and distal parts of        │
│ forearms (consistent with erect or semi-erect suspension position).     │
│ Color: Bluish-purple. FIXED - consistent with PMI 8-12 hours.           │
│ Rigor Mortis: Present in all groups of muscles. Fully established.      │
│ PMI estimated: 8-12 hours prior to examination.                         │
│                                                                         │
│ FACE: Congested. Cyanosed.                                              │
│                                                                         │
│ EYES:                                                                   │
│ Conjunctivae: Congested bilaterally with petechial hemorrhages          │
│ (Tardieu spots). Cornea: Clear.                                         │
│ Pupils: Dilated, equal (5 mm each).                                     │
│                                                                         │
│ MOUTH: Lips cyanosed. Froth (fine, slightly blood-tinged) at            │
│ corners of mouth. Tongue: Protruding slightly beyond teeth. Tip          │
│ of tongue bluish. No bite mark.                                         │
│                                                                         │
│ NECK - LIGATURE MARK (KEY FINDING):                                     │
│ A well-defined, oblique, pale-yellowish/brownish parchment-like         │
│ ligature mark is present encircling the neck.                           │
│ Position: Lower third of neck, above larynx                             │
│ Direction: Oblique, runs upward toward point of suspension              │
│            (left mastoid region - consistent with knot position)        │
│ Width: Approximately 2.5 cm (consistent with rope used)                 │
│ Depth: Well-impressed groove, deeper on right side, less marked         │
│        on left (toward knot - inverted V pattern)                       │
│ Character: Parchment-like, dry, firm, yellowish-brown                  │
│ Extent: Incomplete - does not encircle neck posteriorly                 │
│         (interrupted at point of suspension - TYPICAL of hanging)       │
│ Abrasions: Present along inferior border of mark                        │
│                                                                         │
│ No other external injuries noted.                                       │
│ No defense injuries on hands/forearms.                                  │
│                                                                         │
│ INTERNAL EXAMINATION:                                                   │
│                                                                         │
│ SCALP: No contusion. SKULL: No fracture.                                │
│ BRAIN: Weight 1350 g. Congested. Petechial hemorrhages on surface.      │
│ Cerebral edema present. Gyri: Slightly flattened.                       │
│                                                                         │
│ NECK DISSECTION (done layer by layer from behind):                      │
│ Skin at ligature mark: Shows fibrous compression, dryness.              │
│ Subcutaneous tissue: Dry, compressed whitish band beneath mark.         │
│ Petechial hemorrhages around ligature mark in subcutaneous tissue.      │
│ Neck muscles: Above ligature mark - congested.                          │
│               Below ligature mark - relatively normal.                  │
│ Hyoid bone: INTACT (commonly intact in hanging vs strangulation).       │
│             (Note: Fracture in ~25% cases of hanging, esp. elderly)     │
│ Thyroid cartilage: INTACT. No fracture.                                 │
│ Cricoid cartilage: Intact.                                              │
│ Larynx: Congested mucosa.                                               │
│ Trachea: Congested. No foreign body.                                    │
│ Cervical vertebrae: C1-C7 intact. No fracture-dislocation.              │
│   (Note: Fracture-dislocation of C2 = judicial hanging/"hangman's       │
│   fracture" - NOT present in this case of incomplete suspension)        │
│ Carotid arteries: Intimal tears with sub-intimal hemorrhage             │
│                   (sign of ante-mortem suspension).                     │
│                                                                         │
│ PLEURA: No hemothorax. No pneumothorax.                                 │
│                                                                         │
│ HEART: Weight 290 g. Chambers: Right heart - dilated, engorged          │
│ with dark fluid blood. Left heart - relatively empty. Coronary          │
│ arteries: No significant stenosis. Myocardium: Pale, no infarction.     │
│                                                                         │
│ LUNGS: R: 490 g, L: 460 g. CONGESTED. Edematous. Subpleural            │
│ petechial hemorrhages (Tardieu spots) present on both surfaces.         │
│ Cut surface: Frothy blood-stained fluid oozes on compression.           │
│                                                                         │
│ STOMACH: Contains ~150 mL of partially digested food.                   │
│ Mucosa: Normal. No corrosion.                                           │
│                                                                         │
│ LIVER: Weight 1550 g. Congested. No necrosis.                           │
│ SPLEEN: Weight 180 g. Congested.                                        │
│ KIDNEYS: Both normal weight. Congested cortex.                          │
│ URINARY BLADDER: Contains 80 mL urine. (Incontinence may occur           │
│ at time of death - consistent with history.)                            │
│                                                                         │
│ GENITALS: Penile erection had occurred (consistent with hanging          │
│ - cadaveric priapism from venous engorgement).                          │
├─────────────────────────────────────────────────────────────────────────┤
│ SAMPLES PRESERVED:                                                      │
│ Viscera (stomach + liver + kidney + intestine) in saturated NaCl.       │
│ Blood in plain container (no preservative) for alcohol.                 │
│ Urine preserved.                                                        │
│ Histopathology: Lung, brain, heart tissue fixed in 10% formalin.        │
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION:                                                                │
│                                                                         │
│ CAUSE OF DEATH:                                                         │
│ I (a): Asphyxia due to hanging.                                         │
│ I (b): Compression of neck structures by ligature.                     │
│ II:    Nil.                                                             │
│                                                                         │
│ MANNER: Consistent with SUICIDE (suicidal hanging).                     │
│                                                                         │
│ BASIS:                                                                  │
│ 1. Oblique, ascending ligature mark typical of hanging (not             │
│    horizontal as in strangulation).                                     │
│ 2. Mark incomplete - typical of suicidal hanging.                       │
│ 3. No defense injuries.                                                 │
│ 4. Internal neck injuries consistent with ante-mortem suspension.       │
│ 5. Generalized asphyxial changes: Congestion, petechiae, edema.        │
│                                                                         │
│ PMI: Approximately 8-12 hours prior to examination.                     │
│ Age as assessed: 30-40 years.                                           │
│                                                                         │
│ Examining Officer: Dr. ___________________                              │
│ Qualification: MD/MS (FMT)  Designation: Medical Officer                │
│ Date: _____________  Signature: _____________                           │
└─────────────────────────────────────────────────────────────────────────┘
Key Differentiating Points - Hanging vs. Strangulation:
FeatureHangingManual Strangulation
Ligature mark directionOblique/ascendingHorizontal
Mark completenessIncomplete (open at knot)Complete, encircles neck
Mark widthDepends on materialFinger-width marks
Hyoid fractureRare (25%)Common (50%+)
PetechiaePresent but lessVery prominent
MannerUsually suicideUsually homicide
Carotid dissectionCommonMay be present
Defense injuriesAbsentUsually present

REPORT 2: DEATH DUE TO DROWNING

┌─────────────────────────────────────────────────────────────────────────┐
│                   POST-MORTEM EXAMINATION REPORT                        │
│                       DEATH BY DROWNING                                 │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 02/2026      Date: 09/07/2026    Time: 11:00 AM          │
│ DECEASED: Suresh Patel, 28 years, Male                                  │
│ Circumstances: Body found floating in river/well/pond                   │
│ CR No.: __________ Under Section: 174/194 BNSS                         │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION:                                                   │
│                                                                         │
│ Build: Average. Height: 168 cm. Weight: 62 kg.                          │
│                                                                         │
│ POSTMORTEM CHANGES:                                                     │
│ Livor Mortis: PINK/RED color (due to cold water environment).           │
│ Distribution: Over posterior surfaces.                                  │
│ Rigor Mortis: Present in all muscle groups.                             │
│                                                                         │
│ SKIN:                                                                   │
│ Generalized GOOSE SKIN (cutis anserina / anserina skin):                │
│ Erection of hair follicles due to cold water - seen on arms, thighs.   │
│ WASHERWOMAN'S HANDS (macerated, pale, wrinkled skin of palms,           │
│ soles, fingertips): Present - suggests prolonged immersion.             │
│ Skin: Pale, sodden, wrinkled.                                           │
│                                                                         │
│ FACE: Pale / slightly cyanosed. Congested.                              │
│                                                                         │
│ EYES: Conjunctivae: Congested. Petechial hemorrhages. Cornea: Clear.    │
│ Pupils: Dilated.                                                        │
│                                                                         │
│ MOUTH/NOSE:                                                             │
│ FINE WHITE FROTH at mouth and nostrils (characteristic of drowning).    │
│ Froth: Copious, fine, persistent, mushroom-shaped on exposure to air.   │
│ (Formed by mixing of air, mucus, and water in airways)                  │
│                                                                         │
│ HANDS: Grasping of weeds/mud/grass may be present (cadaveric spasm -   │
│        sign of ante-mortem entry into water).                           │
│                                                                         │
│ No external injuries (except possible impact injuries if jumped/fell).  │
│ No ligature marks.                                                      │
│                                                                         │
│ INTERNAL EXAMINATION:                                                   │
│                                                                         │
│ SKULL: No fracture. BRAIN: Edematous. Weight 1380 g.                    │
│ Cerebral edema present. Petechiae.                                      │
│                                                                         │
│ NECK: Hyoid intact. No ligature mark. No injury.                        │
│                                                                         │
│ CHEST CAVITY:                                                           │
│ Ribs: Intact. Pleura: Bilateral pleural effusion (water) may be         │
│ present. No pneumothorax.                                               │
│                                                                         │
│ LUNGS (MOST IMPORTANT ORGAN IN DROWNING):                               │
│ Weight: R: 820 g, L: 790 g (MARKEDLY INCREASED - normal 400 g each).   │
│ WATERLOGGED - heavy, voluminous, pit on finger pressure.                │
│ Color: Pale pink to bluish-grey.                                        │
│ Crepitations: PRESENT on palpation (crepitant).                         │
│ EMPHYSEMA AQUOSUM: Over-inflation with water, markings of ribs visible  │
│ on surface (Rib markings present).                                      │
│ Cut surface: Frothy, pale, blood-stained fluid oozes freely.            │
│ Subpleural petechial hemorrhages (TARDIEU SPOTS): Present.              │
│ Pleural surfaces: Impression of ribs visible (Paltauf's sign/spots).    │
│ PALTAUF'S HEMORRHAGES: Subpleural pale pink hemorrhagic areas           │
│ (dilution of blood by water in fresh water drowning).                   │
│                                                                         │
│ HEART: Right chambers dilated, engorged. Left - normal/empty.           │
│ Weight 300 g. No coronary disease.                                      │
│                                                                         │
│ STOMACH:                                                                │
│ WATER IN STOMACH: Contains 200-500 mL of muddy/turbid water.            │
│ (Swallowed during struggle - confirms ante-mortem drowning.)            │
│ Sand, weeds, debris may be present.                                     │
│ Mucosa: Congested, hemorrhagic in places.                               │
│                                                                         │
│ DUODENUM/INTESTINES: May contain water (confirm drowning).              │
│                                                                         │
│ MIDDLE EAR: Hemorrhage into middle ear (Rodriques sign).                │
│                                                                         │
│ SPHENOID SINUS: Water/mud present (confirmatory sign of drowning).      │
│                                                                         │
│ LIVER: Weight 1600 g. Congested.                                        │
│ SPLEEN: Normal. KIDNEYS: Congested.                                     │
├─────────────────────────────────────────────────────────────────────────┤
│ SPECIAL INVESTIGATIONS:                                                 │
│                                                                         │
│ 1. DIATOM TEST (Pfaff's method):                                        │
│    Bone marrow / Femur / Kidney sent for diatom examination.            │
│    Presence of diatoms identical to those in drowning medium            │
│    = CONFIRMATORY of ante-mortem drowning (diatoms reach circulation    │
│    while heart still pumping - not in post-mortem immersion).           │
│                                                                         │
│ 2. GETTLER'S TEST (Chloride test):                                      │
│    Blood chloride: Left heart vs. Right heart comparison.               │
│    Fresh water drowning: Left heart blood MORE dilute than right.       │
│    (Osmotic dilution from absorbed fresh water.)                        │
│                                                                         │
│ 3. STRONTIUM TEST: Serum strontium levels.                              │
│                                                                         │
│ 4. Swabs from genitalia (if sexual assault suspected).                  │
│                                                                         │
│ Samples: Viscera, blood, urine, lung, bone marrow preserved.            │
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION:                                                                │
│                                                                         │
│ CAUSE OF DEATH:                                                         │
│ I (a): Asphyxia due to drowning.                                        │
│ I (b): Immersion in water with aspiration.                              │
│ II:    Nil.                                                             │
│                                                                         │
│ MANNER: Consistent with ACCIDENTAL drowning.                            │
│         (Suicide/Homicide cannot be excluded without further            │
│          investigation - deferred to Investigating Officer.)             │
│                                                                         │
│ Basis: Waterlogged lungs, froth at mouth/nose, water in stomach,        │
│        goose skin, Paltauf's hemorrhages, emphysema aquosum.            │
│                                                                         │
│ PMI: Difficult to estimate due to water immersion. Body may have        │
│      been in water approximately 12-24 hours.                           │
│                                                                         │
│ Signature: Dr. _______________  Date: _______________                   │
└─────────────────────────────────────────────────────────────────────────┘

REPORT 3: DEATH DUE TO ELECTRIC SHOCK (Electrocution)

┌─────────────────────────────────────────────────────────────────────────┐
│                   POST-MORTEM EXAMINATION REPORT                        │
│                       DEATH BY ELECTROCUTION                            │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 03/2026      Date: 09/07/2026                            │
│ DECEASED: Mohan Lal, 22 years, Male                                     │
│ Circumstances: Found near live electric wire / Contact with appliance   │
│ CR No.: __________ Under Section: 174/194 BNSS                         │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION:                                                   │
│                                                                         │
│ Build: Average. Height: 170 cm. Weight: 65 kg.                          │
│                                                                         │
│ POSTMORTEM CHANGES:                                                     │
│ Livor Mortis: Present over posterior surfaces. Bluish-purple.           │
│ Rigor Mortis: Present in all groups.                                    │
│ PMI: Approximately 4-6 hours.                                           │
│                                                                         │
│ FACE: Congested. Cyanosed.                                              │
│ EYES: Conjunctivae petechiae. Dilated pupils.                           │
│                                                                         │
│ ELECTRIC MARK (JOULE BURN / ENTRY WOUND - KEY FINDING):                 │
│ Present on: Right palm (web space between thumb and index finger)       │
│ Size: 2 x 1.5 cm                                                        │
│ Shape: Irregular, central pale crater with surrounding brownish-red     │
│        hyperemia; raised edges; dry, yellowish parchment center.        │
│ Character: Hard, firm, leathery; surrounding blistering present.        │
│ ARBORESCENT (LIGHTNING-TREE/LICHTENBERG FIGURE) markings:              │
│ Present on right forearm - fern-like branching reddish streaks          │
│ along skin.                                                             │
│                                                                         │
│ EXIT WOUND (if present):                                                │
│ Present on: Right foot/heel                                             │
│ Size: 3 x 2 cm                                                          │
│ Character: Larger and more explosive than entry; irregular; blowout     │
│ appearance.                                                             │
│ (Note: Exit wound usually larger and more explosive than entry)         │
│                                                                         │
│ SINGING OF HAIR: Present over right hand and forearm.                   │
│ METALLIZATION: Copper/metalite particles embedded in skin               │
│                (demonstrate with X-ray or chemical analysis).           │
│                                                                         │
│ CLOTHING: Burnt / torn at entry and exit sites.                         │
│ Shoes: Sole may show melted/exit site.                                  │
│                                                                         │
│ INTERNAL EXAMINATION:                                                   │
│                                                                         │
│ SKULL: No fracture (unless thrown by current). BRAIN: Edematous.        │
│ Weight 1360 g. Petechial hemorrhages. Cerebral edema.                   │
│                                                                         │
│ NECK: No injury. Hyoid intact.                                          │
│                                                                         │
│ HEART:                                                                  │
│ Weight 305 g. Cardiac arrhythmia is cause of death (cannot be seen      │
│ on autopsy - diagnosis made from history + electrical evidence).        │
│ Subendocardial hemorrhages may be present.                              │
│ Contraction band necrosis on histopathology (if taken).                 │
│ Right chambers: Engorged, dilated.                                      │
│ Coronary arteries: Patent.                                              │
│                                                                         │
│ LUNGS: Weight 450 g each. Congested. Edematous.                         │
│ Subpleural petechiae. Pulmonary edema present.                          │
│                                                                         │
│ MUSCLES ALONG PATH OF CURRENT:                                          │
│ Right forearm and arm muscles: Vacuolization, disruption visible on     │
│ section. Hemorrhage in muscle bundles.                                  │
│                                                                         │
│ STOMACH: Normal contents. No corrosion.                                 │
│ LIVER: Congested. SPLEEN: Congested. KIDNEYS: Congested.                │
│                                                                         │
│ SPINAL CORD: Hemorrhagic foci may be seen (path of current).            │
│                                                                         │
│ FRACTURES: Vertebral compression fractures possible if thrown.          │
│ TONGUE: Bite mark possible (tetanic jaw spasm at moment of shock).      │
│                                                                         │
│ HISTOPATHOLOGY (IMPORTANT - send sections from entry wound):            │
│ Entry wound: Vacuolization of keratinocytes, "streaming" of nuclear     │
│ chromatin along the direction of current flow.                          │
│ "Nuclear elongation" pattern at bases of rete ridges.                   │
│ Contraction band necrosis in myocardium.                                │
├─────────────────────────────────────────────────────────────────────────┤
│ SAMPLES:                                                                │
│ Viscera for chemical analysis. Blood. Urine.                            │
│ Tissue from entry/exit wound in formalin (histopathology).              │
│ Cardiac tissue in formalin.                                             │
│ Muscle along path of current.                                           │
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION:                                                                │
│                                                                         │
│ CAUSE OF DEATH:                                                         │
│ I (a): Cardiac arrhythmia (ventricular fibrillation) due to             │
│        electrocution.                                                   │
│ I (b): Passage of high-voltage electrical current through body.         │
│ II:    Cerebral edema, pulmonary edema.                                 │
│                                                                         │
│ MANNER: Accidental (Occupational/domestic electrocution).               │
│         Homicidal electrocution rare but cannot be excluded.            │
│                                                                         │
│ Basis: Presence of entry and exit electrical burns with characteristic  │
│ Joule burn morphology, arborescent markings, metallization, and         │
│ generalized asphyxial changes.                                          │
│                                                                         │
│ Note: In lightning strike - multiple entry/exit sites, Lichtenberg      │
│ figures more prominent, clothes blown off, keraunoparalysis,            │
│ ruptured eardrums, cataracts.                                           │
│                                                                         │
│ PMI: Approximately 4-6 hours.                                           │
│ Signature: Dr. _______________  Date: _______________                   │
└─────────────────────────────────────────────────────────────────────────┘

REPORT 4: ROAD TRAFFIC ACCIDENT (RTA)

┌─────────────────────────────────────────────────────────────────────────┐
│                   POST-MORTEM EXAMINATION REPORT                        │
│                   ROAD TRAFFIC ACCIDENT (RTA)                           │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 04/2026    Date: 09/07/2026                              │
│ DECEASED: Anil Singh, 40 years, Male                                    │
│ Circumstances: Hit by vehicle on highway / Two-wheeler accident          │
│ FIR No.: __________ Under Section: 304A/304 IPC / BNS                  │
│ Police Station: ______________ Investigating Officer: ___________        │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION:                                                   │
│                                                                         │
│ Build: Average. Height: 168 cm. Weight: 66 kg.                          │
│                                                                         │
│ POSTMORTEM CHANGES:                                                     │
│ Livor Mortis: Present posteriorly. Color: Bluish-red. Fixed.            │
│ Rigor Mortis: Present in jaw, limbs - Fully established.                │
│ PMI: 6-12 hours.                                                        │
│                                                                         │
│ CLOTHING: Torn, soiled with mud and blood at multiple sites.            │
│ Tire marks/tread impressions: Present on right side of chest.           │
│                                                                         │
│ INJURIES - RTA CLASSIFICATION:                                          │
│                                                                         │
│ A. PRIMARY IMPACT (Direct contact with vehicle):                        │
│    1. Bumper injury:                                                    │
│       Depressed fracture/contusion, anterior aspect left tibia 10 cm   │
│       above ankle (H: 52 cm from heel = bumper height indicator).       │
│    2. Radiator/Hood impact:                                             │
│       Multiple lacerations and contusions: Right shoulder, chest wall.  │
│                                                                         │
│ B. SECONDARY IMPACT (Body thrown onto bonnet/windshield):               │
│    3. Laceration: Scalp, vertex, 6 x 2 cm, bone deep.                  │
│    4. Subdural hematoma (found internally).                             │
│    5. Contusion: Right temporal region 5 x 4 cm.                       │
│                                                                         │
│ C. TERTIARY IMPACT (Fallen to ground):                                  │
│    6. Road rash (graze/abrasion): Extensive, right side of face,        │
│       right elbow, right hip - dirt embedded, parallel linear pattern   │
│       (direction indicates direction of fall/skid).                     │
│    7. Contusion: Right forearm, 8 x 5 cm.                               │
│                                                                         │
│ D. CRUSH/RUNOVER INJURIES (if runover):                                 │
│    8. Tire tread mark: Oblique impression across right chest wall.      │
│    9. Patterned contusion matching tire tread present.                  │
│   10. Crushing fractures: Multiple ribs right side 3rd-7th.            │
│                                                                         │
│ HEAD:                                                                   │
│ Scalp laceration: Vertex - 6 x 2 cm (see above).                       │
│ Contusions: Right temporal x2, left parietal x1.                       │
│ Face: Multiple abrasions. Nose: Fractured (deviated).                   │
│                                                                         │
│ EYES: Right eye: Subconjunctival hemorrhage. Left: Normal.              │
│                                                                         │
│ CHEST: Multiple rib fractures R: 3rd-7th, L: 5th-7th.                  │
│ Paradoxical movement present.                                           │
│                                                                         │
│ ABDOMEN: Distended. Superficial lacerations over left side.             │
│                                                                         │
│ PELVIS: Acetabular fracture - right side.                               │
│                                                                         │
│ LIMBS: Right tibial fracture (bumper injury).                           │
│        Left radius fracture (defensive - raised arm).                   │
│                                                                         │
│ INTERNAL EXAMINATION:                                                   │
│                                                                         │
│ SCALP: Contusions, lacerations as described.                            │
│ SKULL FRACTURES:                                                        │
│ Compound depressed fracture: Right temporal-parietal region 7 x 4 cm.  │
│ Contre-coup fracture: Left temporal fossa (fracture opposite to impact).│
│                                                                         │
│ BRAIN: Weight 1380 g.                                                   │
│ Subdural hematoma: Right side - 80 mL dark clotted blood.              │
│ Extradural hematoma: Right temporal - 40 mL fresh blood.               │
│ Contrecoup contusion: Left temporal/frontal lobe - hemorrhagic.         │
│ Coup contusion: Right temporal lobe.                                    │
│ Cerebral edema: SEVERE. Gyri flattened, herniations of uncus.           │
│ Diffuse axonal injury suspected (histopathology required).              │
│ Brainstem: Petechial hemorrhages. Duret hemorrhages present.            │
│                                                                         │
│ NECK: No fracture. Hyoid intact.                                        │
│ Cervical vertebrae: C4-C5 fracture-subluxation noted.                  │
│                                                                         │
│ CHEST:                                                                  │
│ BILATERAL HEMOTHORAX: R: 600 mL, L: 300 mL dark blood.                 │
│ Pneumothorax: Left.                                                     │
│ Lung lacerations: Right lower lobe - 2 sites.                          │
│ Contused lung: Left lower lobe.                                        │
│ CARDIAC TAMPONADE: Hemopericardium 50 mL.                               │
│ HEART: Myocardial contusion: Anterior wall. Right atrium tear.          │
│ AORTA: Transection of aorta at isthmus (just distal to left            │
│         subclavian origin) - traumatic aortic rupture.                  │
│                                                                         │
│ ABDOMEN:                                                                │
│ Free blood in peritoneal cavity: 800 mL.                               │
│ LIVER: Ruptured, multiple lacerations right lobe.                       │
│ SPLEEN: Ruptured, central hematoma.                                     │
│ KIDNEY: Left kidney contusion. Right: Normal.                           │
│ BLADDER: Ruptured (if full at time of impact).                          │
│ MESENTERY: Contusion, hemorrhage.                                       │
│ PELVIS: Acetabular fracture R + iliac crest fracture L.                 │
├─────────────────────────────────────────────────────────────────────────┤
│ SAMPLES: Blood (for alcohol - no preservative), urine, vitreous humor,  │
│ histopathology (brain for DAI - beta-APP staining).                     │
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION:                                                                │
│                                                                         │
│ CAUSE OF DEATH:                                                         │
│ I (a): Hemorrhagic shock and traumatic brain injury.                    │
│ I (b): Multiple organ injuries due to blunt force trauma.               │
│ II:    Bilateral hemothorax, pneumothorax, traumatic aortic rupture,    │
│        hepatic and splenic laceration.                                  │
│                                                                         │
│ MANNER: ACCIDENTAL - Road Traffic Accident.                             │
│                                                                         │
│ All injuries are consistent with RTA - blunt force trauma, patterned   │
│ contusions, and tire impressions consistent with vehicle impact.        │
│                                                                         │
│ Bumper height: 52 cm from heel consistent with [car type].              │
│                                                                         │
│ Blood alcohol concentration requested (chemical analysis).              │
│ PMI: 6-12 hours. Age: 38-42 years.                                      │
│                                                                         │
│ Signature: Dr. _______________  Date: _______________                   │
└─────────────────────────────────────────────────────────────────────────┘

REPORT 5: DEATH DUE TO CARDIAC ARREST (Natural Death)

┌─────────────────────────────────────────────────────────────────────────┐
│                   POST-MORTEM EXAMINATION REPORT                        │
│                    DEATH DUE TO CARDIAC CAUSE                           │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 05/2026    Date: 09/07/2026                              │
│ DECEASED: Rajesh Verma, 58 years, Male                                  │
│ Circumstances: Found dead at home; known hypertensive, diabetic.        │
│ CR No.: __________ Under Section: 174/194 BNSS                         │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION:                                                   │
│                                                                         │
│ Build: Obese. Height: 168 cm. Weight: 88 kg. BMI: ~31.                  │
│                                                                         │
│ POSTMORTEM CHANGES:                                                     │
│ Livor Mortis: Present over posterior surfaces. Dark bluish-purple.      │
│ Fixed. PMI: 8-12 hours.                                                 │
│ Rigor Mortis: Fully established.                                        │
│                                                                         │
│ Face: Pale / slightly congested.                                        │
│ Eyes: Petechiae absent. Arcus senilis present.                          │
│ Mouth: No froth. No cyanosis. Tongue: Not protruding.                   │
│ Neck: No ligature mark. No injury.                                      │
│ Chest: Surgical scar (if previous CABG/sternotomy): ___________         │
│ Abdomen: Obese. No injury.                                              │
│ Limbs: Lower limb edema: Bilateral pitting, up to ankles.              │
│ No external injuries.                                                   │
│                                                                         │
│ INTERNAL EXAMINATION:                                                   │
│                                                                         │
│ SKULL: No fracture. BRAIN: Weight 1400 g. Mild edema. Old ischemic      │
│ infarct may be present in basal ganglia (chronic hypertension).         │
│                                                                         │
│ NECK: Hyoid intact. Atheromatous carotid arteries.                      │
│                                                                         │
│ CHEST:                                                                  │
│ No hemothorax. Bilateral pleural effusion: R: 200 mL, L: 180 mL        │
│ (consistent with cardiac failure / CCF).                                │
│                                                                         │
│ HEART - PRIMARY ORGAN OF INTEREST:                                      │
│ Weight: 480 g (INCREASED - normal 250-350 g).                           │
│ Shape: Globular (evidence of cardiomegaly).                             │
│                                                                         │
│ PERICARDIUM: Intact. Pericardial fluid: 50 mL straw-colored.            │
│                                                                         │
│ LEFT VENTRICLE:                                                         │
│ Wall thickness: 1.8 cm (THICKENED - normal 0.8-1.2 cm).                │
│ CONCENTRIC HYPERTROPHY - consistent with long-standing hypertension.    │
│                                                                         │
│ RIGHT VENTRICLE: Wall thickness 0.5 cm. Normal.                         │
│                                                                         │
│ CORONARY ARTERIES:                                                      │
│ LAD (Left Anterior Descending): SEVERE stenosis - 90% occlusion at     │
│ proximal one-third. Atheromatous plaque, calcified. Lumen reduced       │
│ to 1 mm.                                                                │
│ LCX (Left Circumflex): Moderate stenosis 60%.                           │
│ RCA (Right Coronary): Moderate stenosis 50%.                            │
│ FRESH THROMBUS: Present in LAD lumen (acute coronary event).            │
│                                                                         │
│ MYOCARDIUM:                                                             │
│ Area of infarction: Anterior wall, interventricular septum.             │
│ Character: Pale, yellowish, soft (48-72 hour old infarct);              │
│            OR Dark mottled (24-48h); OR Pale grey (>1 week old).        │
│ PALLOR and MOTTLING: Present in anterior wall.                          │
│ Subendocardial hemorrhage: Present.                                     │
│ Old infarct scars (fibrous pale areas): Present in posterior wall       │
│ (chronic ischemic heart disease).                                       │
│                                                                         │
│ AORTA: Atherosclerosis - severe. Multiple calcified plaques.            │
│ No dissection.                                                          │
│                                                                         │
│ VALVES: Mitral: Thickened, calcified. Aortic: Calcified (aortic         │
│         sclerosis). No vegetations.                                     │
│                                                                         │
│ LUNGS: Weight: R: 620 g, L: 590 g (INCREASED - pulmonary edema).        │
│ Color: Congested, pink, waterlogged. Cut surface: Frothy fluid.         │
│ Hemosiderin-laden macrophages ("heart failure cells") on smear.         │
│                                                                         │
│ LIVER: Weight 1800 g (INCREASED). "NUTMEG LIVER" pattern:              │
│ Congested, dark red center with pale periphery on cut section.          │
│ Consistent with chronic passive venous congestion (right heart failure).│
│                                                                         │
│ KIDNEYS: Enlarged, congested. Cortex: Granular surface ("granular       │
│ contracted kidney" - hypertensive nephropathy).                         │
│                                                                         │
│ SPLEEN: Weight 250 g. Congested, firm.                                  │
│                                                                         │
│ STOMACH: Empty or minimal contents. Normal mucosa.                      │
│ PANCREAS: Features of diabetes mellitus (islet atrophy, fibrosis).      │
│                                                                         │
│ ADRENALS: Normal.                                                       │
│                                                                         │
│ HISTOPATHOLOGY:                                                         │
│ Myocardium: Contraction band necrosis (very early ischemia, <1h).       │
│             Coagulative necrosis (>4-6h).                               │
│             Inflammatory infiltrate (>24h - PMN, then macrophages).     │
│             Granulation tissue (5-10 days).                             │
│             Fibrosis (>2-3 weeks).                                      │
├─────────────────────────────────────────────────────────────────────────┤
│ SAMPLES: Blood, urine, vitreous humor (for electrolytes - sudden        │
│ cardiac death). Cardiac tissue for histopathology.                      │
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION:                                                                │
│                                                                         │
│ CAUSE OF DEATH:                                                         │
│ I (a): Acute myocardial infarction.                                     │
│ I (b): Acute coronary thrombosis of LAD.                                │
│ II:    Severe coronary artery disease (atherosclerosis), hypertensive   │
│        heart disease (LVH), diabetes mellitus, obesity.                 │
│                                                                         │
│ MANNER: NATURAL.                                                        │
│                                                                         │
│ This is consistent with sudden natural death due to acute coronary      │
│ event on a background of long-standing ischemic heart disease.          │
│                                                                         │
│ PMI: Approximately 8-12 hours.                                          │
│ Age: 55-62 years (consistent with stated age).                          │
│                                                                         │
│ Signature: Dr. _______________  Date: _______________                   │
└─────────────────────────────────────────────────────────────────────────┘

REPORT 6: DEATH DUE TO POISONING (Organophosphate)

┌─────────────────────────────────────────────────────────────────────────┐
│                   POST-MORTEM EXAMINATION REPORT                        │
│                    DEATH BY POISONING (OP COMPOUND)                     │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 06/2026    Date: 09/07/2026                              │
│ DECEASED: Savitri Devi, 30 years, Female                                │
│ Circumstances: Found unconscious after allegedly consuming pesticide.   │
│ CR No.: __________ Under Section: 302/304/306 IPC (BNS)                 │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION:                                                   │
│                                                                         │
│ Build: Average. Height: 155 cm. Weight: 50 kg.                          │
│                                                                         │
│ POSTMORTEM CHANGES:                                                     │
│ Livor Mortis: Present posteriorly. Bluish-purple. Fixed.                │
│ Rigor Mortis: Fully established. PMI: 6-10 hours.                       │
│                                                                         │
│ BODY ODOR: Strong garlic-like / pungent odor from mouth/body fluids.   │
│ (Characteristic of organophosphate/sulphur compounds.)                  │
│                                                                         │
│ FACE: Congested, cyanosed.                                              │
│                                                                         │
│ EYES:                                                                   │
│ PUPILS: CONSTRICTED (MIOSIS) bilaterally - 2 mm each (HALLMARK).        │
│ Conjunctivae: Congested, petechiae present.                             │
│                                                                         │
│ MOUTH:                                                                  │
│ Profuse frothing at mouth - copious, white froth.                       │
│ Tongue: Moist. Not bitten. Excess salivation noted.                     │
│                                                                         │
│ SKIN: Diaphoresis (sweating). Skin appears moist.                       │
│                                                                         │
│ NO EXTERNAL INJURIES.                                                   │
│ No ligature marks. No needle marks (unless IV attempted in hospital).   │
│                                                                         │
│ CLOTHING: May show pesticide stain.                                     │
│                                                                         │
│ INTERNAL EXAMINATION:                                                   │
│                                                                         │
│ SKULL: Intact. BRAIN: Weight 1340 g. CONGESTED. Edematous.              │
│ Petechiae on surface. Cerebral edema.                                   │
│                                                                         │
│ NECK: No injury. Hyoid intact.                                          │
│                                                                         │
│ CHEST: No hemothorax.                                                   │
│                                                                         │
│ LUNGS: Weight: R: 590 g, L: 560 g (INCREASED due to edema).            │
│ Color: CONGESTED, pink-red, heavy, waterlogged.                         │
│ Cut surface: COPIOUS FROTHY FLUID - blood-stained, abundant.            │
│ (Bronchorrhea - excess secretions in bronchi.)                          │
│ Subpleural petechiae (Tardieu spots): Present.                          │
│ Bronchi: Contain frothy fluid.                                          │
│ Bronchospasm features: Distended with trapped air.                      │
│                                                                         │
│ HEART: Weight 290 g. Dilated. Engorged right chambers.                  │
│ Subendocardial hemorrhages.                                             │
│                                                                         │
│ STOMACH:                                                                │
│ Contents: STRONG PUNGENT SMELL - garlic/sulphur odor on opening.        │
│ Volume: ~300 mL greenish-brown liquid.                                  │
│ Mucosa: HYPEREMIC, hemorrhagic, erosions present.                       │
│ Chemical irritant effect visible.                                       │
│ Corrosion: Not present (OP compounds - no direct corrosion).            │
│                                                                         │
│ SMALL INTESTINE: Hyperemic mucosa. Increased secretions.                │
│                                                                         │
│ LIVER: Weight 1580 g. Congested. No necrosis in OP poisoning.           │
│ (Note: In paracetamol - centrilobular necrosis would be present.)       │
│                                                                         │
│ SPLEEN: Congested. KIDNEYS: Congested.                                  │
│                                                                         │
│ URINARY BLADDER: FULL of urine (involuntary urination - cholinergic).   │
│ Urine: ~200 mL. Preserved for toxicology.                               │
│                                                                         │
│ ADRENALS: Normal.                                                       │
├─────────────────────────────────────────────────────────────────────────┤
│ SAMPLES PRESERVED (CRITICAL FOR CHEMICAL ANALYSIS):                     │
│ 1. Stomach + contents (in separate sealed container, NO preservative).  │
│ 2. Liver (500 g) in saturated NaCl.                                     │
│ 3. Kidney (one complete) in saturated NaCl.                             │
│ 4. Small intestine (30 cm with contents) in saturated NaCl.            │
│ 5. Blood: 50 mL in plain container - NO PRESERVATIVE (for OP).         │
│ 6. Urine: 50 mL plain container.                                        │
│ 7. Vitreous humor: 5 mL.                                                │
│ 8. Bile: 10 mL.                                                         │
│ 9. Brain tissue: 200 g.                                                 │
│ 10. Lung tissue for histopathology.                                     │
│ NOTE: All samples sealed separately and labeled with case no. + content.│
│ Sent to: Chemical Examiner, FSL __________________ on ___________       │
│ Ref No.: _________________                                              │
│ Analysis requested: Organophosphate screen, Cholinesterase activity.    │
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION:                                                                │
│                                                                         │
│ CAUSE OF DEATH:                                                         │
│ I (a): Respiratory failure and acute pulmonary edema.                   │
│ I (b): Organophosphate compound poisoning.                              │
│ II:    Cholinergic crisis with bronchorrhea and bronchospasm.           │
│                                                                         │
│ MANNER: Consistent with SUICIDAL poisoning (pending chemical            │
│         analysis confirmation).                                         │
│                                                                         │
│ Basis: Miosis, profuse bronchorrhea, copious froth, garlic odor,        │
│        hyperemic GI mucosa - SLUDGE syndrome features present on PM.   │
│                                                                         │
│ NOTE: Final opinion subject to chemical analysis results.               │
│       Red blood cell cholinesterase activity confirmation essential.    │
│                                                                         │
│ PMI: 6-10 hours. Age: 28-32 years.                                      │
│                                                                         │
│ Signature: Dr. _______________  Date: _______________                   │
└─────────────────────────────────────────────────────────────────────────┘

REPORT 7: DEATH DUE TO BURNS (Fire / Flame)

┌─────────────────────────────────────────────────────────────────────────┐
│                   POST-MORTEM EXAMINATION REPORT                        │
│                       DEATH DUE TO BURNS                                │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 07/2026    Date: 09/07/2026                              │
│ DECEASED: Geeta Sharma, 24 years, Female                                │
│ Circumstances: Burns (bride burning / accidental kerosene burn)         │
│ CR No.: __________ Under Section: 302/304B/306 IPC                     │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION:                                                   │
│                                                                         │
│ BODY WEIGHT: Severely reduced due to fluid loss.                        │
│                                                                         │
│ BURNS ASSESSMENT:                                                       │
│ Using RULE OF NINES:                                                    │
│ Head and neck: 9%  Right arm: 9%  Left arm: 9%                          │
│ Anterior trunk: 18%  Posterior trunk: 18%                               │
│ Right leg: 18%  Left leg: 18%  Perineum: 1%                            │
│ Total BSA Burned: _____% (Document carefully)                           │
│                                                                         │
│ DEGREE OF BURNS:                                                        │
│ 1st degree (erythema only): Areas: _________________                    │
│ 2nd degree (blistering): Areas: ____________________                    │
│ 3rd degree (full thickness - charring, leathery): Areas: ___________    │
│                                                                         │
│ CLOTHING: Burnt/charred at sites corresponding to burn areas.           │
│ Kerosene/petrol odor: Present / Absent.                                 │
│                                                                         │
│ VITAL REACTION (ANTE-MORTEM BURNS):                                     │
│ 1. Vital blistering (fluid inside blisters with protein and leucocytes).│
│ 2. Hyperemia and inflammatory reaction at burn margins.                 │
│ 3. Soot in airways (below glottis = ante-mortem).                       │
│ 4. Pugilistic posture (boxing stance): Due to heat-induced muscle       │
│    contraction - NOT a sign of fighting.                                │
│                                                                         │
│ POST-MORTEM BURNS:                                                      │
│ Dry, leathery, split skin. Peeling. No fluid in blisters. No vital      │
│ reaction at margins.                                                    │
│                                                                         │
│ INTERNAL EXAMINATION:                                                   │
│                                                                         │
│ RESPIRATORY TRACT:                                                      │
│ SOOT: Soot deposits in trachea, bronchi (BELOW CORDS = ante-mortem).   │
│ (Above cords only = post-mortem smoke entry.)                           │
│ Larynx: Edematous, soot-stained.                                        │
│ Trachea: Soot-lined mucosa.                                             │
│ Bronchi: Contain carbonaceous material.                                 │
│                                                                         │
│ LUNGS: CHERRY RED color (Carbon monoxide poisoning concurrent).         │
│ Edematous. Congested. Weight increased.                                 │
│                                                                         │
│ BLOOD: Cherry red (carboxyhemoglobin - CO poisoning from smoke).        │
│ COHb levels requested from FSL.                                         │
│                                                                         │
│ BRAIN: Edematous. Cherry red coloration.                                │
│                                                                         │
│ STOMACH: Stress ulcers (Curling's ulcers) may be present.               │
│ Submucosal hemorrhages along greater curvature.                         │
│                                                                         │
│ HEART: Subendocardial hemorrhages. Fatty changes.                       │
│                                                                         │
│ SKULL: Epidural "heat hematoma" (lenticular, dark red, in temples)      │
│        - NOT a sign of trauma - artifact of heat in burning.            │
│ Note: True traumatic EDH is bright red and has fracture usually.        │
│                                                                         │
│ HEAT FRACTURES: Skull may show "explosion" type fractures from          │
│ steam pressure in diploe - NOT ante-mortem blunt force.                 │
├─────────────────────────────────────────────────────────────────────────┤
│ SAMPLES:                                                                │
│ Blood in plain sealed vial (for COHb estimation - to FSL URGENTLY).    │
│ Vitreous humor. Viscera. Blistered skin biopsy (histopathology).        │
│ Soot swab from airways. Urine for cyanide (if synthetic material burnt).│
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION:                                                                │
│                                                                         │
│ CAUSE OF DEATH:                                                         │
│ I (a): Carboxyhemoglobin poisoning and respiratory failure.             │
│ I (b): Inhalation of smoke and toxic gases.                             │
│ II:    Burns involving ____% BSA (2nd-3rd degree), burn shock.          │
│                                                                         │
│ MANNER: To be determined by investigation. Burns are ANTE-MORTEM        │
│         (vital reaction present; soot below glottis).                   │
│                                                                         │
│ Note: No evidence of blunt force trauma pre-mortem. No fractures        │
│       inconsistent with heat effects. No restraint marks.               │
│                                                                         │
│ Final opinion: Pending chemical analysis for COHb levels and toxicology.│
│                                                                         │
│ Signature: Dr. _______________  Date: _______________                   │
└─────────────────────────────────────────────────────────────────────────┘

REPORT 8: DEATH DUE TO FIREARM INJURY

┌─────────────────────────────────────────────────────────────────────────┐
│                   POST-MORTEM EXAMINATION REPORT                        │
│                     DEATH BY FIREARM INJURY                             │
├─────────────────────────────────────────────────────────────────────────┤
│ PM Report No.: 08/2026    Date: 09/07/2026                              │
│ DECEASED: Vikram Singh, 32 years, Male                                  │
│ Circumstances: Gunshot wound                                            │
│ CR No.: __________ Under Section: 302/307 IPC / BNS                    │
│ Request by: Inspector _________, PS __________                          │
├─────────────────────────────────────────────────────────────────────────┤
│ EXTERNAL EXAMINATION:                                                   │
│                                                                         │
│ ENTRY WOUND:                                                            │
│ Location: Right temporal region, 3 cm above the right ear.             │
│ Size: 1.2 x 1.2 cm                                                      │
│ Shape: Circular, punched-out appearance.                                │
│ Edges: INVERTED (pushing inward) - ENTRY.                               │
│ Marginal abrasion collar: Present (2-3 mm wide, around entry).          │
│ Powder tattooing/stippling: Present within 60 cm radius around wound.  │
│ Blackening: Present (contact/close range).                              │
│ Burns of skin/hair: Present (very close/contact range).                 │
│ Contusion ring/abrasion ring: Present.                                  │
│ Muzzle stamp: Present (star-shaped laceration if contact - applied      │
│               muzzle to skin over bone).                                │
│                                                                         │
│ EXIT WOUND:                                                             │
│ Location: Left temporal region.                                         │
│ Size: 3 x 2.5 cm                                                        │
│ Shape: IRREGULAR, stellate, explosive.                                  │
│ Edges: EVERTED (pushed outward) - EXIT.                                 │
│ NO abrasion collar at exit. NO tattooing. NO blackening.                │
│ Size LARGER than entry.                                                 │
│                                                                         │
│ RANGE DETERMINATION:                                                    │
│ Contact shot: Muzzle stamp + cruciate laceration + smoke deposit       │
│               under skin edge.                                          │
│ Close range (<15 cm): Blackening + tattooing + burning.                 │
│ Medium range (15-60 cm): Tattooing without blackening.                  │
│ Long range (>60 cm): Abrasion collar + contusion ring only.             │
│ THIS CASE: Close range (blackening + stippling present).                │
│                                                                         │
│ INTERNAL EXAMINATION:                                                   │
│                                                                         │
│ SKULL: Beveling of skull:                                               │
│ Entry wound: Internal bevel (inner table larger than outer) - ENTRY.   │
│ Exit wound: External bevel (outer table larger than inner) - EXIT.      │
│ Fracture lines: Radiating from both entry and exit.                     │
│                                                                         │
│ BRAIN: Destroyed right temporal lobe. Bullet track visible:            │
│ Hemorrhagic lacerated track from right to left temporal lobe.           │
│ Gunshot residue in track.                                               │
│ Mass hemorrhage. Brain weight: Significantly reduced.                   │
│ Left: Contre-coup laceration.                                           │
│                                                                         │
│ BULLET RECOVERED: Yes / No (if present - describe, photograph,          │
│ handle with gloves, preserve in separate container, hand to police).    │
│                                                                         │
│ CHEST/ABDOMEN: No injury (unless multiple shots).                       │
│ HEART: Pale. No injury.                                                 │
│ LUNGS: Congested. No direct injury.                                     │
├─────────────────────────────────────────────────────────────────────────┤
│ SAMPLES:                                                                │
│ Wound swabs for GSR (gunshot residue).                                  │
│ Blood, urine, vitreous for toxicology.                                  │
│ Bullet (if recovered) handed to IO with proper documentation.           │
│ Skull bone from entry and exit for beveling demonstration.              │
│ Clothing (with GSR markings) handed to FSL.                             │
├─────────────────────────────────────────────────────────────────────────┤
│ OPINION:                                                                │
│                                                                         │
│ CAUSE OF DEATH:                                                         │
│ I (a): Destruction of brain and massive intracranial hemorrhage.        │
│ I (b): Penetrating gunshot wound to head.                               │
│ II:    Nil.                                                             │
│                                                                         │
│ MANNER: HOMICIDAL (single close-range shot, not typical of suicide).    │
│         (Suicidal firearms typically: contact range, temporal/mouth;    │
│          homicidal: variable range, back of head, multiple shots.)      │
│                                                                         │
│ Range of fire: CLOSE RANGE (<15 cm) based on blackening and tattooing. │
│                                                                         │
│ Direction of fire: Right to left (entry right temporal, exit left).     │
│                                                                         │
│ Signature: Dr. _______________  Date: _______________                   │
└─────────────────────────────────────────────────────────────────────────┘

PART C: ADDITIONAL MEDICO-LEGAL FORMS


FORM 3: INJURY REPORT / WOUND CERTIFICATE

┌─────────────────────────────────────────────────────────────────────────┐
│                      WOUND CERTIFICATE / INJURY REPORT                  │
│                         (MLC Form - Outpatient/Casualty)                │
├─────────────────────────────────────────────────────────────────────────┤
│ MLC No.: _______________  Date: _______________  Time: ________________  │
│ Hospital: ___________________________________________________________    │
│                                                                         │
│ PATIENT DETAILS:                                                        │
│ Name: ________________________________ Age: ______ Sex: ____________    │
│ Address: ___________________________________________________________    │
│ Brought by: _________________________ Relation: ____________________    │
│                                                                         │
│ REFERRING AUTHORITY:                                                    │
│ Police / Magistrate / Self / Relative                                   │
│ FIR No.: ____________ PS: _____________ Date: ______________________    │
│ Referred by (Officer name): ______________________________________      │
│                                                                         │
│ HISTORY AS GIVEN BY PATIENT / INFORMANT:                                │
│ _____________________________________________________________           │
│ _____________________________________________________________           │
│                                                                         │
│ GENERAL CONDITION ON ADMISSION:                                         │
│ Conscious / Unconscious / Semiconscious  BP: ______ Pulse: _____        │
│ RR: _____ SpO2: _____ Temperature: _____                                │
│                                                                         │
│ INJURIES NOTED (each injury described individually):                    │
│                                                                         │
│ Injury 1:                                                               │
│ Nature: Abrasion / Contusion / Laceration / Incised wound / Firearm     │
│ Site: _________________________________ Size: ___________________       │
│ Shape: __________________ Edges: __________________                     │
│ Depth: ___________________                                              │
│ Surroundings: __________________________________________                │
│ Age of injury: Fresh / Old / Intermediate (approx _____ hours/days)     │
│ Ante-mortem / Post-mortem: ___________________                          │
│                                                                         │
│ Injury 2: (repeat as above for each injury)                             │
│                                                                         │
│ RADIOLOGICAL FINDINGS: (if X-ray done)                                  │
│ _____________________________________________________________           │
│                                                                         │
│ OPINION:                                                                │
│ 1. Nature of injuries:                                                  │
│    Simple / Grievous (as per IPC Sec 319-320 / BNS equivalent)          │
│                                                                         │
│ 2. Probable cause:                                                      │
│    Blunt force / Sharp force / Firearm / Self-inflicted / Others        │
│                                                                         │
│ 3. Age of injuries:                                                     │
│    Consistent with alleged time of assault: Yes / No                    │
│                                                                         │
│ 4. Probable weapon used: __________________________________              │
│                                                                         │
│ 5. Whether injuries are sufficient to cause:                            │
│    Death / Grievous injury / Simple injury                              │
│                                                                         │
│ Name: ________________________ Qualification: _____________________     │
│ Designation: ___________________ Signature: _______________________    │
│ Institution: ____________________ Date: ___________________________     │
└─────────────────────────────────────────────────────────────────────────┘

FORM 4: VISCERA FORWARDING MEMO (To Chemical Examiner / FSL)

┌─────────────────────────────────────────────────────────────────────────┐
│                      VISCERA FORWARDING MEMO                            │
│                (For Chemical Analysis by FSL / Chemical Examiner)       │
├─────────────────────────────────────────────────────────────────────────┤
│ To,                                                                     │
│ The Director, Forensic Science Laboratory / Chemical Examiner           │
│ Government of _____________________                                     │
│                                                                         │
│ From,                                                                   │
│ Dr. ____________________________                                        │
│ Department of Forensic Medicine                                         │
│ ________________________ Hospital                                       │
│                                                                         │
│ Reference: PM Report No. _______________ Date: ________________________ │
│ CR / FIR No.: _______________ PS: ___________________________________   │
│                                                                         │
│ Details of deceased: Name: _________________ Age: _____ Sex: _____      │
│ Date of PM: _________________ Time: ___________________________________  │
│                                                                         │
│ VISCERA/SAMPLES SENT:                                                   │
│                                                                         │
│ Container No. | Contents          | Preservative      | Quantity        │
│ ─────────────┼───────────────────┼───────────────────┼─────────────    │
│      1       │ Stomach+contents  │ Sat. NaCl soln.   │ Whole           │
│      2       │ Small intestine   │ Sat. NaCl soln.   │ 30 cm + cont.   │
│      3       │ Liver             │ Sat. NaCl soln.   │ 500 g           │
│      4       │ Kidney            │ Sat. NaCl soln.   │ 1 whole         │
│      5       │ Blood             │ None (plain)       │ 50 mL           │
│      6       │ Urine             │ None (plain)       │ 50 mL           │
│      7       │ Vitreous humor    │ None              │ Both eyes       │
│      8       │ Bile              │ None              │ All             │
│      9       │ Brain             │ Sat. NaCl soln.   │ 200 g           │
│     10       │ Lung              │ Sat. NaCl soln.   │ 100 g           │
│     11       │ _______________   │ _________________ │ _____________   │
│                                                                         │
│ Analysis requested:                                                     │
│ [ ] Organophosphate / Carbamate screen                                  │
│ [ ] Alcohol (ethanol) estimation                                        │
│ [ ] Heavy metals (As, Pb, Hg, Tl)                                       │
│ [ ] Cyanide                                                             │
│ [ ] Carbon monoxide (COHb) estimation                                   │
│ [ ] Drug screen (opiates, benzodiazepines, barbiturates)                │
│ [ ] Corrosives (acid, alkali)                                           │
│ [ ] Paracetamol / Salicylate levels                                     │
│ [ ] All poisons                                                         │
│ [ ] Others: ________________________                                    │
│                                                                         │
│ CLINICAL SUSPICION: _________________________________________________   │
│                                                                         │
│ All containers sealed with: Wax seal / Tape seal                        │
│ Sealed in the presence of: ________________________________________     │
│ (2 witnesses to sign)                                                   │
│ Witness 1: _______________________  Signature: ____________________    │
│ Witness 2: _______________________  Signature: ____________________    │
│                                                                         │
│ Forwarded through: Police (IO Name: __________________________)         │
│ Date of forwarding: ____________________                                │
│                                                                         │
│ Signature of MO: ____________________  Date: _______________________   │
│ Designation: _________________________                                  │
└─────────────────────────────────────────────────────────────────────────┘

FORM 5: SUPPLEMENTARY OPINION / HISTOPATHOLOGY REQUEST

┌─────────────────────────────────────────────────────────────────────────┐
│               HISTOPATHOLOGY REQUISITION / SUPPLEMENTARY OPINION        │
├─────────────────────────────────────────────────────────────────────────┤
│ To,                                                                     │
│ The Head, Department of Pathology                                       │
│ ___________________________ Hospital / Medical College                  │
│                                                                         │
│ PM Report No.: ____________ Date: _____________ CR No.: ____________    │
│ Name of Deceased: ___________________________ Age: _____ Sex: _____     │
│                                                                         │
│ TISSUES SENT:                                                           │
│ 1. Heart (myocardium, coronary artery cross sections)                   │
│ 2. Lung (bilateral)                                                     │
│ 3. Brain (cortex, brainstem, cerebellum)                                │
│ 4. Liver (portal zone + centrilobular)                                  │
│ 5. Kidney (cortex + medulla)                                            │
│ 6. Specific tissues: __________________                                 │
│                                                                         │
│ All fixed in 10% neutral buffered formalin.                             │
│                                                                         │
│ STAINS REQUESTED:                                                       │
│ [ ] Routine H&E (all tissues)                                           │
│ [ ] Special stains: PAS / Masson's trichrome / Perl's Prussian blue     │
│ [ ] Congo red (if amyloid suspected)                                    │
│ [ ] Oil Red O (fat embolism)                                            │
│ [ ] Beta-APP immunostaining (diffuse axonal injury)                     │
│ [ ] CD68 (macrophage infiltration - age of infarction)                  │
│                                                                         │
│ Clinical question: _______________________________________________       │
│                                                                         │
│ Signature: Dr. _______________ Date: _______________                   │
└─────────────────────────────────────────────────────────────────────────┘

FORM 6: DIATOM TEST REQUEST (for Drowning Cases)

┌─────────────────────────────────────────────────────────────────────────┐
│              DIATOM EXAMINATION REQUEST (DROWNING CASES)                │
├─────────────────────────────────────────────────────────────────────────┤
│ To,                                                                     │
│ The Director, Forensic Science Laboratory                               │
│ _____________________________                                           │
│                                                                         │
│ PM Report No.: ___________ CR No.: ___________ Date: ___________        │
│ Deceased: _______________________________                               │
│                                                                         │
│ SAMPLES SENT FOR DIATOM EXAMINATION:                                    │
│ 1. Bone marrow (from femur) - 50 g                                      │
│ 2. Kidney tissue - 50 g                                                 │
│ 3. Brain tissue - 50 g                                                  │
│ 4. Liver tissue - 50 g                                                  │
│ 5. Lung tissue - 50 g                                                   │
│ 6. Water sample from alleged drowning site - 500 mL                     │
│                                                                         │
│ Purpose: Comparison of diatom species and morphology between body       │
│ tissues and drowning medium to confirm/exclude ante-mortem drowning.    │
│                                                                         │
│ Basis: Diatoms entering alveoli during active breathing penetrate        │
│ blood-lung barrier and are carried to distant organs (bone marrow,      │
│ kidney, brain). Presence in bone marrow = strong evidence of            │
│ ante-mortem drowning.                                                   │
│                                                                         │
│ Signature: Dr. _______________ Date: _______________                   │
└─────────────────────────────────────────────────────────────────────────┘

PART D: QUICK REFERENCE - PM FINDINGS BY CAUSE OF DEATH


Master Diagnostic PM Findings Table

Mode of DeathHallmark External FindingsHallmark Internal FindingsKey Test
HangingOblique ascending incomplete ligature mark, cyanosis, petechiae, penile erectionDry subcutaneous band under mark, carotid intimal tears, petechiae on brain/lungs, right heart distended-
Ligature strangulationHorizontal complete ligature mark, petechiae, cyanosisHyoid/thyroid fracture common, laryngeal edema, asphyxial changes-
DrowningWasherwoman's hands, goose skin, froth at mouth/nose, pink lividityWaterlogged lungs (2x weight), emphysema aquosum, water in stomach/sinuses, Paltauf's hemorrhagesDiatom test, Gettler's chloride test
Electric shockJoule burn (entry), arborescent marks, exit wound (larger), singeingContraction band necrosis (histology), cerebral/pulmonary edema, NO pathognomonic internal findingHistopathology of wound
RTAPatterned contusions (tire marks), bumper injury, abrasions (road rash)Skull fractures, cerebral hemorrhage/DAI, hemothorax, organ lacerations, aortic transectionBAC (alcohol), DAI staining
Cardiac arrestObese, no external injuries, edemaCardiomegaly, LVH, coronary stenosis+thrombus, myocardial infarction, nutmeg liver, pulmonary edemaHistopathology (coronary + myocardium)
OP PoisoningMiosis, profuse froth, garlic odor, moist skinPulmonary edema, bronchorrhea, hyperemic GI mucosa, congested organsChemical analysis (FSL), RBC cholinesterase
Burns% BSA burns, vital reaction at margin, pugilistic postureSoot BELOW glottis, cherry-red blood, Curling's ulcers, heat hematoma (NOT trauma)COHb estimation
FirearmEntry (small, inverted edges, collar) vs. Exit (large, everted), GSRSkull beveling, brain laceration/track, bullet if presentGSR, ballistic analysis
CyanideBitter almond odor, pink/cherry lividity, no external traumaBright red blood + venous blood, congestion everywhere, rapid death changesChemical analysis for HCN
CO poisoningCherry-red lividity, cherry-red skin/mucosa, no external injuriesCherry-red all organs, pulmonary edema, carboxyhemoglobin in bloodCOHb blood level (FSL)

Postmortem Interval (PMI) Estimation Chart

FindingTime Estimate
Algor mortis: Warm body<2 hours
Body cool to touch4-6 hours
Body cold at core>10-12 hours
Livor Mortis appears2-4 hours
Livor Mortis deepens/spreads4-8 hours
Livor Mortis FIXED8-12 hours
Rigor Mortis begins (jaw/neck)1-3 hours
Rigor Mortis fully established6-12 hours
Rigor Mortis passing (secondary flaccidity)24-48 hours
Early decomposition (greenish discoloration RIF)36-72 hours
Marbling4-7 days
Bloating / Gas5-10 days
SkeletonizationWeeks to months

Legal Framework Quick Reference

ProvisionPurpose
Sec. 174 CrPC / Sec. 194 BNSSPolice inquest in cases of unnatural/suspicious death
Sec. 176 CrPC / Sec. 195 BNSSMagistrate inquest (dowry death, custodial death, suicide)
Sec. 45 Indian Evidence ActExpert opinion admissible as evidence
Sec. 302 IPC / Sec. 101 BNSMurder
Sec. 304A IPC / Sec. 106 BNSCausing death by negligence (RTA)
Sec. 304B IPC / Sec. 80 BNSDowry death
Sec. 306 IPC / Sec. 108 BNSAbetment of suicide
Sec. 309 IPC / Sec. 226 BNSAttempt to suicide (decriminalized now)
Sec. 174A IPCPreservation of viscera

Sources: The Essentials of Forensic Medicine & Toxicology, 36th ed. 2026 (KS Narayan Reddy) | Parikh's Textbook of Medical Jurisprudence, Forensic Medicine & Toxicology | PC Dikshit's Textbook of Forensic Medicine & Toxicology
Important Note: All PM reports are legal documents. They must be written clearly, objectively, and signed by the examining officer. Opinions should be confined to findings observed. The final manner of death in suspicious cases should always be given with the qualifier "pending chemical analysis/further investigation" where applicable. Any corrections must be initialed. Do not overwrite.

Master guide for iPd clinical cases

Before I dive in, let me clarify what you need — "iPD clinical cases" could mean a few different things.
Asking for Preferences

What does 'iPD clinical cases' mean in your context? · What scope/specialty are you looking for?

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Here is the complete master guide:

🏥 MASTER GUIDE: IPD CLINICAL CASES

In-Patient Department — All Specialties

Sources: Goldman-Cecil Medicine | Harrison's Principles | Tintinalli's Emergency Medicine | Sabiston Surgery | Murray & Nadel's Respiratory Medicine | Sleisenger & Fordtran's GI | Rosen's Emergency Medicine

HOW TO WRITE AN IPD CASE — UNIVERSAL FORMAT

Every IPD case follows this structured skeleton:
1. PRESENTING COMPLAINTS (PC)        → Chief symptom + duration
2. HISTORY OF PRESENTING ILLNESS     → Chronological story of the illness
   (HOPI)
3. PAST HISTORY (PH)                 → Similar illness, surgeries, admissions
4. PERSONAL HISTORY                  → Diet, sleep, bowel, bladder, menstrual,
                                        addictions, occupation
5. FAMILY HISTORY (FH)               → Hereditary/communicable conditions
6. SOCIOECONOMIC HISTORY             → SES, living conditions, water/sanitation
7. TREATMENT HISTORY                 → Current and past medications
8. GENERAL PHYSICAL EXAMINATION      → Built, nourishment, pallor, icterus,
   (GPE)                               cyanosis, clubbing, lymphadenopathy,
                                        edema, JVP, pulse, BP, RR, Temp, SpO2
9. SYSTEMIC EXAMINATION              → Focused system(s) in detail
10. PROVISIONAL DIAGNOSIS            → Based on clinical findings
11. DIFFERENTIAL DIAGNOSIS           → 2-3 alternatives
12. INVESTIGATIONS                   → In logical order (bedside → labs → imaging)
13. FINAL DIAGNOSIS                  → After results
14. TREATMENT                        → Non-pharmacological + pharmacological
15. PROGRESS NOTES                   → Day-by-day in-patient notes
16. DISCHARGE SUMMARY               → Condition on discharge + follow-up

SECTION 1: INTERNAL MEDICINE (GENERAL MEDICINE)


CASE 1: ACUTE MYOCARDIAL INFARCTION (STEMI)

Ward Admission Scenario:
A 58-year-old male, hypertensive, smoker, admitted with severe crushing substernal chest pain radiating to left arm and jaw, with sweating and breathlessness for 2 hours.

PRESENTING COMPLAINTS:

  1. Severe chest pain - 2 hours
  2. Sweating - 2 hours
  3. Breathlessness - 1 hour
  4. Nausea - 2 hours

HISTORY OF PRESENTING ILLNESS:

Patient was apparently well until 2 hours ago when he developed sudden onset severe crushing/squeezing pain in the centre of the chest, rated 9/10 in severity. Pain radiates to left arm and jaw. Associated with profuse sweating, nausea, and breathlessness. No relief with rest or antacids. No prior similar episodes. Denies pleuritic character, positional change in pain, or cough. Patient is a known hypertensive on amlodipine for 5 years. Heavy smoker (1 pack/day × 20 years).

PAST HISTORY:

  • Hypertension: 5 years, on amlodipine 5 mg OD
  • No prior MI, no PCI/CABG
  • No diabetes mellitus, no CKD

PERSONAL HISTORY:

  • Diet: Non-vegetarian
  • Smoker: 20 pack-years
  • Alcohol: Occasional
  • No regular exercise

FAMILY HISTORY:

  • Father died of MI at age 55 (premature CAD)

GENERAL PHYSICAL EXAMINATION:

ParameterFinding
BuiltAverage
NourishmentAdequate
PallorPresent (mild)
IcterusAbsent
CyanosisAbsent
ClubbingAbsent
LymphadenopathyAbsent
EdemaAbsent
Pulse96/min, irregular, low volume
BP100/70 mmHg (hypotension)
RR24/min
Temp37.2°C
SpO294% on room air
JVPElevated (4 cm above sternal angle)

SYSTEMIC EXAMINATION:

CVS:
  • Apex beat: Not well localized
  • S1 S2 heard, S3 gallop present (LV dysfunction)
  • No murmurs
  • Bilateral fine crepitations at bases (pulmonary edema)
Respiratory: Bilateral basal crackles
Abdomen: Soft, no organomegaly
CNS: Alert, oriented

PROVISIONAL DIAGNOSIS:

Acute STEMI (inferior wall / anterior wall) with Killip class II heart failure

DIFFERENTIAL DIAGNOSIS:

  1. Unstable angina / NSTEMI
  2. Aortic dissection (Type A)
  3. Acute pericarditis

INVESTIGATIONS:

IMMEDIATE (Bedside):
  • ECG: ST elevation ≥1 mm in ≥2 contiguous leads (inferior: II, III, aVF; anterior: V1-V4)
  • SpO2 monitoring
  • IV access × 2
Bloods (STAT):
  • Troponin I / T: Elevated (>99th percentile upper reference limit)
  • CK-MB: Elevated
  • CBC: Leucocytosis (stress response)
  • RFT/LFT: Baseline
  • Electrolytes: Na+, K+, Ca2+ (K+ critical before thrombolysis)
  • Blood glucose
  • PT/INR, aPTT (before anticoagulation)
  • Lipid profile
  • ABG (if breathless)
Imaging:
  • CXR PA/AP: Cardiomegaly, Kerley B lines, pulmonary venous congestion
  • Echo (bedside): RWMA (regional wall motion abnormality), EF assessment

FINAL DIAGNOSIS:

Acute Anterior STEMI with Killip Class II (ECG: ST elevation V1-V4, Troponin I: 8.2 ng/mL)

TREATMENT:

A. IMMEDIATE MANAGEMENT (MONA + Antiplatelet + Anticoagulation):
DrugDoseRoutePurpose
O22-4 L/min (if SpO2 <90%)Nasal prongsHypoxia correction
Aspirin300 mg STAT (chew)OralAntiplatelet
Clopidogrel300 mg STAT (loading)OralAntiplatelet
Morphine2-4 mg IVIV slowPain relief
GTN0.4 mg sublingual × 3 (if SBP >90)SLVasodilation
Heparin60 units/kg IV bolus → 12 units/kg/hIVAnticoagulation
Atorvastatin80 mgOralStatin (high intensity)
B. REPERFUSION (TIME-CRITICAL - door-to-balloon <90 min or door-to-needle <30 min):
  • Primary PCI: Preferred if available within 90 min (cathlab referral)
  • Thrombolysis (if PCI not available within 120 min):
    • Streptokinase 1.5 million units IV over 60 min, OR
    • Tenecteplase (TNK-tPA): Weight-based single IV bolus
    • Contraindications: Prior ICH, active bleed, BP >180/110, recent surgery <3 months
C. SUPPORTIVE:
  • Bed rest, cardiac monitoring, continuous telemetry
  • IV access, Foley catheter (urine output monitoring)
  • Nil orally until stable; then liquid diet
  • Anxiolytics: Lorazepam 1 mg IV PRN
D. SECONDARY PREVENTION:
  • Beta-blocker: Metoprolol 25 mg BD (start in 24h if stable)
  • ACE inhibitor: Ramipril 2.5 mg OD (within 24h)
  • DAPT: Aspirin 75 mg + Clopidogrel 75 mg OD × 12 months
  • Statin: Atorvastatin 80 mg OD lifelong

PROGRESS NOTES (Day-wise):

Day 1: ECG: ST resolution >50% after thrombolysis. Troponin peak at 12h. Telemetry: Occasional VPCs. BP stabilized 110/70. SpO2 98% on 2L O2. Crepitations persist. Echo: EF 40%, anterior RWMA.
Day 2: SpO2 on room air 96%. Tolerating oral diet. No chest pain. Furosemide 40 mg IV for pulmonary congestion. Urine output 1.2 mL/kg/h.
Day 3: Off O2. Clinically stable. Echocardiogram repeated: EF 42%. Ambulation started. Statin, ACEI, beta-blocker continued.
Day 5-7: Discharge planning. Patient education: Lifestyle modification, smoking cessation, diet, regular exercise, medication adherence.

DISCHARGE SUMMARY:

  • Diagnosis: Acute Anterior STEMI (thrombolysis with TNK-tPA, successful reperfusion)
  • EF: 42% (mildly reduced)
  • Discharge medications: Aspirin 75 mg + Clopidogrel 75 mg + Atorvastatin 80 mg + Ramipril 2.5 mg + Metoprolol 25 mg BD + Furosemide 20 mg OD
  • Follow-up: Cardiology OPD in 1 week; Repeat Echo at 6 weeks
  • Advice: Strict smoking cessation, cardiac rehabilitation, low-salt diet

CASE 2: COMMUNITY-ACQUIRED PNEUMONIA (CAP)

Ward Admission Scenario:
A 45-year-old male presents with high-grade fever, productive cough with rusty sputum, right-sided pleuritic chest pain, and breathlessness for 5 days.

PRESENTING COMPLAINTS:

  1. Fever - 5 days
  2. Cough with rust-colored sputum - 4 days
  3. Right-sided chest pain worsening on breathing - 3 days
  4. Breathlessness - 2 days

HOPI:

Sudden onset high-grade fever (measured 39.8°C at home) with chills and rigors 5 days back. Productive cough producing rust-colored, blood-tinged sputum. Sharp right-sided pleuritic chest pain aggravated on breathing and coughing. Progressive breathlessness - initially on exertion, now at rest. Preceded by upper respiratory symptoms (cold, sore throat) 1 week back. No hemoptysis, weight loss, night sweats, or TB contact (rule out TB).

GPE:

ParameterFinding
PallorMild
Pulse108/min, regular
BP100/70 mmHg
RR28/min
Temp39.4°C
SpO291% on room air
CURB-65 Score:
  • Confusion: No (0)
  • BUN >7 mmol/L: Yes (1)
  • RR ≥30: No (0)
  • BP <90/60: No (0)
  • Age ≥65: No (0)
  • Score = 1 → Low risk, outpatient vs. inpatient (borderline)
  • PSI/PORT score calculated → Class III → Admit

SYSTEMIC EXAMINATION - RESPIRATORY:

  • Inspection: Decreased chest expansion right side
  • Palpation: Increased tactile fremitus right infrascapular
  • Percussion: DULL on right infrascapular and axillary regions
  • Auscultation: Bronchial breathing + coarse crepitations right lower zone; Aegophony positive

PROVISIONAL DIAGNOSIS:

Community-Acquired Pneumonia (Right lower lobe) - likely bacterial (Streptococcus pneumoniae)

DIFFERENTIAL DIAGNOSIS:

  1. Pulmonary tuberculosis (sputum AFB)
  2. Lung abscess
  3. Pleural effusion with underlying consolidation

INVESTIGATIONS:

  • CXR PA: Right lower zone consolidation (homogeneous opacity with air bronchogram)
  • CBC: TLC 18,400/µL (neutrophilia), N: 84%, L: 10%
  • CRP: 92 mg/L (elevated)
  • PCT (Procalcitonin): 1.8 ng/mL (bacterial)
  • Sputum C/S: Gram-positive diplococci (Streptococcus pneumoniae)
  • Blood cultures × 2: Pending
  • S. pneumoniae urinary antigen: Positive
  • RFT, LFT, Electrolytes, Blood sugar: Baseline
  • HIV screening: (if risk factors)
  • ABG: pH 7.44, PaO2 58 mmHg, PaCO2 32 mmHg → Type 1 respiratory failure

TREATMENT:

Non-pharmacological:
  • Admit to ward; O2 via face mask 6-8 L/min (target SpO2 ≥94%)
  • Semi-recumbent position
  • IV access; oral hydration/IV fluids
  • Incentive spirometry
  • Physiotherapy - chest percussion
Pharmacological:
DrugDoseRouteFrequency
Inj. Ceftriaxone1 gIV12 hourly
Tab. Azithromycin500 mgOralOD × 5 days
Tab. Paracetamol500 mgOralSOS for fever
Inj. Heparin5000 unitsSCBD (DVT prophylaxis)
Mucolytic (Ambroxol)30 mgOralTDS
Atypical coverage rationale: Azithromycin covers Mycoplasma, Chlamydia, Legionella alongside ceftriaxone for Streptococcus.
Switch to oral: After 48-72h of clinical improvement (fever <37.8°C, improving SpO2, tolerating oral)

PROGRESS NOTES:

Day 1-2: Fever persisting, SpO2 94% on 6L O2. Cultures pending. Day 3: Fever defervescence. SpO2 97% on 2L. Sputum culture confirms Strep. pneumoniae (sensitive to penicillin). Switch to oral Amoxicillin-Clavulanate 625 mg TDS. Day 5: Afebrile × 48h. SpO2 97% RA. CXR: Clearing. Discharge.

DISCHARGE:

  • Tab. Amoxicillin-Clavulanate 625 mg TDS × 5 more days
  • Pneumococcal vaccine at 6-8 weeks
  • Influenza vaccine
  • Stop smoking advice
  • Follow-up in 6 weeks with repeat CXR

CASE 3: DIABETIC KETOACIDOSIS (DKA)

Ward Admission Scenario:
A 24-year-old known Type 1 diabetic female admitted with vomiting, abdominal pain, deep rapid breathing, and confusion for 12 hours. Omitted insulin for 2 days.

PRESENTING COMPLAINTS:

  1. Vomiting - 12 hours
  2. Abdominal pain - 12 hours
  3. Deep rapid breathing - 8 hours
  4. Confusion - 4 hours

HOPI:

Known Type 1 DM on insulin (Insulin glargine + aspart). Omitted insulin doses for 2 days due to poor oral intake during an upper respiratory infection. Developed nausea, vomiting (3-4 episodes, non-bilious), and central abdominal pain. Noticed increased thirst and urination over 2 days. Progressive breathlessness (deep sighing breaths). Confused and drowsy over last 4 hours.

GPE:

ParameterFinding
GCS12/15 (E3V4M5)
Pulse118/min, weak, thready
BP96/70 mmHg
RR32/min (Kussmaul breathing)
Temp37.8°C
SpO298%
BreathFruity/acetone odor (ketones)
DehydrationSevere (dry mucosa, sunken eyes, poor turgor)
PallorMild

SYSTEMIC EXAMINATION:

  • Abdomen: Diffuse tenderness (DKA itself causes pseudoperitoneum - exclude surgical cause)
  • CNS: Drowsy, responding to voice; pupils equal and reactive

PROVISIONAL DIAGNOSIS:

Diabetic Ketoacidosis (DKA) with severe dehydration and altered sensorium

INVESTIGATIONS:

BEDSIDE (STAT):
  • Glucometer: HI (>500 mg/dL) → Confirm with lab
  • Urine dipstick: Ketones 4+, Glucose 4+
BLOODS:
TestValueNormal
Blood glucose542 mg/dL70-100
ABG: pH7.067.35-7.45
ABG: HCO38 mEq/L22-26
ABG: PCO222 (compensatory)35-45
Anion gap32 mEq/L8-12
Serum Na+128 mEq/L (corrected Na 136)136-145
Serum K+3.2 mEq/L (BEFORE insulin - may be depleted)3.5-5.0
BUN42 mg/dL (dehydration)7-20
Creatinine1.8 mg/dL0.6-1.2
Serum ketonesStrongly positive-
CBCTLC 14,200 (infection/stress)-
DKA Diagnostic Criteria (confirmed):
  • Blood glucose >250 mg/dL ✓
  • pH <7.3 ✓
  • HCO3 <15 mEq/L ✓
  • Anion gap >12 ✓
  • Urine/serum ketones positive ✓
Severity: SEVERE (pH <7.1, HCO3 <5, AG >30, altered consciousness)

TREATMENT PROTOCOL:

Phase 1 - Resuscitation (0-1h):
  • IV access × 2 (large bore)
  • 0.9% Normal saline: 1 L over first hour (correct shock/dehydration)
  • O2 via NRB mask
  • Catheterize (urine output monitoring - target >0.5 mL/kg/h)
  • NGT if vomiting persisting
Phase 2 - Potassium replacement (BEFORE insulin if K+ <3.5):
  • K+ = 3.2 → Replace first: KCl 40 mEq in 1L NS over 4h (central line)
  • DO NOT start insulin until K+ ≥3.5 (insulin shifts K+ intracellularly → fatal hypokalemia)
Phase 3 - Insulin infusion:
  • Regular insulin 0.1 unit/kg/h IV (= 7 units/h for 70 kg)
  • Target glucose fall: 50-70 mg/dL/hour
  • When glucose <250 mg/dL: Switch IV fluid to D5W + reduce insulin to 0.05 units/kg/h
Phase 4 - Ongoing fluid replacement:
  • 0.9% NS: 500 mL/h × 4h → 250 mL/h × 4h → 125 mL/h as tolerated
  • When glucose <250: Add dextrose to maintain glucose 150-200 mg/dL
  • Total deficit: Approximately 5-8 L
Monitoring (CRITICAL):
  • Glucose hourly
  • Electrolytes (K+) every 2h
  • ABG every 2-4h
  • Urine output hourly
  • GCS every 2h
Precipitant treatment: Treat underlying infection (antibiotics if sepsis suspected)
DKA Resolution criteria:
  • Blood glucose <200 mg/dL
  • pH >7.3
  • HCO3 ≥15 mEq/L
  • Anion gap <12
Transition to subcutaneous insulin:
  • Give first SC dose of long-acting insulin 2h BEFORE stopping IV insulin
  • Resume usual insulin regimen

PROGRESS NOTES:

0-2h: Glucose 542 → 380. pH 7.06 → 7.14. K+ 3.2 → replaced. NS running. 4h: Glucose 260. pH 7.24. K+ 3.8. Switched to D5W + reduced insulin. 8h: Glucose 192. pH 7.32. HCO3 16. AG 14. Vomiting stopped. Alert. 12h: DKA resolving. Started oral fluids. Glargine given SC. 24h: pH 7.38. Glucose stable. Anion gap normal. Oral diet tolerated. IV insulin stopped (after 2h overlap).

DISCHARGE:

  • Insulin regime adjusted
  • DM education: Sick day rules (NEVER omit insulin even if not eating)
  • Self-monitoring blood glucose (SMBG)
  • HbA1c in 3 months
  • Endocrinology OPD follow-up

CASE 4: UPPER GI BLEED (Variceal)

Ward Admission Scenario:
A 50-year-old male with known alcoholic liver cirrhosis admitted with hematemesis (2 large episodes, ~500 mL fresh blood) and melena for 6 hours.

PRESENTING COMPLAINTS:

  1. Vomiting blood - 6 hours (2 episodes, ~500 mL)
  2. Passage of black tarry stools - 4 hours
  3. Dizziness and weakness - 4 hours

HOPI:

Known alcoholic cirrhosis (Child-Pugh B, on propranolol and lactulose). Suddenly vomited bright red blood in 2 large episodes. Black tarry stools × 1. Presently dizzy, feeling faint on standing, and extremely weak. History of previous variceal bleed 2 years ago (banding done).

GPE:

ParameterFinding
GCS13/15
PallorSevere +++
JaundicePresent ++
Pulse122/min, thready, weak
BP86/50 mmHg (supine)
Postural drop+25 mmHg systolic
RR24/min
SpO295%

SYSTEMIC EXAMINATION:

  • Abdomen: Moderate ascites, splenomegaly, liver edge not palpable (cirrhosis)
  • Hands: Palmar erythema, Dupuytren's contracture, leuconychia, flapping tremor (hepatic encephalopathy)
  • Chest: Spider angiomata × 4
Rockall Score: Pre-endoscopy = 4 (moderate risk)
Child-Pugh Score: B (7 points)

INVESTIGATIONS:

IMMEDIATE:
  • CBC: Hb 6.8 g/dL, PCV 22%, Platelet 68,000 (hypersplenism)
  • PT/INR: 2.4 (coagulopathy of liver disease)
  • LFT: Bilirubin 4.2, Albumin 2.8, ALT 78
  • RFT: Creatinine 1.6, BUN 42 (blood in gut)
  • Electrolytes: Na 128, K 3.0
  • Blood group and crossmatch (4 units PRBC)
  • ABG
Imaging:
  • CXR: No free air (exclude perforation)
  • USG abdomen: Portal hypertension, splenomegaly, ascites - no thrombus

TREATMENT:

STEP 1 - RESUSCITATION (SIMULTANEOUS):
  • 2 large bore IV cannulas (14-16G)
  • IV NS/Ringer's lactate: 500 mL rapidly (avoid over-expansion → re-bleed)
  • Target Hb 7-8 g/dL (restrictive transfusion strategy = better outcomes)
  • Blood transfusion: 2 units PRBC (crossmatched)
  • FFP: 2 units (for coagulopathy, INR >2)
  • Platelet transfusion if <50,000 before endoscopy
STEP 2 - PHARMACOLOGICAL (start BEFORE endoscopy):
DrugDoseRouteDuration
Terlipressin2 mg IV q4h → 1 mg q4hIV bolus72 hours
Somatostatin/Octreotide50 mcg bolus → 25-50 mcg/hIV infusion72 hours
Pantoprazole80 mg bolus → 8 mg/hIV infusion72 hours
Ceftriaxone1 g IV ODIV7 days (SBP prophylaxis)
STEP 3 - URGENT ENDOSCOPY (within 12h, ideally 6h):
  • Endoscopic variceal ligation (EVL) - primary modality
  • If active bleed not controlled: Sclerotherapy (cyanoacrylate for gastric varices)
  • Balloon tamponade (Sengstaken-Blakemore tube) if EVL fails - bridge to TIPS
STEP 4 - SECONDARY PREVENTION:
  • Propranolol: Restart when stable (reduces portal pressure, prevents re-bleed)
  • Repeat EVL sessions every 2-4 weeks until variceal obliteration
  • TIPS (Transjugular Intrahepatic Portosystemic Shunt): If 2 endoscopy sessions fail
HEPATIC ENCEPHALOPATHY PREVENTION:
  • Lactulose 30 mL TDS (reduce ammonia)
  • Avoid sedation, avoid protein excess
  • Rifaximin 550 mg BD (adjunct)
ASCITES MANAGEMENT:
  • Spironolactone 100 mg + Furosemide 40 mg OD
  • Albumin 1.5 g/kg on Day 1 of SBP diagnosis (if concurrent)
  • Fluid restriction to 1.5 L/day

DISCHARGE:

  • Propranolol (titrate to HR 55-60 or reduce resting HR by 25%)
  • EVL repeat in 2 weeks
  • Lactulose + Rifaximin
  • Complete alcohol cessation (counselling referral)
  • Liver transplant evaluation

CASE 5: STROKE / CVA (Ischemic)

Ward Admission Scenario:
A 65-year-old hypertensive male with sudden onset left-sided weakness, facial deviation, and slurred speech for 2 hours.

PRESENTING COMPLAINTS:

  1. Sudden weakness of left arm and leg - 2 hours
  2. Deviation of mouth - 2 hours
  3. Slurred speech - 2 hours

HOPI:

Sudden onset at rest (while watching TV) of left-sided weakness of face, arm, and leg. Drooping of left side of face. Slurred, difficult-to-understand speech. Mild headache. No seizures, no loss of consciousness, no vision changes. Last seen normal (LKNW) by family: 2 hours ago. Known hypertensive not taking medicines regularly. H/o AF on aspirin.

GPE:

ParameterFinding
GCS14/15
BP178/102 (both arms)
Pulse82/min, irregular
RR18/min
Stroke Code Activated: NIHSS calculated
NIHSS Score: 14 (moderate-severe stroke)
FAST Score: Face + Arm + Speech + Time = +++ (positive all)

SYSTEMIC EXAMINATION - CNS:

  • Higher functions: Alert, oriented, dysarthria
  • Cranial nerves: CNVII LMN palsy left side (face)
  • Motor: Left upper limb 0/5, left lower limb 1/5 (power)
  • Tone: Decreased left (acute phase)
  • Reflexes: Brisk left, Babinski positive left
  • Sensory: Diminished to touch/pain left side
  • Cerebellar: Not assessable
  • No meningism
CVS: Atrial fibrillation

PROVISIONAL DIAGNOSIS:

Acute Ischemic Stroke - Right MCA territory (AF as source of cardioembolism)

INVESTIGATIONS:

IMMEDIATE (within 25 min of arrival):
  • Non-contrast CT head (NCCT): Rule out hemorrhage → NEGATIVE for bleed (dark CSF spaces, no hyperdense lesion in first 6h)
  • ECG: AF with normal ventricular rate
  • Blood glucose (hypoglycemia mimics stroke): 128 mg/dL
  • INR/PT: 1.1 (not on anticoagulant)
  • CBC, RFT, Electrolytes
CT Angiography: Proximal right MCA occlusion confirmed
Diffusion-weighted MRI (DWI): Ischemic infarct right MCA territory

TREATMENT:

THROMBOLYSIS DECISION (IV tPA - Alteplase/Tenecteplase):
  • Time window: Within 4.5 hours of onset (patient at 2h → ELIGIBLE)
  • Contraindications checked: No recent surgery, no bleed on CT, BP controllable, no coagulopathy
  • Alteplase 0.9 mg/kg IV (max 90 mg):
    • 10% as bolus over 1 min
    • Remaining 90% over 60 min infusion
  • Monitor: BP every 15 min during infusion, neurological checks
BP MANAGEMENT (CRITICAL):
  • For thrombolysis: Bring BP to <185/110 before starting
  • Labetalol 10-20 mg IV or Nicardipine 5 mg/h
  • After thrombolysis: Keep <180/105 for 24h
ENDOVASCULAR THROMBECTOMY (EVT) - Mechanical:
  • Large vessel occlusion on CTA (MCA M1) → EVT within 24h of onset
  • Transfer to neurointerventional suite
ANTIPLATELET (if no tPA):
  • Aspirin 300 mg STAT + Clopidogrel 75 mg OD (dual antiplatelet × 21 days for minor stroke)
ANTICOAGULATION (AF-related cardioembolic stroke):
  • DEFER anticoagulation 2-14 days (hemorrhagic transformation risk)
  • After CT confirms no bleed at 5-7 days: Start DOAC (Rivaroxaban 20 mg OD or Apixaban 5 mg BD)
  • WARFARIN if valve disease (target INR 2-3)
SUPPORTIVE:
  • Nil orally (swallowing assessment with GUSS tool first)
  • NG tube feeding if dysphagia
  • IV fluids: NS (not dextrose - may worsen cerebral edema)
  • Head end elevation 30°
  • Avoid hyperthermia (paracetamol for temp >37.5°C)
  • DVT prophylaxis: Enoxaparin 40 mg SC + TED stockings
  • Monitor glucose: Keep 140-180 mg/dL (both hypo and hyperglycemia worsen outcome)
  • Urinary catheter (retention risk)
REHABILITATION (start within 24-48h):
  • Physiotherapy: Range of motion, positioning
  • Speech therapy: Dysarthria/aphasia
  • Occupational therapy
  • Neurology/Rehab team

DISCHARGE:

  • DOAC for AF (Apixaban 5 mg BD)
  • Antihypertensive: Perindopril 4 mg OD
  • Statin: Atorvastatin 40 mg OD
  • Antiplatelet (if no anticoagulation)
  • Physiotherapy and speech therapy (outpatient)
  • Target BP <130/80, LDL <70 mg/dL

CASE 6: SEPSIS / SEPTIC SHOCK

Ward Admission Scenario:
A 72-year-old diabetic male admitted with high fever, low BP, confusion, and decreased urine output for 24 hours (source: UTI).

PRESENTING COMPLAINTS:

  1. Fever with chills - 3 days
  2. Burning micturition, foul-smelling urine - 3 days
  3. Confusion - 24 hours
  4. Low BP, weakness - 12 hours

GPE:

ParameterFinding
GCS10/15
Temp39.6°C
HR118/min, weak
BP82/52 mmHg
RR26/min
SpO294%
UO<0.5 mL/kg/h
SOFA Score: 8 (Organ dysfunction: Kidney + CNS + Cardiovascular) qSOFA: 3/3 (AMS + RR >22 + SBP <100) = Sepsis highly likely

INVESTIGATIONS:

  • Lactate: 4.8 mmol/L (>2 = sepsis; >4 = septic shock)
  • Procalcitonin: 28 ng/mL
  • Blood cultures × 2 (before antibiotics)
  • Urine R/M: Pus cells +++, bacteria +++
  • Urine C/S: Sent (result in 48h)
  • CBC: TLC 22,000; CRP 180
  • RFT: Creatinine 2.8 (AKI), BUN 64
  • ABG: pH 7.28, HCO3 14, lactate 4.8

SURVIVING SEPSIS BUNDLE (1-HOUR BUNDLE):

Within 1 hour:
  1. Measure lactate (done - 4.8 mmol/L)
  2. Blood cultures × 2 BEFORE antibiotics
  3. Broad-spectrum antibiotics STAT:
    • Piperacillin-Tazobactam 4.5 g IV q6h + Gentamicin 5 mg/kg OD
  4. Crystalloid: 30 mL/kg NS IV over 3 hours (2100 mL for 70 kg)
  5. Vasopressors if MAP <65 after fluids:
    • Norepinephrine: Start 0.1-0.5 mcg/kg/min (target MAP ≥65 mmHg)
Ongoing management:
  • ICU admission (SOFA ≥8, vasopressor requirement)
  • Central line (CVP monitoring)
  • Arterial line (continuous BP)
  • Foley catheter (UO target >0.5 mL/kg/h)
  • Hydrocortisone 200 mg/day IV if vasopressor-refractory
  • Insulin infusion for glucose >180 mg/dL
  • DVT prophylaxis
  • Stress ulcer prophylaxis (pantoprazole)
  • Source control: Urology consult (urinary tract - catheterization/drainage)

DISCHARGE:

  • Culture-directed antibiotics for 5-7 days total
  • Urology follow-up (stone/BPH if UTI source)
  • Diabetes management optimization

SECTION 2: SURGERY


CASE 7: ACUTE APPENDICITIS

Ward Admission Scenario:
A 22-year-old male with pain starting around the navel and shifting to right iliac fossa over 24 hours, with nausea, vomiting, and fever.

PRESENTING COMPLAINTS:

  1. Pain abdomen - 24 hours (central → RIF)
  2. Nausea and vomiting - 20 hours
  3. Fever - 12 hours
  4. Anorexia - 24 hours

HOPI:

Started with dull periumbilical pain 24 hours ago. After 6-8 hours, pain shifted to right iliac fossa, became sharp and constant (Kocherization / McBurney's point pain). Nausea and vomiting × 3 (non-bilious). Low-grade fever. Complete anorexia. Walking bent slightly forward (reduces peritoneal stretch). No previous similar episodes. No diarrhea, no urinary symptoms (rule out renal colic).

GPE:

  • Temp: 38.2°C, HR 98/min, BP 120/76, RR 18
  • Anxious, guarding right side on walking
  • No jaundice, no lymphadenopathy

SYSTEMIC EXAMINATION - ABDOMEN:

  • Inspection: Moves poorly with breathing right side; no distension
  • Palpation: Maximum tenderness at McBurney's point (1/3 from ASIS to umbilicus)
    • Rebound tenderness: Positive (peritoneal irritation)
    • Rovsing's sign: Positive (LIF pressure causes RIF pain)
    • Psoas sign: Positive (pain on right hip flexion)
    • Obturator sign: Positive (pain on internal rotation of right hip)
    • Guarding/rigidity: +1 right lower quadrant
  • Percussion: Tenderness
  • Auscultation: Reduced bowel sounds
Alvarado Score:
ParameterScore
Migration of pain to RIF1
Anorexia1
Nausea/vomiting1
Tenderness in RIF2
Rebound tenderness1
Elevated temperature1
Leucocytosis2
Shift to left1
Total9/10 → HIGH RISK (≥7 = operate)

INVESTIGATIONS:

  • CBC: TLC 16,400, Neutrophils 88% (left shift)
  • CRP: 78 mg/L
  • Urine R/M: Normal (rule out UTI/renal colic)
  • Urine pregnancy test (females): Negative
  • Blood group and crossmatch
  • BMP baseline
  • USG abdomen: Non-compressible, enlarged appendix >6 mm; periappendiceal fat stranding
  • CT abdomen + pelvis (if USG inconclusive): Confirms - appendicular diameter 9 mm, periappendiceal inflammation

FINAL DIAGNOSIS:

Acute Appendicitis (Alvarado 9, USG confirmed)

TREATMENT:

Pre-operative:
  • Nil orally from time of diagnosis
  • IV Ringer's Lactate 1L over 8h
  • Inj. Ceftriaxone 1g IV stat (pre-op antibiotic)
  • Inj. Metronidazole 500 mg IV stat
  • Inj. Ondansetron 4 mg IV (anti-emetic)
  • Consent for laparoscopic appendicectomy
  • Anaesthesia fitness
Surgical - Laparoscopic Appendicectomy:
  • Under GA
  • 3-port technique (umbilical 10mm + suprapubic 5mm + left iliac fossa 5mm)
  • Identify appendix, mesoappendix divided, base ligated (Endoloop/stapler)
  • Appendix retrieved in endobag
  • Peritoneal lavage if pus present
  • Drains only if perforation
  • Specimen to histopathology (exclude carcinoid/Crohn's)
Post-operative:
  • IV antibiotics continued 24h (uncomplicated) or 5-7 days (perforated)
  • Start oral liquids in 6h if laparoscopic
  • Analgesia: Paracetamol + Diclofenac
  • DVT prophylaxis: LMWH + stockings
  • Discharge Day 1-2 post-op (laparoscopic)

SECTION 3: OBSTETRICS & GYNAECOLOGY


CASE 8: ECLAMPSIA

Ward Admission Scenario:
A 24-year-old primigravida at 35 weeks gestation admitted with convulsions at home, BP 180/120, and pedal edema for 2 weeks.

PRESENTING COMPLAINTS:

  1. Convulsions - 1 episode, 1 hour ago (tonic-clonic, duration 2 min)
  2. Severe headache - 3 days
  3. Blurring of vision - 2 days
  4. Swelling of feet - 2 weeks

OBSTETRIC HISTORY:

  • Primi gravida, 35 weeks (LMP-based)
  • ANC: Irregularly attended (3 visits only; last visit BP noted as 140/90 at 30 weeks - not followed up)
  • No prior hypertension before pregnancy

GPE:

ParameterFinding
GCS12/15 (post-ictal)
BP182/118 mmHg
Pulse106/min
RR20/min
SpO296%
Pedal edemaBilateral pitting, up to knees
Facial puffinessPresent
Reflexes: Deep tendon reflexes brisk +++, ankle clonus 5 beats

OBSTETRIC EXAMINATION:

  • Fundal height: 34 weeks size
  • FHR: 148 bpm (reassuring)
  • Presentation: Cephalic
  • Station: -3 (not engaged)
  • Cervix: Closed, uneffaced

INVESTIGATIONS:

  • Urine dipstick: Protein +++
  • Urine albumin: 24h - 4.8 g/day (severe range)
  • CBC: Hb 10.2, Platelets 98,000 (HELLP developing)
  • LFT: AST 120, ALT 98 (elevated - HELLP)
  • LDH: 680 (elevated)
  • Peripheral smear: Schistocytes (hemolysis)
  • RFT: Creatinine 1.4
  • Coagulation: PT 16s, aPTT 42s
  • USG with Doppler: Fetal wellbeing assessment; uterine artery notching; umbilical artery absent end-diastolic flow
Diagnosis: ECLAMPSIA with evolving HELLP Syndrome

TREATMENT:

IMMEDIATE PRIORITIES (in order):
1. Secure Airway, Breathing, Circulation:
  • Left lateral position (prevent aspiration)
  • O2 10 L/min via NRB mask
  • IV access × 2
  • Continuous fetal monitoring (CTG)
2. TERMINATE SEIZURES + PREVENT RECURRENCE:
DrugDoseRoute
MgSO4 (Zuspan regimen) - FIRST LINE
Loading4 g in 20 mL NS over 20 min IVIV slow
Maintenance1-2 g/h continuous infusionIV infusion
Total treatment24h after delivery or last seizure-
MONITOR FOR MgSO4 TOXICITY:
Knee jerksLoss = toxicity (>7 mEq/L)Check hourly
Urine output>25 mL/h requiredFoley catheter
RR>12/min required
Antidote if toxicity:Calcium gluconate 1 g IVIV push
3. CONTROL BLOOD PRESSURE:
  • Target: SBP 140-155 mmHg, DBP 90-105 mmHg
  • Labetalol: 20 mg IV → repeat 40 mg → 80 mg at 10 min intervals (max 300 mg)
  • Hydralazine: 5-10 mg IV q20 min
  • Oral: Nifedipine 10 mg sublingual/oral
4. DELIVERY (DEFINITIVE TREATMENT):
  • Eclampsia = indication for urgent delivery regardless of gestational age
  • If cervix favorable (Bishop score ≥6): Induce labor (oxytocin)
  • If cervix unfavorable or fetal distress: Emergency LSCS
  • Continue MgSO4 during labor and for 24h post-delivery
5. SUPPORTIVE:
  • Strict fluid balance (risk of pulmonary edema - restrict to 80-100 mL/h)
  • Foley catheter hourly output
  • Steroid: Dexamethasone 12 mg IM q12h × 2 doses (fetal lung maturity at 35 weeks)
  • ICU/HDU admission

PROGRESS NOTES:

Hour 1: MgSO4 loading given, no further seizures. BP 158/100 after labetalol. Hour 4: LSCS under GA (cervix closed, fetal distress on CTG). Male baby 2.2 kg, APGAR 6/9. Neonatal ICU admission. 6h post-delivery: BP 150/95. Platelets 86,000. MgSO4 continued. 24h post-delivery: MgSO4 stopped. No seizures. BP 148/92. Oral Nifedipine LA started. Day 3: BP improving. Platelets recovering. Baby doing well in NICU.

DISCHARGE (Day 5):

  • Oral antihypertensives: Labetalol 200 mg BD + Nifedipine LA 30 mg OD
  • MgSO4 course complete
  • Advise: Home BP monitoring, OPD follow-up in 1 week
  • Risk counselling: 25-40% recurrence risk in next pregnancy
  • Reassess antihypertensives at 6 weeks postpartum

SECTION 4: PAEDIATRICS


CASE 9: PEDIATRIC FEBRILE SEIZURES + BACTERIAL MENINGITIS

Ward Admission Scenario:
A 14-month-old male child brought with high fever and 2 episodes of generalized tonic-clonic convulsions lasting >5 minutes each, with bulging fontanelle and neck stiffness.

PRESENTING COMPLAINTS:

  1. Fever - 2 days (high grade)
  2. Convulsions - 2 episodes (today, each >5 min)
  3. Vomiting - 5 episodes
  4. Irritability and lethargy - 1 day

HOPI:

Sudden onset high-grade fever 2 days ago. Today, 2 episodes of generalized tonic-clonic seizures each lasting approximately 5-7 minutes (not stopping on their own - prolonged). Vomiting × 5 (projectile, non-bilious). Increasingly irritable, inconsolable crying, then becoming lethargic and difficult to arouse. No prior seizures. Not vaccinated (incomplete immunization). No family history of epilepsy.

BIRTH HISTORY:

Full term, normal vaginal delivery, no neonatal complications

IMMUNIZATION HISTORY:

Incomplete - missed Hib vaccine (conjugate meningitis vaccine)

GPE:

ParameterFinding(Z-score)
Weight9.8 kg(Normal for age)
Temp40.2°C
HR164/minTachycardia
RR36/minTachypnea
BP90/60 mmHg
SpO297%
Anterior fontanelleBulgingRaised ICP
SkinMacular purpuric rash on legs (non-blanching)Meningococcemia?

NEUROLOGICAL EXAMINATION:

  • Neck stiffness: Present (meningism)
  • Kernig's sign: Positive (resistance to knee extension when hip flexed)
  • Brudzinski's sign: Positive (involuntary hip flexion when neck flexed)
  • GCS: 10/15 (E2V3M5) - post-ictal + encephalopathy
  • Pupils: 4mm, equal, reactive
  • Fundoscopy: Papilledema present (raised ICP confirmed)

PROVISIONAL DIAGNOSIS:

Bacterial Meningitis (likely Meningococcal given non-blanching rash + incomplete Hib vaccination)

INVESTIGATIONS:

  • CBC: TLC 24,600, Polymorphs 92%, Platelets 58,000
  • CRP: 212 mg/L, PCT: 48 ng/mL
  • Blood culture × 2 (STAT, BEFORE antibiotics - 10-15 min window only)
  • Blood glucose: 48 mg/dL (HYPOGLYCEMIA - treat immediately)
  • Electrolytes: Na 122 (SIADH - hyponatremia)
  • RFT: Normal
  • Coagulation: PT 18s, APTT 52s (DIC risk)
CT Head (before LP - papilledema present → LP risk of herniation):
  • Cerebral edema, no mass, no herniation → LP safe after mannitol
Lumbar Puncture:
CSF ParameterValueInterpretation
Opening pressure320 mm H2ORaised
AppearanceTurbid, purulentBacterial
Glucose15 mg/dLLow (<40% of blood)
Protein280 mg/dLHigh
Cells3200 WBC (95% PMN)Bacterial
Gram stainGram-negative diplococciN. meningitidis

TREATMENT:

IMMEDIATE:
  • IV access (IO if no IV access)
  • O2 via face mask
  • Dextrose: D10W 2 mL/kg IV for hypoglycemia (correct glucose first)
ANTIBIOTICS (WITHIN 30 MIN OF DIAGNOSIS - LIFE-SAVING):
DrugDoseRouteFrequency
Inj. Cefotaxime100 mg/kg/dayIVq6h (divided)
OR Ceftriaxone100 mg/kg/dayIVq12h (divided)
Duration7-10 days for N. meningitidis
DEXAMETHASONE (start BEFORE or WITH 1st dose of antibiotic):
  • 0.15 mg/kg IV q6h × 4 days
  • Reduces neurological sequelae (deafness, neurological disability)
  • Give 15-20 min BEFORE antibiotics (reduces cytokine-driven inflammation)
RAISED ICP MANAGEMENT:
  • Head elevation 30°
  • Mannitol 0.5-1 g/kg IV over 20 min (if herniation signs)
  • Restrict fluids to 2/3 maintenance initially (SIADH → correct hyponatremia slowly)
  • Correct Na+ by no more than 10-12 mEq/L per 24h (rapid correction → central pontine myelinolysis)
  • 3% NaCl: 3-5 mL/kg if severe symptomatic hyponatremia
SEIZURE MANAGEMENT:
  • Active seizure: Lorazepam 0.05-0.1 mg/kg IV (or diazepam 0.2 mg/kg IV/PR)
  • Maintenance AED: Levetiracetam 20 mg/kg IV loading → 15 mg/kg/day divided BD
  • Phenobarbital if unavailable: 20 mg/kg IV loading
MENINGOCOCCAL PROPHYLAXIS:
  • Close contacts: Rifampicin 10 mg/kg BD × 2 days (or Ciprofloxacin single dose in adults)
  • Notify public health authority (notifiable disease)
SUPPORTIVE:
  • ICU/PICU admission
  • Continuous monitoring: Neuro checks every hour, BP, urine output
  • Cooling blanket for hyperthermia
  • NPO initially; NG feeds if stable
  • DVT prophylaxis not routine in young children

PROGRESS NOTES:

Day 1: Blood culture positive N. meningitidis. Fever persisting. GCS 10. Rash not spreading. Day 2: GCS improving to 12. Fever down to 38.2. Na correcting slowly. Antibiotics continuing. Day 3: Alert. Tolerating oral. Rash fading. Meningism reducing. Day 5: Afebrile. No seizures 72h. Normal GCS. Fontanelle flat. Oral antibiotics transition. Day 7: Discharge planning. Audiology referral (hearing loss - common sequelae).

DISCHARGE:

  • Complete 14-day course (7 days IV + 7 days oral)
  • Audiology follow-up (sensorineural hearing loss in 10-30%)
  • Neurodevelopmental assessment at 6 weeks
  • COMPLETE immunization catch-up schedule
  • Meningococcal vaccine (ACWY and B) for child + close contacts

SECTION 5: IPD PROGRESS NOTE FORMAT


DAILY PROGRESS NOTE TEMPLATE

┌──────────────────────────────────────────────────────────────┐
│ DATE: ___________  TIME: ___________  DAY: Day ___ of IPD    │
│ Ward: ________  Bed No.: _______  IP No.: ________________   │
├──────────────────────────────────────────────────────────────┤
│ SUBJECTIVE (Patient's complaints):                           │
│ ____________________________________________________________  │
│                                                              │
│ OBJECTIVE (Clinical findings today):                         │
│ Temp: ____°C  HR: ____/min  BP: ____mmHg  RR: ____/min       │
│ SpO2: ____% on ____L O2  Weight: ____kg  UO: ____mL/h        │
│                                                              │
│ Examination:                                                 │
│ General: ___________________________________________________  │
│ System-specific: ___________________________________________  │
│                                                              │
│ Investigation results today:                                 │
│ ____________________________________________________________  │
│                                                              │
│ ASSESSMENT:                                                  │
│ ____________________________________________________________  │
│                                                              │
│ PLAN (for next 24 hours):                                    │
│ 1. __________________________________________________________ │
│ 2. __________________________________________________________ │
│ 3. __________________________________________________________ │
│                                                              │
│ Signature: _____________  Designation: _________________     │
└──────────────────────────────────────────────────────────────┘

DISCHARGE SUMMARY FORMAT

┌──────────────────────────────────────────────────────────────┐
│               DISCHARGE SUMMARY                              │
│ IP No.: ________  Ward: ________  Bed: _______               │
├──────────────────────────────────────────────────────────────┤
│ Patient: ________________  Age: ___  Sex: ___                │
│ DOA (Date of Admission): ________  Time: ________            │
│ DOD (Date of Discharge): ________  Time: ________            │
│ Length of Stay: _________ days                               │
│ Admitted under: Dr. _________________________                │
├──────────────────────────────────────────────────────────────┤
│ PRESENTING COMPLAINTS: ______________________________________ │
│                                                              │
│ DIAGNOSIS (Final):                                           │
│ Primary: ___________________________________________________ │
│ Secondary: _________________________________________________ │
│ Comorbidities: _____________________________________________ │
├──────────────────────────────────────────────────────────────┤
│ HOSPITAL COURSE (Brief summary):                             │
│ ____________________________________________________________  │
│ ____________________________________________________________  │
├──────────────────────────────────────────────────────────────┤
│ KEY INVESTIGATIONS:                                          │
│ ____________________________________________________________  │
├──────────────────────────────────────────────────────────────┤
│ PROCEDURES DONE:                                             │
│ ____________________________________________________________  │
├──────────────────────────────────────────────────────────────┤
│ CONDITION AT DISCHARGE:                                      │
│ □ Stable  □ Improved  □ Unchanged  □ LAMA  □ DAMA           │
│ □ Referred to ___________________                            │
├──────────────────────────────────────────────────────────────┤
│ DISCHARGE MEDICATIONS:                                       │
│ 1. __________________________________________________________ │
│ 2. __________________________________________________________ │
│ 3. __________________________________________________________ │
│ (Attach separate prescription)                               │
├──────────────────────────────────────────────────────────────┤
│ DIETARY ADVICE: ____________________________________________  │
│ PHYSICAL ACTIVITY: _________________________________________  │
│ SPECIAL INSTRUCTIONS: ______________________________________  │
├──────────────────────────────────────────────────────────────┤
│ FOLLOW-UP:                                                   │
│ OPD: ________________________  Date: ______________________  │
│ Tests to bring: _____________________________________________│
│ Emergency: Return immediately if ___________________________  │
├──────────────────────────────────────────────────────────────┤
│ Consultant: Dr. ________________________  Sign: _________    │
│ Resident: Dr. __________________________  Sign: _________    │
│ Institution Stamp: ____________________                      │
└──────────────────────────────────────────────────────────────┘

QUICK REFERENCE: COMMON IPD CASES ACROSS SPECIALTIES

SpecialtyCaseKey Diagnosis FeatureEmergency Treatment
MedicineSTEMIST elevation ECG + TroponinAspirin + tPA / PCI
CAPConsolidation + neutrophiliaCeftriaxone + Azithromycin
DKAGlucose >250 + AG metabolic acidosisFluids + insulin (after K+)
StrokeNIHSS + CT headAlteplase within 4.5h
SepsisSOFA ≥2 + infection1-hour bundle
UGI bleedHematemesis + melaenaResuscitate + endoscopy
SurgeryAcute appendicitisAlvarado ≥7 + USGLaparoscopic appendicectomy
Acute cholecystitisMurphy's sign + gallstonesAntibiotics + cholecystectomy
Intestinal obstructionAbsolute constipation + dilated loopsNG decompression + surgery
Hernia (strangulated)Tender irreducible swellingEmergency repair
Obs-GyneEclampsiaSeizures + HTN + proteinuriaMgSO4 + antihypertensives + deliver
PPHBlood loss >500 mL post-deliveryOxytocin + uterine massage + bimanual
Ectopic pregnancyAmenorrhea + pain + free fluidEmergency laparoscopy
APHAntepartum bleedingDepends on placenta praevia vs. abruption
PaediatricsMeningitisNeck stiffness + CSF findingsCeftriaxone + dexamethasone
BronchiolitisWheeze + hyperinflation in <2yOxygen + hydration
Severe malnutritionMUAC <11.5 cm + kwashiorkor/marasmusF-75 → F-100 rehabilitation
Febrile seizureFever + seizure, 6m-5yrRule out meningitis; diazepam
PsychiatryOD/self-harmToxidrome + psychiatric hxAntidote + psychiatry
Acute psychosisHallucinations + delusionsHaloperidol/olanzapine
Ortho# NOFElderly + fall + short-limb externally rotatedHemiarthroplasty
Compartment syndrome6 Ps: Pain, Pressure, Paresthesia, Paralysis, Pallor, PulselessnessFasciotomy STAT

Sources: Goldman-Cecil Medicine International Edition | Harrison's Principles of Internal Medicine 22e | Tintinalli's Emergency Medicine | Sabiston Textbook of Surgery | Murray & Nadel's Respiratory Medicine | Sleisenger & Fordtran's GI and Liver Disease | Rosen's Emergency Medicine

Generate a Word document with 10 more IPD cases (other specialties)

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Good. I now have enough clinical content. Let me write the Word document.
Running Command

mkdir -p /home/daytona/workspace/ipd-cases && ls /home/daytona/workspace/ipd-cases/

Writing File

~/ipd-cases/generate.js

const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  HeadingLevel, AlignmentType, BorderStyle, WidthType, ShadingType,
  VerticalAlign, PageBreak, TableOfContents, PageNumber, Footer,
  Header, NumberFormat
} = require('docx');
const fs = require('fs');

// ─── Helpers ──────────────────────────────────────────────────────────────────

const BLUE  = "1F3864";
const LBLUE = "2E75B6";
const TEAL  = "0070C0";
const GREY  = "F2F2F2";
const WHITE = "FFFFFF";
const DKGREY = "595959";

function h1(text) {
  return new Paragraph({
    text, heading: HeadingLevel.HEADING_1,
    spacing: { before: 400, after: 120 },
    run: { color: WHITE }
  });
}
function h2(text) {
  return new Paragraph({
    text, heading: HeadingLevel.HEADING_2,
    spacing: { before: 300, after: 80 },
  });
}
function h3(text) {
  return new Paragraph({
    children: [new TextRun({ text, bold: true, color: TEAL, size: 22 })],
    spacing: { before: 200, after: 60 },
  });
}
function h4(text) {
  return new Paragraph({
    children: [new TextRun({ text, bold: true, color: DKGREY, size: 20 })],
    spacing: { before: 160, after: 40 },
  });
}
function body(text, opts = {}) {
  return new Paragraph({
    children: [new TextRun({ text, size: 20, ...opts })],
    spacing: { before: 60, after: 60 },
  });
}
function bullet(text, level = 0) {
  return new Paragraph({
    children: [new TextRun({ text, size: 20 })],
    bullet: { level },
    spacing: { before: 40, after: 40 },
  });
}
function pageBreak() {
  return new Paragraph({ children: [new PageBreak()] });
}
function sectionBanner(text) {
  return new Paragraph({
    children: [new TextRun({ text, bold: true, color: WHITE, size: 28 })],
    shading: { type: ShadingType.CLEAR, fill: LBLUE },
    spacing: { before: 300, after: 200 },
    alignment: AlignmentType.CENTER,
  });
}
function caseHeader(num, title, specialty) {
  return new Paragraph({
    children: [
      new TextRun({ text: `CASE ${num}: `, bold: true, color: WHITE, size: 26 }),
      new TextRun({ text: title, bold: true, color: WHITE, size: 26 }),
      new TextRun({ text: `  [${specialty}]`, color: "C9D1D9", size: 22 }),
    ],
    shading: { type: ShadingType.CLEAR, fill: BLUE },
    spacing: { before: 400, after: 200 },
    indent: { left: 200 },
  });
}
function subHeader(text) {
  return new Paragraph({
    children: [new TextRun({ text, bold: true, color: WHITE, size: 20 })],
    shading: { type: ShadingType.CLEAR, fill: TEAL },
    spacing: { before: 160, after: 80 },
    indent: { left: 100 },
  });
}
function note(text) {
  return new Paragraph({
    children: [new TextRun({ text: `📌 Note: ${text}`, italics: true, size: 18, color: "7030A0" })],
    spacing: { before: 80, after: 80 },
    indent: { left: 400 },
  });
}

// Simple 2-col key-value table
function kvTable(rows) {
  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: rows.map(([k, v]) => new TableRow({
      children: [
        new TableCell({
          children: [new Paragraph({ children: [new TextRun({ text: k, bold: true, size: 18 })] })],
          shading: { type: ShadingType.CLEAR, fill: GREY },
          width: { size: 35, type: WidthType.PERCENTAGE },
        }),
        new TableCell({
          children: [new Paragraph({ children: [new TextRun({ text: v, size: 18 })] })],
          width: { size: 65, type: WidthType.PERCENTAGE },
        }),
      ],
    })),
    margins: { top: 60, bottom: 60, left: 80, right: 80 },
  });
}

// Multi-column header table
function headerTable(cols, rows) {
  return new Table({
    width: { size: 100, type: WidthType.PERCENTAGE },
    rows: [
      new TableRow({
        children: cols.map(c => new TableCell({
          children: [new Paragraph({ children: [new TextRun({ text: c, bold: true, size: 18, color: WHITE })] })],
          shading: { type: ShadingType.CLEAR, fill: LBLUE },
          verticalAlign: VerticalAlign.CENTER,
        })),
        tableHeader: true,
      }),
      ...rows.map(row => new TableRow({
        children: row.map((cell, i) => new TableCell({
          children: [new Paragraph({ children: [new TextRun({ text: cell, size: 18 })] })],
          shading: { type: ShadingType.CLEAR, fill: i === 0 ? GREY : WHITE },
        })),
      })),
    ],
    margins: { top: 60, bottom: 60, left: 80, right: 80 },
  });
}

function spacer() {
  return new Paragraph({ text: "", spacing: { before: 80, after: 80 } });
}

// ─── Document Content ─────────────────────────────────────────────────────────

const children = [

  // ── COVER PAGE ──────────────────────────────────────────────────────────────
  new Paragraph({
    children: [new TextRun({ text: "🏥  IPD CLINICAL CASES", bold: true, size: 56, color: BLUE })],
    alignment: AlignmentType.CENTER,
    spacing: { before: 1200, after: 200 },
  }),
  new Paragraph({
    children: [new TextRun({ text: "Master Guide — 10 Additional Cases Across Specialties", size: 28, color: DKGREY, italics: true })],
    alignment: AlignmentType.CENTER,
    spacing: { before: 0, after: 600 },
  }),
  kvTable([
    ["Specialties Covered", "Nephrology · Pulmonology · Orthopaedics · Gastroenterology · Psychiatry · ENT · Ophthalmology · Haematology · Endocrinology · Dermatology"],
    ["Format", "PC → HOPI → PH → GPE → Systemic Exam → Diagnosis → Investigations → Treatment → Progress Notes → Discharge"],
    ["Purpose", "Ward rounds, clinical postings, MBBS / PG exam preparation, intern training"],
    ["Sources", "Goldman-Cecil Medicine · Harrison's Principles 22e · Schwartz's Surgery · Brenner & Rector's Kidney · Tintinalli's EM"],
  ]),
  pageBreak(),

  // ══════════════════════════════════════════════════════════════════════════
  // CASE 1 — NEPHROLOGY: Acute Kidney Injury (AKI)
  // ══════════════════════════════════════════════════════════════════════════
  caseHeader(1, "ACUTE KIDNEY INJURY (AKI) — POST-OPERATIVE", "Nephrology"),
  subHeader("PRESENTING COMPLAINTS"),
  bullet("Decreased urine output — 24 hours"),
  bullet("Swelling of face and lower limbs — 12 hours"),
  bullet("Nausea and vomiting — 8 hours"),
  bullet("Recent abdominal surgery (lap cholecystectomy) — 3 days ago"),
  spacer(),
  subHeader("HISTORY OF PRESENTING ILLNESS"),
  body("60-year-old male, 3 days post laparoscopic cholecystectomy for acute cholecystitis. Day 1 post-op was uneventful. On Day 2, urine output began declining (<0.5 mL/kg/h). By Day 3, oliguric (<200 mL/day), facial and pedal edema appeared. Nausea and vomiting preventing oral intake. Pre-operative creatinine was 1.0 mg/dL. Received gentamicin + metronidazole post-op. History of hypertension and NSAID use for back pain for 6 months."),
  spacer(),
  subHeader("PAST / PERSONAL HISTORY"),
  bullet("Hypertension — 8 years, on Amlodipine"),
  bullet("NSAID (Diclofenac 50mg BD) × 6 months (nephrotoxic risk)"),
  bullet("No prior CKD, no diabetes"),
  spacer(),
  subHeader("GENERAL PHYSICAL EXAMINATION"),
  headerTable(["Parameter","Finding"],
    [["Pulse","96/min"],["BP","158/100 mmHg"],["RR","20/min"],["SpO2","97%"],["Pedal edema","Bilateral pitting +++"],["Facial puffiness","Present"],["JVP","Elevated 5 cm"],["Urine output","80 mL in last 8h (oliguria)"]]),
  spacer(),
  subHeader("SYSTEMIC EXAMINATION"),
  bullet("Cardiovascular: S1 S2 heard, no murmurs. JVP elevated."),
  bullet("Respiratory: Bilateral basal crackles (fluid overload)"),
  bullet("Abdomen: Surgical wound healing well. No peritonism."),
  bullet("CNS: Alert, mildly confused (uraemic encephalopathy early)"),
  spacer(),
  subHeader("PROVISIONAL DIAGNOSIS"),
  body("Acute Kidney Injury — Stage 2 (KDIGO) — Mixed Aetiology: Post-operative + aminoglycoside nephrotoxicity + NSAID-induced renal vasoconstriction", { bold: true }),
  spacer(),
  subHeader("DIFFERENTIAL DIAGNOSIS"),
  bullet("Pre-renal AKI (inadequate post-op fluids)"),
  bullet("Obstructive (ureteric injury post-surgery)"),
  bullet("Acute tubular necrosis (ATN) from gentamicin"),
  spacer(),
  subHeader("INVESTIGATIONS"),
  headerTable(["Test","Value","Interpretation"],
    [["Serum Creatinine","4.2 mg/dL (baseline 1.0)","KDIGO Stage 2-3 AKI"],
     ["BUN","78 mg/dL","Uraemia"],
     ["Serum K+","5.8 mEq/L","Hyperkalaemia"],
     ["Na+","128 mEq/L","Dilutional hyponatraemia"],
     ["Bicarbonate","14 mEq/L","Metabolic acidosis"],
     ["CBC","TLC 14,200, Hb 9.8","Anaemia"],
     ["Urine Na+","<20 mEq/L (pre-renal component)","Tubular preservation"],
     ["FENa","<1%","Pre-renal or early ATN"],
     ["USG KUB","No hydronephrosis, normal echogenicity","No obstruction"],
     ["ECG","Peaked T-waves","Hyperkalaemia effect"],
     ["CXR","Pulmonary venous congestion","Fluid overload"]]),
  spacer(),
  subHeader("KDIGO AKI STAGING"),
  headerTable(["Stage","Creatinine Criterion","Urine Output"],
    [["1","1.5–1.9× baseline OR rise ≥0.3 mg/dL in 48h",">0.5 mL/kg/h"],
     ["2","2.0–2.9× baseline","0.5 mL/kg/h × 12h"],
     ["3 (This patient)","≥3× baseline OR Cr ≥4 mg/dL","<0.3 mL/kg/h × 24h or anuria 12h"]]),
  spacer(),
  subHeader("TREATMENT"),
  h4("Immediate Management"),
  bullet("STOP nephrotoxins: Gentamicin stopped, NSAIDs stopped, ACE inhibitors held"),
  bullet("IV access — central line for monitoring"),
  bullet("Foley catheter — strict input/output hourly"),
  bullet("Fluid challenge (if pre-renal component): 250 mL NS bolus over 30 min → assess response"),
  spacer(),
  h4("Hyperkalaemia (K+ 5.8 — URGENT)"),
  headerTable(["Drug","Dose","Mechanism","Onset"],
    [["Calcium gluconate 10%","10 mL IV over 3 min","Cardiac membrane stabilisation","Immediate"],
     ["Insulin + Dextrose","10 units + 50 mL D50 IV","Shifts K+ intracellularly","15–30 min"],
     ["Sodium bicarbonate","50 mEq IV (if acidotic)","K+ redistribution","30 min"],
     ["Resonium (Kayexalate)","15g PO TDS","GI K+ removal","Hours"],
     ["Haemodialysis","If K+ >6.5 or ECG changes","Definitive removal","Immediate"]]),
  spacer(),
  h4("Fluid Management"),
  bullet("No aggressive fluid loading — already fluid overloaded (JVP elevated, crackles)"),
  bullet("Restrict fluids to insensible losses + previous hour urine output"),
  bullet("Consider early dialysis for refractory fluid overload"),
  spacer(),
  h4("Metabolic Acidosis"),
  bullet("If pH <7.2: Sodium bicarbonate 50-100 mEq IV infusion"),
  bullet("Target pH >7.25"),
  spacer(),
  h4("Renal Replacement Therapy (RRT) Indications — AEIOU"),
  bullet("A — Acidosis (pH <7.2 refractory)"),
  bullet("E — Electrolytes (K+ >6.5 / refractory)"),
  bullet("I — Intoxication (drug removal)"),
  bullet("O — Overload (pulmonary oedema refractory to diuretics)"),
  bullet("U — Uraemia (encephalopathy / pericarditis / Cr >10)"),
  note("This patient meets 3 AEIOU criteria — nephrology consulted for CRRT/IHD"),
  spacer(),
  subHeader("PROGRESS NOTES"),
  bullet("Day 1: Creatinine 4.2. K+ managed with insulin/dextrose + resonium. Fluid restricted. CRRT initiated."),
  bullet("Day 3: Creatinine 3.8. Urine output improving to 0.8 mL/kg/h. K+ 4.9. Crackles reducing."),
  bullet("Day 5: Creatinine 2.4. CRRT weaned. Diuretic phase begun (furosemide 80mg IV)."),
  bullet("Day 8: Creatinine 1.6. Urine output 2 mL/kg/h (polyuric recovery phase). Oral diet tolerated."),
  spacer(),
  subHeader("DISCHARGE SUMMARY"),
  bullet("Diagnosis: AKI Stage 3 — ATN + Nephrotoxic — recovered"),
  bullet("Discharge creatinine: 1.4 mg/dL (near baseline)"),
  bullet("Discharge medications: Antihypertensive resumed, no NSAIDs ever, no aminoglycosides"),
  bullet("Follow-up: Nephrology OPD in 2 weeks with repeat RFT"),
  bullet("Patient counselled: Avoid nephrotoxins (NSAIDs, ibuprofen, contrast agents)"),
  pageBreak(),

  // ══════════════════════════════════════════════════════════════════════════
  // CASE 2 — PULMONOLOGY: Acute Exacerbation of COPD
  // ══════════════════════════════════════════════════════════════════════════
  caseHeader(2, "ACUTE EXACERBATION OF COPD (AECOPD)", "Pulmonology / Respiratory Medicine"),
  subHeader("PRESENTING COMPLAINTS"),
  bullet("Worsening breathlessness — 3 days"),
  bullet("Increased cough with purulent (yellow-green) sputum — 5 days"),
  bullet("Fever — 2 days"),
  bullet("Unable to speak full sentences — 1 day"),
  spacer(),
  subHeader("HISTORY OF PRESENTING ILLNESS"),
  body("68-year-old male, heavy smoker (45 pack-years, still smoking), known COPD on Tiotropium + LABA/ICS inhaler. Baseline dyspnoea: MRC Grade 3 (stops after walking 100m on flat). 3 days ago, breathlessness worsened acutely (now at rest), cough increased with thick purulent sputum (Anthonisen Type 1 exacerbation). Mild fever. No haemoptysis. No chest pain. Last exacerbation 4 months ago requiring hospitalisation. Has received influenza vaccine but not pneumococcal."),
  spacer(),
  subHeader("GENERAL PHYSICAL EXAMINATION"),
  headerTable(["Parameter","Finding"],
    [["Pulse","106/min"],["BP","142/88 mmHg"],["RR","28/min"],["SpO2","82% on room air"],["Temp","38.4°C"],["Cyanosis","Peripheral cyanosis present"],["Pursed-lip breathing","Present"],["Use of accessory muscles","Present (sternomastoid, scalenes)"],["Barrel chest","Present (AP diameter increased)"]]),
  spacer(),
  subHeader("SYSTEMIC EXAMINATION — RESPIRATORY"),
  bullet("Inspection: Barrel-shaped chest, restricted chest expansion, accessory muscle use"),
  bullet("Palpation: Trachea central, reduced tactile fremitus bilateral"),
  bullet("Percussion: HYPERRESONANCE bilateral (air trapping)"),
  bullet("Auscultation: Prolonged expiration, widespread expiratory wheeze + coarse crackles"),
  bullet("No bronchial breathing (rules out consolidation currently)"),
  spacer(),
  subHeader("INVESTIGATIONS"),
  headerTable(["Test","Value","Significance"],
    [["ABG (on room air)","pH 7.31 / PaCO2 68 / PaO2 48 / HCO3 32","Type 2 RF + Compensated resp. acidosis"],
     ["SpO2","82% → 90% on controlled O2 2L","Hypoxaemia"],
     ["CXR","Hyperinflated lungs, flat diaphragm, no consolidation","Emphysema pattern"],
     ["Sputum C/S","H. influenzae — Ampicillin-sensitive","Infective exacerbation"],
     ["ECG","P pulmonale, RBBB pattern","Cor pulmonale (RVH)"],
     ["Echo","RV dilatation, PA pressure 52 mmHg","Pulmonary hypertension"],
     ["FEV1/FVC","0.55 (46% predicted)","GOLD Stage 3 COPD"],
     ["CBC","TLC 14,800, neutrophilia","Bacterial infection"],
     ["CRP","112 mg/L","Inflammation"]]),
  spacer(),
  subHeader("TREATMENT"),
  h4("Controlled Oxygen Therapy (CRITICAL — hypercapnic drive)"),
  bullet("Target SpO2 88–92% (NOT 96–100% — hyperoxia worsens CO2 retention)"),
  bullet("24% or 28% Venturi mask (NOT NRB mask)"),
  bullet("Repeat ABG in 30–60 min to check CO2 response"),
  spacer(),
  h4("Bronchodilators"),
  headerTable(["Drug","Dose","Route","Frequency"],
    [["Salbutamol (SABA)","2.5 mg","Nebuliser","Every 20 min × 3 then q4h"],
     ["Ipratropium (SAMA)","0.5 mg","Nebuliser","q6h (add to SABA neb)"],
     ["Aminophylline","5 mg/kg loading → 0.5 mg/kg/h","IV (if severe)","Continuous if nebulisers fail"]]),
  spacer(),
  h4("Corticosteroids"),
  bullet("Prednisolone 40 mg PO OD × 5 days (or IV methylprednisolone 40 mg OD if PO not tolerated)"),
  bullet("Reduces recovery time, treatment failure, length of stay"),
  spacer(),
  h4("Antibiotics (Anthonisen Type 1 — all 3 criteria: increased dyspnoea + sputum volume + purulence)"),
  bullet("Amoxicillin-Clavulanate 625 mg PO TDS × 5–7 days"),
  bullet("If Pseudomonas risk (frequent exacerbations, severe GOLD): Ciprofloxacin 400 mg IV BD"),
  spacer(),
  h4("Non-Invasive Ventilation (NIV — BiPAP)"),
  bullet("Indication: pH <7.35 + PaCO2 >45 + RR >25 despite above measures"),
  bullet("Settings: IPAP 12-20 cmH2O, EPAP 4-6 cmH2O"),
  bullet("This patient: pH 7.31 → NIV INITIATED"),
  bullet("Repeat ABG in 1-2h: pH 7.37, PaCO2 58 → Good response to NIV"),
  spacer(),
  h4("Invasive Ventilation Triggers"),
  bullet("Failure of NIV (pH <7.25 on NIV), GCS <8, haemodynamic instability"),
  spacer(),
  subHeader("PROGRESS NOTES"),
  bullet("Day 1: NIV started. SpO2 91%. pH improved to 7.37. Antibiotics + steroids started."),
  bullet("Day 2: Off NIV 4h trials. SpO2 90% on 28% Venturi. Sputum less purulent."),
  bullet("Day 3: Tolerating off NIV. Nebulisers q6h. Oral steroids continued."),
  bullet("Day 5: SpO2 93% on room air. Wheeze reducing. Started weaning to MDI inhalers."),
  spacer(),
  subHeader("DISCHARGE"),
  bullet("COPD review — upgrade to GOLD Group D management"),
  bullet("Tiotropium 18 mcg OD + Indacaterol/Glycopyrronium (LABA/LAMA) + ICS (Budesonide/Formoterol)"),
  bullet("Pulmonary rehabilitation referral"),
  bullet("Pneumococcal vaccine today + Influenza annual"),
  bullet("STRICT SMOKING CESSATION — NRT prescribed + counselling"),
  bullet("Home O2 assessment (if SpO2 <88% on 6-min walk test)"),
  pageBreak(),

  // ══════════════════════════════════════════════════════════════════════════
  // CASE 3 — ORTHOPAEDICS: Fracture Neck of Femur
  // ══════════════════════════════════════════════════════════════════════════
  caseHeader(3, "FRACTURE NECK OF FEMUR (# NOF)", "Orthopaedics"),
  subHeader("PRESENTING COMPLAINTS"),
  bullet("Fall from standing height — 6 hours ago"),
  bullet("Pain in right hip — since fall"),
  bullet("Inability to walk or bear weight — since fall"),
  spacer(),
  subHeader("HISTORY OF PRESENTING ILLNESS"),
  body("78-year-old female with known osteoporosis (on bisphosphonate irregularly). Mechanical fall at home while going to bathroom at night. Immediate severe right hip pain. Unable to get up or weight-bear. No head injury, no loss of consciousness. Brought to hospital by family. Known hypertensive, on aspirin for AF."),
  spacer(),
  subHeader("GENERAL PHYSICAL EXAMINATION"),
  headerTable(["Parameter","Finding"],
    [["General","Anxious, in pain, co-operative"],["BP","138/84 mmHg"],["HR","88/min, irregular (AF)"],["Temp","37.0°C"],["SpO2","97%"],["Right lower limb","SHORTENED + EXTERNALLY ROTATED (classic)"],["Active movement","Absent (pain)"],["Passive movement","Severely restricted, pain on log-rolling"]]),
  spacer(),
  subHeader("SYSTEMIC EXAMINATION — ORTHOPAEDIC"),
  bullet("Shortening: True shortening of right lower limb (2.5 cm vs left)"),
  bullet("External rotation: Heel points outward ~90° (no internal rotation possible)"),
  bullet("Tenderness: Groin/hip tenderness on axial loading"),
  bullet("Neurovascular: Distal pulses palpable, sensation intact, toes moving"),
  bullet("Bryant's triangle: Abnormal — loss of triangle on right"),
  spacer(),
  subHeader("INVESTIGATIONS"),
  headerTable(["Test","Value","Significance"],
    [["X-Ray Hip (AP + Lateral)","Displaced subcapital # neck of femur — Garden Grade IV","Surgical — hemiarthroplasty"],
     ["CBC","Hb 10.2, PLT 180,000","Pre-op anaemia"],
     ["PT/INR","1.2 (aspirin held)","Acceptable for surgery"],
     ["RFT","Normal","No CKD"],
     ["ECG","AF with normal ventricular rate","Rate controlled"],
     ["Echo","EF 58%, no significant valve disease","Fit for surgery"],
     ["DEXA scan (planned)","T-score −3.2 (osteoporosis)","Fragility fracture confirmed"],
     ["Blood group + crossmatch","A+ve","For operative blood loss"]]),
  spacer(),
  h4("Garden Classification"),
  headerTable(["Grade","Description"],
    [["I","Incomplete / valgus impacted — undisplaced"],
     ["II","Complete but undisplaced"],
     ["III","Complete, partially displaced"],
     ["IV (This patient)","Complete, fully displaced — avascular necrosis risk HIGH"]]),
  spacer(),
  subHeader("TREATMENT"),
  h4("Pre-operative"),
  bullet("Analgesia: Fascia iliaca block (nerve block) + Paracetamol 1g IV q6h"),
  bullet("Avoid NSAIDs (age + renal risk + on aspirin)"),
  bullet("Aspirin held 5 days before surgery (if time permits) — urgent case, proceed"),
  bullet("Anticoagulation: Enoxaparin 20 mg SC (prophylactic dose until surgery, then therapeutic post-op for AF)"),
  bullet("Blood transfusion if Hb <8 g/dL pre-op"),
  bullet("Urinary catheter"),
  bullet("IV fluids: Hartmann's 1L over 12h"),
  bullet("NBM from midnight"),
  spacer(),
  h4("Surgical Management"),
  bullet("CEMENTED HEMIARTHROPLASTY (Austin Moore or Thompson prosthesis) — preferred for displaced # NOF in elderly"),
  bullet("Total Hip Replacement (THR): If pre-existing hip OA or high functional demand"),
  bullet("Internal fixation (DHS/cannulated screws): For undisplaced # NOF (Garden I/II)"),
  bullet("Timing: Surgery within 48h of admission → reduces mortality by 30%"),
  spacer(),
  h4("Post-operative"),
  bullet("Day 1: Weight-bear as tolerated with frame (physiotherapy mobilisation)"),
  bullet("Enoxaparin 40 mg SC OD × 28-35 days (VTE prophylaxis — high risk)"),
  bullet("Transition AF anticoagulation: Start DOAC (Apixaban) Day 2 post-op"),
  bullet("Fall prevention assessment: OT evaluation, bed rails, hip protectors"),
  bullet("Pressure ulcer prevention: Regular turning, pressure mattress"),
  spacer(),
  h4("Osteoporosis Management (Secondary Fracture Prevention)"),
  bullet("Zoledronic acid 5 mg IV infusion once yearly (preferred post # NOF)"),
  bullet("Calcium 1200 mg + Vitamin D3 800-1000 IU OD (lifelong)"),
  bullet("DEXA follow-up"),
  spacer(),
  subHeader("DISCHARGE"),
  bullet("Day 5-7 post-op (when mobilising safely with frame)"),
  bullet("Physiotherapy OPD × 6 weeks"),
  bullet("Zoledronic acid infusion arranged"),
  bullet("DOAC (Apixaban) for AF + extended VTE prophylaxis"),
  bullet("Geriatric assessment: Falls risk, cognitive assessment, medication review"),
  pageBreak(),

  // ══════════════════════════════════════════════════════════════════════════
  // CASE 4 — GASTROENTEROLOGY: Acute Pancreatitis
  // ══════════════════════════════════════════════════════════════════════════
  caseHeader(4, "ACUTE PANCREATITIS (SEVERE)", "Gastroenterology / Surgery"),
  subHeader("PRESENTING COMPLAINTS"),
  bullet("Severe epigastric pain radiating to back — 12 hours"),
  bullet("Nausea and vomiting × 8 episodes — 12 hours"),
  bullet("Fever — 6 hours"),
  spacer(),
  subHeader("HISTORY OF PRESENTING ILLNESS"),
  body("48-year-old male, heavy alcohol drinker (daily ETOH, binge last night). Sudden onset severe epigastric pain, 10/10, band-like, radiating to back, partially relieved by leaning forward. Persistent vomiting. Fever. Similar but milder episode 6 months ago (not investigated). No gallstones known. No recent ERCP."),
  spacer(),
  subHeader("GENERAL PHYSICAL EXAMINATION"),
  headerTable(["Parameter","Finding"],
    [["Pulse","118/min (SIRS)"],["BP","94/62 mmHg (shock)"],["RR","26/min"],["Temp","38.8°C"],["SpO2","93%"],["Abdomen","Distended, exquisitely tender epigastrium"],["Grey Turner sign","Bruising in flanks (haemorrhagic pancreatitis)"],["Cullen sign","Periumbilical bruising (severe)"],["Bowel sounds","Absent (paralytic ileus)"]]),
  spacer(),
  subHeader("INVESTIGATIONS"),
  headerTable(["Test","Value","Significance"],
    [["Serum Amylase","2840 U/L (>3× normal)","Pancreatitis confirmed"],
     ["Serum Lipase","4210 U/L","More specific than amylase"],
     ["WBC","18,400 (SIRS criterion)","Systemic inflammation"],
     ["CRP","280 mg/L (>150 = severe)","Severe pancreatitis marker"],
     ["Serum Ca2+","1.8 mmol/L","Hypocalcaemia (saponification)"],
     ["Blood glucose","240 mg/dL","Islet cell damage"],
     ["ALT","320 U/L (3× normal)","Gallstone component possible"],
     ["Creatinine","2.4 mg/dL","AKI (organ failure = severe)"],
     ["PaO2 on ABG","58 mmHg","Respiratory failure (ARDS)"],
     ["CECT Abdomen","Pancreatic necrosis 50%, peripancreatic fluid, no pseudocyst yet","Balthazar Grade E"]]),
  spacer(),
  h4("SEVERITY SCORING"),
  headerTable(["Score","Value","Interpretation"],
    [["Ranson's Criteria (at 48h)","6/11","Severe (>3 = severe; >6 = high mortality)"],
     ["APACHE II","18","Severe pancreatitis"],
     ["BISAP Score","4/5","High mortality risk"],
     ["Revised Atlanta","Severe (organ failure >48h + necrosis)","ICU admission required"]]),
  spacer(),
  subHeader("TREATMENT"),
  h4("Resuscitation (IV Fluid Therapy — CORNERSTONE)"),
  bullet("Aggressive crystalloid resuscitation: Ringer's Lactate 500 mL/h × 2h, then 250 mL/h"),
  bullet("Ringer's Lactate preferred over NS (reduces SIRS, lactic acidosis)"),
  bullet("Target: HR <90, MAP >65, UO >0.5 mL/kg/h, Hct 35–44%"),
  bullet("Monitor fluid responsiveness: avoid over-resuscitation → abdominal compartment syndrome"),
  spacer(),
  h4("Analgesia"),
  bullet("IV Morphine 2-4 mg q4h PRN (opioid analgesia safe in pancreatitis)"),
  bullet("Tramadol if morphine unavailable"),
  bullet("Avoid NSAIDs (AKI risk)"),
  spacer(),
  h4("Nutrition"),
  bullet("Nil orally until pain controlled AND bowel sounds return (usually 24-48h)"),
  bullet("Early enteral nutrition via NG/NJ tube preferred over TPN"),
  bullet("Start NG feeds within 48-72h (reduces infectious complications, gut barrier)"),
  bullet("TPN only if enteral route not tolerated"),
  spacer(),
  h4("Antibiotics"),
  bullet("NOT routinely given in acute pancreatitis"),
  bullet("Indication: Proven infected necrosis (CT-guided FNA + positive culture)"),
  bullet("If infected necrosis confirmed: Imipenem 500 mg IV q8h or Meropenem"),
  spacer(),
  h4("Organ Support"),
  bullet("Respiratory: O2 via face mask, CPAP/BiPAP if SpO2 <90% — ARDS protocol"),
  bullet("Renal: IV fluids, early nephrology consult if AKI persisting"),
  bullet("ICU: APACHE >8, organ failure, haemodynamic instability"),
  spacer(),
  h4("Intervention"),
  bullet("ERCP within 24h: Only if concurrent acute cholangitis (jaundice + fever + RUQ pain)"),
  bullet("NOT for acute pancreatitis alone"),
  bullet("Percutaneous drainage: For symptomatic pseudocyst or infected fluid collection >4cm"),
  bullet("Necrosectomy: For infected pancreatic necrosis not responding to antibiotics (step-up approach)"),
  spacer(),
  subHeader("DISCHARGE"),
  bullet("Duration: 7-14 days for severe acute pancreatitis"),
  bullet("ABSOLUTE alcohol abstinence (counselling + disulfiram referral)"),
  bullet("Cholecystectomy (if gallstone cause) — elective, 4-6 weeks after recovery"),
  bullet("Endocrine follow-up: Diabetes monitoring (islet destruction)"),
  bullet("Exocrine follow-up: Pancreatic enzyme replacement if steatorrhoea"),
  pageBreak(),

  // ══════════════════════════════════════════════════════════════════════════
  // CASE 5 — PSYCHIATRY: Acute Psychotic Episode (First Episode)
  // ══════════════════════════════════════════════════════════════════════════
  caseHeader(5, "FIRST-EPISODE ACUTE PSYCHOSIS", "Psychiatry"),
  subHeader("PRESENTING COMPLAINTS (Informant — mother)"),
  bullet("Talking to self and laughing inappropriately — 3 weeks"),
  bullet("Refusing to eat (fearful of food being poisoned) — 2 weeks"),
  bullet("Aggressive behaviour, smashing objects — 3 days"),
  bullet("Not sleeping for 4 days"),
  spacer(),
  subHeader("HISTORY OF PRESENTING ILLNESS"),
  body("22-year-old unmarried male, 1st year engineering dropout. No prior psychiatric history. 3 weeks ago, started behaving oddly — laughing and talking to himself (responding to voices the family can hear no one else speaking). Became fearful that family was poisoning his food — refused all meals. Increasingly agitated over 3 days with aggressive behaviour (broke furniture). Insomnia for 4 days. History of cannabis use for 2 years (daily). No alcohol. No physical illness. No family history of psychosis. No recent stressors (exam failure 2 months ago)."),
  spacer(),
  subHeader("MENTAL STATUS EXAMINATION (MSE)"),
  headerTable(["Domain","Finding"],
    [["Appearance","Unkempt, suspicious, poor eye contact"],
     ["Behaviour","Agitated, hostile, guarded"],
     ["Speech","Disorganised, tangential, neologisms present"],
     ["Mood (subjective)","'They are trying to kill me'"],
     ["Affect","Incongruent — laughing while describing persecution"],
     ["Thought form","Thought disorder — loosening of associations"],
     ["Thought content","PERSECUTORY DELUSIONS (food poisoning, family conspiring); IDEAS OF REFERENCE (TV speaking to him)"],
     ["Perceptions","AUDITORY HALLUCINATIONS — voices commenting on actions (3rd person); VISUAL — sees shadows"],
     ["Cognition","Alert, oriented; attention impaired"],
     ["Insight","Absent — does not believe he is ill"],
     ["Judgement","Markedly impaired"]]),
  spacer(),
  subHeader("INVESTIGATIONS (to rule out organic cause)"),
  headerTable(["Test","Value","Purpose"],
    [["MRI brain","No abnormality","Rule out encephalitis, tumour"],
     ["EEG","Normal","Rule out temporal lobe epilepsy"],
     ["TFT","Normal","Hypothyroidism can mimic psychosis"],
     ["Blood glucose","Normal","Hypoglycaemia"],
     ["Urine drug screen","POSITIVE for cannabis (THC)","Cannabis-induced psychosis component"],
     ["ANA, anti-NMDAR Ab","Negative","Rule out autoimmune encephalitis"],
     ["LFT, RFT","Normal","Baseline for medication"],
     ["Prolactin","Baseline 12 ng/mL","Pre-antipsychotic baseline"]]),
  spacer(),
  subHeader("DIAGNOSIS"),
  body("First Episode Psychosis (DSM-5: Schizophrenia spectrum disorder — Acute Psychotic Episode) with cannabis-use disorder. Duration >1 month with full criteria (hallucinations + delusions + disorganised speech + negative symptoms).", { bold: true }),
  spacer(),
  subHeader("TREATMENT"),
  h4("Acute Management (Agitation Control)"),
  bullet("Safe environment — de-escalation techniques first"),
  bullet("Olanzapine 10 mg IM STAT (for acute agitation — fastest sedation)"),
  bullet("OR Haloperidol 5 mg IM + Promethazine 25 mg IM (Droperidol if available)"),
  bullet("Avoid physical restraint unless immediate danger"),
  spacer(),
  h4("Antipsychotic Therapy (First-line: Second-Generation Antipsychotics)"),
  headerTable(["Drug","Starting Dose","Target","Side Effects to Monitor"],
    [["Risperidone","1 mg OD → 2-4 mg OD","2–6 mg/day","EPS, prolactinaemia, weight gain"],
     ["Olanzapine","5 mg OD → 10-20 mg","10–20 mg/day","Weight gain, metabolic syndrome, sedation"],
     ["Quetiapine","50 mg OD → 150-400 mg","300–600 mg/day","Sedation, orthostatic hypotension"],
     ["Aripiprazole","10 mg OD","15–30 mg/day","Akathisia, activating, less metabolic"]]),
  note("This patient: Risperidone 2 mg BD chosen (evidence for first-episode, fewer metabolic effects)"),
  spacer(),
  h4("Monitoring on Antipsychotics"),
  bullet("Weight, BMI, waist circumference — monthly"),
  bullet("Fasting glucose, lipid profile — at 3 months"),
  bullet("ECG (QTc) — baseline + at 3 months"),
  bullet("Prolactin level — at 3 months"),
  bullet("EPS monitoring: AIMS scale (tardive dyskinesia), akathisia rating scale"),
  spacer(),
  h4("Non-pharmacological"),
  bullet("Psychoeducation: Patient (when insight improves) + family"),
  bullet("Family therapy — expressed emotion reduction"),
  bullet("Cannabis cessation counselling — MANDATORY (cannabis perpetuates psychosis)"),
  bullet("Cognitive Behavioural Therapy for Psychosis (CBTp) — after acute phase"),
  bullet("Social rehabilitation (occupational therapy, vocational training)"),
  spacer(),
  subHeader("DISCHARGE"),
  bullet("Duration: 2-4 weeks typical first-episode admission"),
  bullet("Risperidone 3 mg BD on discharge"),
  bullet("Outpatient psychiatry weekly for first month"),
  bullet("Community mental health team involvement"),
  bullet("ABSOLUTE cannabis cessation"),
  bullet("Duration of antipsychotic: Minimum 1–2 years first episode (risk of relapse high if stopped early)"),
  pageBreak(),

  // ══════════════════════════════════════════════════════════════════════════
  // CASE 6 — HAEMATOLOGY: Sickle Cell Crisis
  // ══════════════════════════════════════════════════════════════════════════
  caseHeader(6, "SICKLE CELL DISEASE — VASO-OCCLUSIVE CRISIS (VOC)", "Haematology"),
  subHeader("PRESENTING COMPLAINTS"),
  bullet("Severe bone pain — bilateral legs, back, chest — 24 hours"),
  bullet("Fever — 12 hours"),
  bullet("Shortness of breath — 6 hours"),
  spacer(),
  subHeader("HISTORY OF PRESENTING ILLNESS"),
  body("28-year-old male, known HbSS (Sickle Cell Anaemia) since childhood, on Hydroxyurea and folic acid. Precipitated by recent upper respiratory tract infection + cold exposure. Classic vaso-occlusive pain — diffuse bone pain (bilateral tibias, lumbosacral back, sternum). Fever 38.9°C. New-onset breathlessness — concern for Acute Chest Syndrome (ACS). 6 prior VOC admissions, 2 prior ACS episodes."),
  spacer(),
  subHeader("GENERAL PHYSICAL EXAMINATION"),
  headerTable(["Parameter","Finding"],
    [["Built","Thin, asthenic"],["Pallor","Severe +++"],["Jaundice","Mild (haemolytic)"],["BP","110/72 mmHg"],["HR","112/min"],["RR","26/min"],["SpO2","93%"],["Temp","38.9°C"],["Joints","No synovitis, but exquisite bone tenderness bilateral tibiae"]]),
  spacer(),
  subHeader("INVESTIGATIONS"),
  headerTable(["Test","Value","Significance"],
    [["Hb","6.2 g/dL","Haemolytic anaemia"],
     ["Reticulocyte count","12% (elevated)","Active haemolysis + marrow response"],
     ["Peripheral smear","Sickle cells, target cells, Howell-Jolly bodies","Sickling + functional asplenia"],
     ["LDH","1280 U/L","Haemolysis marker"],
     ["Indirect bilirubin","4.2 mg/dL","Haemolytic jaundice"],
     ["Blood cultures × 2","Pending","Infectious precipitant"],
     ["CXR","New infiltrate right lower lobe","ACUTE CHEST SYNDROME"],
     ["PaO2","61 mmHg","Hypoxaemia"],
     ["RFT","Cr 1.6 mg/dL","Sickle nephropathy (baseline slightly impaired)"],
     ["Echo","LV mildly dilated, PA pressure 40 mmHg","Pulmonary hypertension (chronic)"]]),
  spacer(),
  subHeader("DIAGNOSIS"),
  body("Sickle Cell Vaso-Occlusive Crisis complicated by ACUTE CHEST SYNDROME (new infiltrate + hypoxia + fever + respiratory symptoms)", { bold: true }),
  spacer(),
  subHeader("TREATMENT"),
  h4("Pain Management — PRIORITY"),
  bullet("IV access — large bore"),
  bullet("IV Morphine: 0.1 mg/kg bolus q20-30 min until pain controlled, then PCA (patient-controlled analgesia) 0.02 mg/kg/dose with 8-min lockout"),
  bullet("IV/Oral Paracetamol 1g q6h (regular)"),
  bullet("NSAID (Ketorolac 15-30 mg IV q6h × 5 days only — caution in sickle nephropathy)"),
  bullet("Pain assessment q2h — NRS scale"),
  spacer(),
  h4("Acute Chest Syndrome Management"),
  bullet("O2 to maintain SpO2 >95% (incentive spirometry reduces ACS)"),
  bullet("Bronchodilators: Salbutamol nebuliser q4h"),
  bullet("ANTIBIOTICS for ACS (atypical organisms common): Ceftriaxone 1g IV OD + Azithromycin 500 mg OD"),
  bullet("BLOOD TRANSFUSION: Exchange transfusion is treatment of choice for moderate-severe ACS"),
  bullet("  → Target HbS <30% after exchange transfusion"),
  bullet("  → Simple top-up transfusion if Hb <6 or falling rapidly"),
  spacer(),
  h4("Fluids & Supportive Care"),
  bullet("IV fluids: NS or D5NS 1.5× maintenance (avoid dehydration — worsens sickling)"),
  bullet("Folic acid 5 mg OD (ongoing)"),
  bullet("Incentive spirometry every 2h (prevents ACS progression)"),
  spacer(),
  h4("Hydroxyurea (long-term Disease-Modifying)"),
  bullet("Continue hydroxyurea 15-35 mg/kg/day OD (reduces crisis frequency by 50%, ACS by 30%, mortality)"),
  bullet("Target HbF increase to >20%"),
  spacer(),
  subHeader("DISCHARGE"),
  bullet("Oral opioids for 48-72h tapering"),
  bullet("Hydroxyurea dose review"),
  bullet("Penicillin V 250 mg BD (lifelong — functional asplenia → encapsulated organism prophylaxis)"),
  bullet("Pneumococcal vaccine (PCV13 + PPSV23) + Meningococcal + Hib (if not given)"),
  bullet("Haematology OPD 2 weeks"),
  pageBreak(),

  // ══════════════════════════════════════════════════════════════════════════
  // CASE 7 — ENDOCRINOLOGY: Thyroid Storm
  // ══════════════════════════════════════════════════════════════════════════
  caseHeader(7, "THYROID STORM (THYROTOXIC CRISIS)", "Endocrinology"),
  subHeader("PRESENTING COMPLAINTS"),
  bullet("Agitation and confusion — 12 hours"),
  bullet("Very high fever — 6 hours"),
  bullet("Heart racing and palpitations — 3 days"),
  bullet("Known hyperthyroidism — on treatment but stopped medications 2 weeks ago"),
  spacer(),
  subHeader("HISTORY OF PRESENTING ILLNESS"),
  body("35-year-old female, known Graves' disease on Carbimazole — STOPPED medications 2 weeks ago due to 'side effects'. Precipitated by URI 5 days ago. Presented with fever 41°C, extreme restlessness, confusion, tachycardia (HR 168). Nausea, vomiting, diarrhoea. Proptosis noted by family (worsening). Tremor of hands. No symptoms of adrenal insufficiency."),
  spacer(),
  subHeader("GENERAL PHYSICAL EXAMINATION"),
  headerTable(["Parameter","Finding"],
    [["Temp","41.2°C (HIGH — key feature)"],["HR","168/min (Atrial fibrillation on ECG)"],["BP","160/60 mmHg (wide pulse pressure)"],["RR","28/min"],["SpO2","96%"],["Sweating","Profuse diaphoresis"],["Thyroid","Diffuse goitre, bruit present"],["Eyes","Proptosis, lid lag, lid retraction, chemosis (Graves' ophthalmopathy)"],["Tremor","Fine tremor bilateral hands"],["Skin","Warm, moist, flushed"],["GCS","12/15 — confused"]]),
  spacer(),
  h4("Burch-Wartofsky Score (BWS) — Thyroid Storm Diagnostic Score"),
  headerTable(["Parameter","Score Points This Patient"],
    [["Temperature 41.2°C","+30"],["HR 168 (>140)","+25"],["AF","+10"],["Marked agitation","+10"],["Diarrhoea/vomiting","+10"],["Absent cardiac failure","+0"],["Total","85 (>45 = Thyroid Storm confirmed)"]]),
  spacer(),
  subHeader("INVESTIGATIONS"),
  headerTable(["Test","Value","Significance"],
    [["TSH","<0.001 mIU/L (suppressed)","Confirms hyperthyroidism"],
     ["Free T4","78 pmol/L (NL: 12-22)","Severely elevated"],
     ["Free T3","22 pmol/L (NL: 3.5-6.5)","Severely elevated"],
     ["TSH receptor Ab (TRAb)","Strongly positive","Graves' disease"],
     ["ECG","AF 168/min","Thyroid-induced AF"],
     ["LFT","ALT 120, Bili 2.4","Hepatic involvement"],
     ["CBC","Leukocytosis (infection)","URI precipitant"],
     ["Blood glucose","78 mg/dL","Normal"],
     ["Cortisol","28 mcg/dL","Rules out adrenal crisis"]]),
  spacer(),
  subHeader("TREATMENT — SEQUENCE CRITICAL"),
  note("Give drugs in this ORDER: 1. Beta-blocker FIRST → 2. PTU/Carbimazole → 3. Iodine (1h after PTU) → 4. Steroids"),
  spacer(),
  h4("Step 1: Beta-Blocker (FIRST and FASTEST — controls symptoms)"),
  bullet("Propranolol 40-80 mg PO q6h (OR 1-2 mg IV slowly if oral not possible)"),
  bullet("Controls tachycardia, tremor, agitation, hyperthermia"),
  bullet("Target HR <100 bpm"),
  spacer(),
  h4("Step 2: Anti-thyroid Drug (Block new hormone synthesis)"),
  bullet("Propylthiouracil (PTU) 200 mg q4h (preferred in thyroid storm — also blocks T4→T3 conversion)"),
  bullet("OR Carbimazole 20-30 mg q4-6h (if PTU unavailable)"),
  spacer(),
  h4("Step 3: Iodine (Lugol's Iodine — give 1 HOUR AFTER PTU)"),
  bullet("Lugol's Iodine 5-10 drops PO TDS (inhibits thyroid hormone release — Wolff-Chaikoff effect)"),
  bullet("MUST be given after PTU — if iodine given first, it can be used as substrate to make MORE T4"),
  spacer(),
  h4("Step 4: Corticosteroids"),
  bullet("Hydrocortisone 100 mg IV q8h (prevents adrenal insufficiency + reduces T4→T3 conversion)"),
  bullet("Dexamethasone 2 mg q6h is alternative"),
  spacer(),
  h4("Supportive"),
  bullet("IV fluids: NS + D5W (replace losses from fever, vomiting, diarrhoea)"),
  bullet("Cooling: Paracetamol + cooling blankets (avoid aspirin — displaces T4 from binding protein)"),
  bullet("Cholestyramine: 4 g QDS (reduces enterohepatic recirculation of thyroid hormones)"),
  bullet("AF rate control: Diltiazem if beta-blocker insufficient (avoid digoxin — reduced efficacy in hyperthyroid state)"),
  bullet("ICU admission"),
  spacer(),
  subHeader("DISCHARGE"),
  bullet("Thyroid storm resolved in 3-5 days with treatment"),
  bullet("Carbimazole + Propranolol (tapering as euthyroid state achieved)"),
  bullet("Definitive treatment: Radioiodine (I-131) or thyroidectomy after 6-8 weeks euthyroid"),
  bullet("Ophthalmology referral (Graves' ophthalmopathy — selenium, steroids)"),
  bullet("MEDICATION COMPLIANCE counselling — never stop anti-thyroid drugs abruptly"),
  pageBreak(),

  // ══════════════════════════════════════════════════════════════════════════
  // CASE 8 — ENT: Peritonsillar Abscess (Quinsy)
  // ══════════════════════════════════════════════════════════════════════════
  caseHeader(8, "PERITONSILLAR ABSCESS (QUINSY)", "ENT / Head & Neck Surgery"),
  subHeader("PRESENTING COMPLAINTS"),
  bullet("Severe sore throat — 7 days (worsening despite antibiotics)"),
  bullet("Difficulty swallowing liquids — 3 days"),
  bullet("Muffled 'hot-potato' voice — 2 days"),
  bullet("Inability to open mouth fully (trismus) — 2 days"),
  bullet("Fever and neck pain — 5 days"),
  spacer(),
  subHeader("HISTORY OF PRESENTING ILLNESS"),
  body("24-year-old male, sore throat for 7 days — was prescribed amoxicillin from pharmacy 5 days ago (no improvement). Worsening throat pain, now unable to swallow even saliva. Muffled voice (bulging pharynx elevating soft palate). Jaw stiffness preventing full mouth opening (trismus). Fever 39.2°C, right-sided neck pain. Drooling present. No rash (rules out scarlet fever). No stridor (important — airway not obstructed yet)."),
  spacer(),
  subHeader("GPE + ENT EXAMINATION"),
  headerTable(["Parameter","Finding"],
    [["BP","118/76, HR 104, Temp 39.2°C",""],
     ["Mouth opening","Limited — 2.5 cm (trismus)",""],
     ["Oropharynx","Uvula DEVIATED to LEFT side (abscess on right)",""],
     ["Right tonsil","Displaced medially + downward; peritonsillar BULGE right superior pole",""],
     ["Soft palate","Right soft palate bulging, erythematous",""],
     ["Cervical nodes","Right submandibular lymphadenopathy — tender",""],
     ["Stridor","ABSENT (airway safe currently)",""],
     ["Drooling","Present",""]]),
  spacer(),
  subHeader("INVESTIGATIONS"),
  headerTable(["Test","Result"],
    [["CBC","TLC 22,000, Neutrophils 90% — bacterial infection"],
     ["CRP","196 mg/L"],
     ["Blood culture","Pending"],
     ["Throat swab","Group A Streptococcus (GAS)"],
     ["CT Neck with contrast","Right peritonsillar rim-enhancing abscess 2.8 × 2.1 cm with central hypodensity (pus)"],
     ["Lateral neck X-ray","No epiglottitis, no deep space infection extension"],
     ["Monospot test","Negative (rule out EBV tonsillitis)"]]),
  spacer(),
  subHeader("TREATMENT"),
  h4("Immediate"),
  bullet("IV access + IV fluids (dehydrated — unable to swallow)"),
  bullet("IV Paracetamol 1g q6h + IV Dexamethasone 10 mg STAT (reduces swelling, improves airway, reduces hospital stay)"),
  bullet("IV Benzylpenicillin 1.2g q6h + Metronidazole 500 mg q8h"),
  bullet("Anti-emetic: IV Ondansetron 4mg q8h"),
  spacer(),
  h4("Definitive — DRAINAGE (Surgical Emergency)"),
  bullet("NEEDLE ASPIRATION (first-line, safe, diagnostic + therapeutic):"),
  bullet("  → Local anaesthetic spray (lignocaine 10% topical)"),
  bullet("  → 18G needle inserted into point of maximum fluctuance (superior pole)"),
  bullet("  → Aspirate pus: Send for C/S"),
  bullet("  → Can repeat if recollects (success rate 90%)"),
  bullet("INCISION AND DRAINAGE (I&D): If aspiration fails or recollects"),
  bullet("INTERVAL TONSILLECTOMY: 6-8 weeks after resolution (if ≥2 quinsy episodes)"),
  bullet("  → HOT tonsillectomy (at time of acute): Controversial, increases bleed risk"),
  spacer(),
  h4("Airway Precautions"),
  bullet("Monitor stridor, SpO2, ability to swallow hourly"),
  bullet("ENT emergency kit at bedside (laryngoscope, ETT, cricothyrotomy kit)"),
  bullet("Anaesthesia team on standby if airway compromise develops"),
  spacer(),
  subHeader("DISCHARGE (Day 3-5)"),
  bullet("IV antibiotics → Oral Amoxicillin-Clavulanate 625 mg TDS × 10 days"),
  bullet("Prednisolone tapering dose (5 days)"),
  bullet("Soft diet, adequate hydration"),
  bullet("ENT OPD for tonsillectomy planning"),
  bullet("Throat swab culture result — target antibiotics"),
  pageBreak(),

  // ══════════════════════════════════════════════════════════════════════════
  // CASE 9 — OPHTHALMOLOGY: Acute Angle Closure Glaucoma
  // ══════════════════════════════════════════════════════════════════════════
  caseHeader(9, "ACUTE ANGLE CLOSURE GLAUCOMA (AACG)", "Ophthalmology"),
  subHeader("PRESENTING COMPLAINTS"),
  bullet("Sudden onset severe right eye pain — 4 hours"),
  bullet("Blurred vision right eye — 4 hours"),
  bullet("Halos around lights — 4 hours"),
  bullet("Nausea and vomiting — 3 hours"),
  bullet("Severe headache — 3 hours"),
  spacer(),
  subHeader("HISTORY OF PRESENTING ILLNESS"),
  body("62-year-old hypermetropic female (known far-sighted), no prior eye disease. Sudden severe right eye pain starting 4 hours ago after watching a film in a dark theatre (pupil dilation in dark → precipitates angle closure). Immediate blurred vision, seeing rainbow halos around lights (corneal oedema). Severe nausea and vomiting (systemic response to acute IOP rise). Severe frontal headache. Patient initially went to Emergency thinking it was a migraine or acute abdomen — correct diagnosis often delayed."),
  subHeader("OPHTHALMIC EXAMINATION"),
  headerTable(["Finding","Right Eye","Left Eye"],
    [["Visual Acuity","6/60 (severely reduced)","6/6 (normal)"],
     ["IOP (Tonometry)","62 mmHg (MARKEDLY ELEVATED)","14 mmHg (normal)"],
     ["Cornea","CLOUDY, hazy (oedematous)","Clear"],
     ["Anterior chamber","SHALLOW + Flare + Cells","Normal depth"],
     ["Pupil","MID-DILATED, FIXED, oval, non-reactive (5-6mm)","Normal 3mm, reactive"],
     ["Fundoscopy","Disc margins blurred (difficult to see — cloudy cornea)","Normal"],
     ["Gonioscopy","Closed drainage angle (360°)","Narrow angle (prophylactic treatment)"]]),
  spacer(),
  subHeader("DIAGNOSIS"),
  body("ACUTE ANGLE CLOSURE GLAUCOMA — Right Eye (Ophthalmic Emergency)", { bold: true }),
  note("IOP >40 mmHg = ophthalmic emergency. Every hour of elevated IOP = permanent optic nerve damage and visual field loss."),
  spacer(),
  subHeader("TREATMENT — EMERGENCY"),
  h4("Immediate Pressure Reduction (Medical — within MINUTES)"),
  headerTable(["Drug","Dose","Mechanism","Route"],
    [["Acetazolamide","500 mg IV STAT → 250 mg PO q6h","Carbonic anhydrase inhibitor → reduces aqueous production","IV then oral"],
     ["Mannitol 20%","1-2 g/kg IV over 45 min","Osmotic — reduces vitreous volume","IV drip"],
     ["Timolol 0.5%","1 drop right eye","Beta-blocker → reduces aqueous production","Topical"],
     ["Brimonidine 0.2%","1 drop right eye q8h","Alpha-2 agonist → reduces production","Topical"],
     ["Pilocarpine 2%","1 drop q15 min × 4 (once IOP <40)","Miotic — pulls iris away from angle","Topical"]]),
  note("Do NOT give pilocarpine when IOP >40 mmHg (ischaemic iris sphincter won't respond; may worsen)"),
  spacer(),
  h4("Anti-emetics"),
  bullet("IV Metoclopramide 10 mg (vomiting makes patient unable to take drops/oral meds)"),
  spacer(),
  h4("Definitive Treatment — Laser Iridotomy (within 24-48h)"),
  bullet("Nd:YAG Laser Peripheral Iridotomy (LPI): Creates a hole in the iris to bypass pupil block"),
  bullet("Relieves angle closure permanently"),
  bullet("Should be performed in BOTH eyes (fellow eye prophylactic LPI — narrow angles bilaterally)"),
  bullet("If laser not available: Surgical iridectomy"),
  spacer(),
  h4("Target IOP"),
  bullet("Reduce IOP to <21 mmHg within 2-4 hours to prevent permanent visual loss"),
  bullet("Repeat IOP measurement every 1 hour until controlled"),
  spacer(),
  subHeader("DISCHARGE"),
  bullet("Laser iridotomy both eyes performed — confirmed patent"),
  bullet("Continue Timolol + Brimonidine drops if IOP remains slightly elevated"),
  bullet("Ophthalmology follow-up Day 1, Week 1, Month 1, then 6-monthly"),
  bullet("Avoid dim-light environments, sympathomimetic medications (antihistamines, antidepressants)"),
  bullet("Alert card: 'Patient has narrow angles — avoid mydriatic drops'"),
  bullet("Visual acuity: Partial recovery expected; permanent loss depends on nerve damage sustained"),
  pageBreak(),

  // ══════════════════════════════════════════════════════════════════════════
  // CASE 10 — DERMATOLOGY: Stevens-Johnson Syndrome (SJS)
  // ══════════════════════════════════════════════════════════════════════════
  caseHeader(10, "STEVENS-JOHNSON SYNDROME (SJS) / TOXIC EPIDERMAL NECROLYSIS (TEN)", "Dermatology"),
  subHeader("PRESENTING COMPLAINTS"),
  bullet("Skin rash with blistering — 4 days (started as red macules)"),
  bullet("Painful erosions in mouth — 5 days"),
  bullet("Eye redness and discharge — 4 days"),
  bullet("Genital sores — 3 days"),
  bullet("Started cotrimoxazole 10 days ago for UTI"),
  spacer(),
  subHeader("HISTORY OF PRESENTING ILLNESS"),
  body("32-year-old female started cotrimoxazole (Trimethoprim-Sulphamethoxazole) 10 days ago for a urinary tract infection. 5 days ago, painful oral ulcers developed. 4 days ago, widespread tender red-purple macules appeared on trunk, face, and extremities, rapidly developing into fluid-filled blisters that ruptured leaving raw denuded areas. Bilateral conjunctivitis. Genital mucosal erosions. Fever 39°C. Painful swallowing (oesophageal mucosa involved). Similar drugs: Sulfa drugs, NSAIDs, anticonvulsants are most common culprits."),
  spacer(),
  subHeader("GENERAL PHYSICAL EXAMINATION"),
  headerTable(["Parameter","Finding"],
    [["Temp","39.1°C"],["HR","108/min"],["BP","106/72 mmHg"],["SpO2","96%"],
     ["Skin — trunk/extremities","DETACHMENT: Confluent dusky-red macules with blistering; Nikolsky sign POSITIVE; 25–30% BSA denudation"],
     ["Oral cavity","Extensive haemorrhagic erosions, crusting of lips"],
     ["Eyes","Bilateral conjunctival injection + pseudomembrane formation"],
     ["Genitalia","Erosions on labia majora"],
     ["Airway","Hoarse voice — mucosal involvement — ALERT"]]),
  spacer(),
  h4("SJS vs TEN Classification"),
  headerTable(["Diagnosis","BSA Detachment","Mortality"],
    [["SJS","<10%","<5%"],
     ["SJS-TEN Overlap (This patient)","10-30%","~15%"],
     ["TEN (Lyell's disease)",">30%","25-35%"]]),
  spacer(),
  h4("SCORTEN Severity Score (Predict mortality)"),
  headerTable(["Criterion","This Patient"],
    [["Age >40 years","No (0)"],
     ["Malignancy","No (0)"],
     ["Heart rate >120","No (0)"],
     ["BSA involvement >10%","Yes (1)"],
     ["Serum urea >10 mmol/L","Yes (1)"],
     ["Serum bicarbonate <20","Yes (1)"],
     ["Serum glucose >14 mmol/L","No (0)"],
     ["Total SCORTEN","3 → Predicted mortality 35%"]]),
  spacer(),
  subHeader("INVESTIGATIONS"),
  headerTable(["Test","Value"],
    [["CBC","Hb 9.8, WBC 14,200 (neutrophilia), PLT 88,000 (thrombocytopenia — poor prognosis)"],
     ["LFT","Bilirubin 2.8, ALT 190 (hepatic involvement)"],
     ["RFT","Creatinine 1.8 (AKI — fluid loss + sepsis)"],
     ["Urine","Protein 2+, RBC + (renal tubular involvement)"],
     ["Blood cultures","PENDING (risk of sepsis from denuded skin)"],
     ["Skin biopsy","Full-thickness epidermal necrosis — confirms TEN/SJS"],
     ["HLA-B*1502","Pending (pharmacogenomics — SJS risk for carbamazepine in Asians)"]]),
  spacer(),
  subHeader("TREATMENT"),
  h4("IMMEDIATE — STOP CAUSATIVE DRUG"),
  body("COTRIMOXAZOLE STOPPED IMMEDIATELY. Every day the drug continues worsens outcome. Document in allergy records.", { bold: true, color: "C00000" }),
  spacer(),
  h4("BURNS UNIT / ICU Transfer"),
  bullet("Manage like major burns patient — burns unit or ICU"),
  bullet("Isolated room, reverse barrier nursing (immunocompromised skin)"),
  spacer(),
  h4("Wound Care"),
  bullet("Non-adherent dressings (Biobrane, Mepitel, petroleum gauze) — do NOT use adhesive dressings"),
  bullet("Gentle debridement of necrotic epidermis"),
  bullet("Hydrogel for denuded areas"),
  bullet("Avoid topical antibiotics routinely (sensitisation risk)"),
  spacer(),
  h4("Fluid Replacement"),
  bullet("Calculate as burns: Parkland formula (3-4 mL/kg per % BSA involved)"),
  bullet("This patient (60 kg, 25% BSA): 3 × 60 × 25 = 4500 mL RL over 24h"),
  bullet("Monitor urine output hourly — target 0.5-1 mL/kg/h"),
  spacer(),
  h4("Nutritional Support"),
  bullet("Early NG feeding: High protein (2 g/kg/day) — massive protein losses from denuded skin"),
  bullet("Vitamin C 1g OD + Vitamin E 400 IU OD"),
  spacer(),
  h4("Ophthalmology — URGENT"),
  bullet("Lubricating eye drops every 2h (artificial tears)"),
  bullet("Topical antibiotics if secondary infection"),
  bullet("Amniotic membrane transplant if pseudomembranes forming"),
  bullet("Daily eye review (risk of symblepharon, corneal scarring, blindness)"),
  spacer(),
  h4("Immunomodulatory Therapy (Controversial)"),
  bullet("Cyclosporin A 3 mg/kg/day IV: Best evidence for halting disease progression (recent RCTs)"),
  bullet("IVIG 1 g/kg/day × 3 days: Second option — inhibits Fas-FasL apoptosis"),
  bullet("Steroids: AVOID — increase infection, mortality in most studies"),
  bullet("Biologics: Infliximab (anti-TNF) — case reports, emerging evidence"),
  spacer(),
  h4("Infection Prevention"),
  bullet("Active surveillance cultures weekly (skin/blood/urine)"),
  bullet("Prophylactic antibiotics NOT recommended — treat infection when confirmed"),
  bullet("Silver sulfadiazine AVOIDED (contains sulfonamide — same drug class that caused SJS)"),
  spacer(),
  subHeader("DISCHARGE NOTES"),
  bullet("Survivors: Permanent sequelae in 35-50% — corneal scarring, dry eye, vaginal stenosis, oesophageal stricture, nail loss"),
  bullet("Dermatology + Ophthalmology + Gynaecology long-term follow-up"),
  bullet("Medical alert bracelet: 'ALLERGIC TO SULFONAMIDES — risk of TEN'"),
  bullet("Register with pharmacovigilance database"),
  bullet("Patch test NEVER — risk of recurrence"),
  bullet("Educate entire family about allergy — potential genetic predisposition"),
  pageBreak(),

  // ── Final Page: Quick Summary Table ─────────────────────────────────────
  sectionBanner("QUICK REFERENCE SUMMARY — ALL 10 CASES"),
  headerTable(
    ["#","Specialty","Diagnosis","Key Hallmark","Critical Treatment"],
    [
      ["1","Nephrology","AKI Stage 3","Oliguria + Creatinine ×3 baseline","STOP nephrotoxins; RRT if AEIOU met"],
      ["2","Pulmonology","AECOPD + Type 2 RF","PaCO2↑ + pH 7.31 + SpO2 82%","Controlled O2 (88-92%) + NIV + Steroids"],
      ["3","Orthopaedics","# NOF Garden IV","Short + Externally rotated leg","Cemented hemiarthroplasty within 48h"],
      ["4","Gastroenterology","Severe Acute Pancreatitis + ACS","Grey Turner + Cullen + Ranson 6","Aggressive Ringer's Lactate + Exchange transfusion"],
      ["5","Psychiatry","First Episode Psychosis","Hallucinations + Delusions + Thought disorder","Risperidone + Cannabis cessation"],
      ["6","Haematology","Sickle Cell VOC + ACS","New infiltrate + HbSS + bone pain","IV Morphine + Exchange transfusion + O2"],
      ["7","Endocrinology","Thyroid Storm","Temp 41°C + HR 168 + BWS 85","Beta-blocker → PTU → Iodine → Steroids (in order)"],
      ["8","ENT","Peritonsillar Abscess","Uvula deviation + trismus + bulge","Needle aspiration + Penicillin + Dexamethasone"],
      ["9","Ophthalmology","Acute Angle Closure Glaucoma","IOP 62 + fixed mid-dilated pupil + cloudy cornea","IV Acetazolamide + Mannitol → Laser Iridotomy"],
      ["10","Dermatology","SJS/TEN","Nikolsky + 25% BSA denudation","STOP drug + Burns care + Cyclosporin/IVIG + Ophthalmology"],
    ]
  ),
  spacer(),
  new Paragraph({
    children: [new TextRun({ text: "Sources: Goldman-Cecil Medicine · Harrison's Principles 22e · Tintinalli's Emergency Medicine · Schwartz's Surgery · Brenner & Rector's Kidney · Current Surgical Therapy 14e · Rosen's Emergency Medicine", italics: true, size: 16, color: DKGREY })],
    alignment: AlignmentType.CENTER,
    spacing: { before: 300, after: 100 },
  }),
];

// ─── Build & Save ─────────────────────────────────────────────────────────────

const doc = new Document({
  title: "IPD Clinical Cases Master Guide",
  description: "10 IPD cases across specialties",
  styles: {
    paragraphStyles: [
      {
        id: "Heading1", name: "Heading 1",
        basedOn: "Normal", next: "Normal",
        run: { size: 28, bold: true, color: WHITE },
        paragraph: { spacing: { before: 400, after: 160 }, shading: { type: ShadingType.CLEAR, fill: BLUE } },
      },
      {
        id: "Heading2", name: "Heading 2",
        basedOn: "Normal", next: "Normal",
        run: { size: 24, bold: true, color: BLUE },
        paragraph: { spacing: { before: 300, after: 80 } },
      },
    ],
  },
  sections: [{
    properties: {
      page: { margin: { top: 720, right: 720, bottom: 720, left: 720 } },
    },
    headers: {
      default: new Header({
        children: [new Paragraph({
          children: [
            new TextRun({ text: "IPD Clinical Cases Master Guide  |  All Specialties  ", size: 16, color: DKGREY }),
            new TextRun({ children: [PageNumber.CURRENT], size: 16, color: DKGREY }),
          ],
          alignment: AlignmentType.RIGHT,
          border: { bottom: { style: BorderStyle.SINGLE, size: 6, color: LBLUE } },
        })],
      }),
    },
    children,
  }],
});

Packer.toBuffer(doc).then(buf => {
  fs.writeFileSync("/home/daytona/workspace/ipd-cases/IPD_Clinical_Cases_Master_Guide.docx", buf);
  console.log("SUCCESS: Document written.");
}).catch(err => {
  console.error("ERROR:", err);
  process.exit(1);
});
Running Command

cd /home/daytona/workspace/ipd-cases && node generate.js 2>&1

Running Command

python3 /home/daytona/skills/docx/scripts/office/validate.py /home/daytona/workspace/ipd-cases/IPD_Clinical_Cases_Master_Guide.docx 2>&1 && ls -lh /home/daytona/workspace/ipd-cases/

Running Command

ls -lh /home/daytona/workspace/ipd-cases/ && python3 -c "import zipfile; z=zipfile.ZipFile('/home/daytona/workspace/ipd-cases/IPD_Clinical_Cases_Master_Guide.docx'); print('Valid ZIP/DOCX. Contents:'); [print(f.filename) for f in z.infolist()[:10]]"

Your Word document is ready. Download it here:

IPD Clinical Cases Master Guide

Word Document · DOCX


What's Inside (35 KB, fully formatted)

The document contains 10 detailed IPD clinical cases across specialties not covered in the previous guide. Every case follows the full 15-step format with colour-coded section banners, key-value tables, drug dosing tables, scoring tables, and progress/discharge notes.

Cases Included

#SpecialtyDiagnosisClinical Hallmark
1NephrologyAKI Stage 3 (Post-op + ATN)Oliguria + Cr ×4 baseline; AEIOU criteria for RRT
2PulmonologyAECOPD + Type 2 Respiratory FailurepH 7.31, PaCO2 68 — NIV initiated; controlled O2 88-92%
3OrthopaedicsFracture NOF — Garden IVShort + externally rotated limb; cemented hemiarthroplasty within 48h
4GastroenterologySevere Acute PancreatitisGrey Turner + Cullen signs; Ranson 6/11; aggressive Ringer's Lactate
5PsychiatryFirst Episode PsychosisMSE with hallucinations/delusions; Risperidone 2 mg BD + cannabis cessation
6HaematologySickle Cell VOC + Acute Chest SyndromeHbSS + new infiltrate + SpO2 93%; exchange transfusion + morphine PCA
7EndocrinologyThyroid Storm (BWS Score 85)Temp 41°C + AF 168 + BWS >45; drug sequence: Beta-blocker → PTU → Iodine → Steroids
8ENTPeritonsillar Abscess (Quinsy)Uvula deviation + trismus; needle aspiration + IV Penicillin + Dexamethasone
9OphthalmologyAcute Angle Closure GlaucomaIOP 62 mmHg + fixed mid-dilated pupil; IV Acetazolamide + Mannitol → Laser Iridotomy
10DermatologySJS/TEN (25% BSA, SCORTEN 3)Nikolsky sign + Cotrimoxazole culprit; STOP drug + Burns care + Cyclosporin/IVIG

Document Features

  • Colour-coded headers (blue case banners, teal section headers)
  • Dosing tables with doses, routes, mechanisms, and timing
  • Scoring tools (KDIGO AKI stages, GOLD COPD, Garden classification, BWS thyroid storm score, SCORTEN, Ranson, Burch-Wartofsky)
  • Clinical pearls (e.g., iodine must be given 1h AFTER PTU; pilocarpine contraindicated when IOP >40; silver sulfadiazine avoided in SJS caused by sulfonamides)
  • Final summary table — all 10 diagnoses with critical treatment in one page

ICU MASTER GUIDE

Asking for Preferences

What format do you want the ICU Master Guide in? · Which areas should the guide cover?

Full comprehensive ICU Master Guide - pulling from critical care textbooks now.
Searching sources...
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.